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ABSTRACT
Effective treatment o f cancer is limited by the use o f  surgery, radiotherapy and 
chemotherapy. Surgery and radiotherapy are only successful if  the disease is 
localised and after it has become widespread these forms o f treatment can only offer 
(in some cases) symptomatic control. Chemotherapeutic drugs have been developed 
with the aim to target proliferating cells. However, because o f the similarity o f  
healthy cells and normal cells, such agents are unable to kill cancer cells selectively. 
Poly(ADP-ribose) polymerase (PARP) an enzyme found in most eukaryotic cells, 
appears to be involved in DNA excision repair. Inhibitors o f PARP have been shown 
to potentiate the cytotoxicity o f both DNA-damaging chemotherapeutic agents and 
radiotherapy. The aim o f this project was to design a prodrug system, bearing a 
trigger moiety consisting o f a nitro group, which when activated under hypoxic 
conditions would release potent PARP inhibitors selectively in solid tumours.
5-Bromo-2-(( 1 -methyl-2-nitroimidazole-5-yl)methyl)isoquinolin-1,2-one was
synthesised by a convergent synthesis. 5-Bromoisoquinolin-l-one, synthesised by an 
efficient novel route, was alkylated with 5-chloromethyl-l-methyl-2-nitroimidazole / 
5 -bromomethyl-1 -methyl-2-nitroimidazole in the presence o f base. Biomimetic 
reduction caused the release o f 5-bromoisoquinolin-l-one. Currently, 5- 
aminoisoquinolin-l-one is o f interest as a PARP inhibitor in haemorrhagic shock and 
renal dysfunction. 5-Chloromethyl-l-methyl-2-nitroimidazole reacted efficiently 
with the anion derived from 5-(Bocamino)isoquinolin-l-one to give 5-amino-2-((l- 
methyl-2-nitroimidazole-5-yl)methyl)isoquinolin-1 -one, after deprotection.
Previous studies have shown that N-oxides can be bioreduced under hypoxic 
conditions. A prodrug was designed based on N-oxide bioreduction. Attempts were 
made to synthesise quinoline-8-carboxamide N-oxide and the analogue 2- 
phenylquinoline-8-carboxamide N-oxide. Although the compounds were not 
achieved, several advances in quinoline chemistry were made.
Curcumin is o f particular interest as a cancer chemopreventative agent. Lithium- 
bromine exchange o f l-bromo-4-(l-ethoxyethoxy)-3-methoxybenzene with
butyllithium followed by quenching with 0 2HCNMe2 and acidic work up gave [2H]- 
vanillin in 27% yield, based on 0 2HCNMe2. Condensation with pentane-2,4-dione 
gave [2H2]-curcumin. Adaptation o f the procedures to use o f OH14CNMe2 gave 
[14C]-curcumin via [14C]-vanillin in 81% chemical yield, 1.20 MBq, 81% 
radiochemical yield, specific radioactivity 12.7 MBq mmol'1.
A CKNO WLEDGEMENTS
I would like to thank my supervisors Dr. Mike Threadgill and the late Dr. Bill Whish 
for their support, encouragement and enthusiasm throughout the research years.
I would like to thank Mr David Wood and Mr Harry Hartell for NMR spectra and Mr 
Chris Cryer for mass spectra.
Many thanks to my postdoctoral and postgraduate colleagues in particular Shane, 
Penny, Jackie, Andy, Sula, Dharshini and Norina for their help and advice.
I would also like to acknowledge Association for International Cancer Research for 
generous financial support.
Finally, a special thank you to my friend Barry for all his love and support and to all 
my family in particular my mum, dad and brother Sajj for their love and support 









1.1 Direct and Indirect Measurements o f Tumour Hypoxia 3
1.2 The Mechanism of Action of Radiation Therapy 5
1.3 Radiosensitisers 7
1.4 Chemosensitisers 10
1.5 Bioreductive Drugs 15
2.0 Poly(ADP-ribose) Polymerase 22
2.1.1 The DNA Binding Domain (DBD) 24
2.1.2 The Automodification Domain 25
2.1.3 The Catalytic Domain 26
2.2.1 Mechanism of Action o f PARP 26
2.2.2 Modification of the Chromatin Structure 27
2.3 Poly(ADP-ribose) Glycohydrolase (PARG) 27
2.4 Mono- and Poly(ADP-ribosyl)ation 28
2.5 Functions of PARP 28
2.5.1 Role of PARP in Viral Replication 28
2.5.2 Role of PARP in Apoptosis 29
2.5.3 Role of PARP in Inflammation 30
2.5.4 Role o f PARP in Ischaemia-Reperfusion Injury 31
2.5.5 Role of PARP in DNA Repair 32
v
3.0 Inhibitors of Poly(ADP-ribose) Polymerase 35
3.1.1 Chemosensitisation 35
3.1.2 Radiosensitisation 3 6
3.2 PARP Inhibitors Developed to Date 38
4.0 Curcumin 46
5.0 Aims and Objectives 52
6.0 Results and Discussion 56
6.1 Critical 2-Nitroimidazole Intermediates 60
6.2 Critical 5-Bromoisoquinolin-l-one Intermediates 66
6.3 Reductively Triggered Release from Prodrug (118) 72
6.4 Synthesis of Prodrug (127) 76
6.5 Attempted Synthesis of Prodrug (129) 79
6.6 Analogues of Prodrug (118) 81
6.7 Other Routes to 1,5-Disubstituted-2-Nitroimidazoles 83
6.8 Critical 2-Nitrothiophene Intermediates 87
6.9 Quinoline-8-Carboxamides and Quinoline-N-oxides 89




List o f Figures, Schemes and Tables
Figure 1. Diagramatic representation of a solid tumour. 3
Figure 2. Illustrates the radicals generated during the interaction of 6
radiation with water and the organic molecules DNA and 
RNA.
Figure 3. Identification of the three domains of PARP. 23
Figure 4. Constituents of Curcuma longa L. 48
Figure 5. SAR necessary in the development of PARP inhibitors. 52
Figure 6. SAR necessary for the bioreducible nitroimidazole moiety. 53
Figure 7. Illustrates the general structure of tumour hypoxia selective 54
prodrugs.
Figure 8. Typical HPLC chromatograms from the reductively 75
triggered drug release study.
Figure 9. Demonstrates the structure of the carboxamide when it is 91
‘in-plane’ and when twisted ‘out-of-plane’.
Scheme 1. Schematic representation o f poly(ADP-ribosyl)ation 38
Scheme 2. Proposed mechanism of bioreductively triggered release of 54
drugs from general nitroimidazole prodrug.
Scheme 3. Reported synthesis o f 2-nitroimidazoles. 57
Scheme 4. Synthesis of l-methyl-2-nitroimidazoles. 59
Scheme 5. Reported synthesis of 5-bromoisoquinolin-l-one. 66
Scheme 6. Synthesis of 5-bromoisoquinolin-l-one and prodrug (118). 67
Scheme 7. Reductively activated release of 5-bromoisoquinolin-l-one 72
(108).
Scheme 8. Synthesis o f 5-amino-2-((l-methyl-2-nitroimidazol-5- 76
yl)methyl)isoquinolin-1 -one.
Scheme 9. Synthesis o f quinazolin-l-one. 80
Scheme 10. Attempted synthesis of analogue (141). 81
Scheme 11. Attempted synthesis o f 2-nitroimidazole-5-methanol. 84
Scheme 12. Attempted synthesis o f prodrugs (161), (162) and (163). 87
Scheme 13. Synthesis of naphthalene-1-carboxamide 92
Scheme 14. Synthesis of quinoline-8-carboxamide. 92
Scheme 15. Attempted synthesis of 8-bromoquinoline N-oxide. 93
Scheme 16. Proposed mechanism for the synthesis of quinoline-8- 94 
carboxamide N-oxide by directed oxidation / hydrolysis.
Scheme 17. Attempted synthesis of quinoline-8-carboxamide and 2- 97 
phenylquinoline-8-carboxamide.
Scheme 18. Schematic representation o f the attack of the Grignard 99 
reagent on 8-methylquinoline N-oxide.
Scheme 19. Schematic representation o f the attack of hydrogen 101 
peroxide on quinoline-2-phenylcarboxaldehyde.
Scheme 20. Synthesis of 14C-labelled curcumin. 104






ADEPT antibody directed enzyme-prodrug therapy
ADP-ribose adenosine diphosphoribose
5-AIQ 5-aminoisoquinolin-l-one








CCNU 1 -(2-chloroethyl)-3-cyclohexyl-l -nitrosourea









DMBA dimethylbenz (a) anthracene
DME 1,2-dimethoxyethane
DMF JV,Af-dimethylformamide
DMFDMA MN-dimethylform amide dimethylacetal
DMS dimethyl sulfate
DNA deoxyribonucleic acid
DNABER deoxyribonucleic acid-base-excision-repair complex
DSBs double stranded breaks
El electron impact
FAB fast atom bombardment
FI zinc finger 1




HMG high mobility group
h n 2 7/,N-bis(2-cliloroethyl)methylamine
HPLC high performance liquid chromatography
IC50 concentration causing 50% inhibition
IKKs I Kappa B Kinase
IN virus-encoded integrase protein
m infrared
K, inhibition constant








m/z mass to charge ratio (mass spectroscopy)
NAD+ nicotinamide adenine dinucleotide
NADPH nicotinamide adenine dinucleotide phosphate (reduced form)
NBS jV-bromo succinim ide
NLS nuclear location signal
NMR nuclear magnetic resonance
NOS nitric oxide synthetase
PARG poly(adenosine diphosphoribose) glycohydrolase
PARP poly(adenosine diphosphoribose) polymerase
PARS poly(adenosine diphosphoribose) polymerase















In the figures and schemes, the charges on N (*) and O (') o f the quinoline-N-oxides 
have been omitted for clarity.
INTRODUCTION
l.o HYPOXIA
Cancer is one o f the most common causes o f mortality today, with one person in three 
estimated to develop the disease sometime during their lifetime. Currently, cancer 
therapy involves the use o f three forms of treatment, surgery, radiotherapy and 
chemotherapy. There are many problems, however, associated with the use of each of 
the above forms o f treatments.
In the case o f surgery and radiotherapy these forms of treatments are only successful if 
the disease is localised, so that it can either be completely removed by surgery or treated 
by radiation therapy. However, once the disease has become widespread, these forms of 
treatment can only offer in some cases symptomatic control but are unable to cure the 
disease.
In the case o f chemotherapy, the majority of the drugs that have been developed target 
the DNA of cells, which are proliferating. This consequently limits their use as selective 
agents due to the similarity between normal and cancer cells and, therefore, many of 
these drugs tend to be toxic to the bone marrow and gastrointestinal tract. However, 
chemotherapeutic agents have been successful in rapidly growing cancers such as 
childhood tumours and Hodgkin’s disease1. Nevertheless, the majority of human 
cancers are the relatively slow-growing solid tumours, including carcinomas of the lung, 
colon and breast, and so this is where the problem is, because such cancers respond 
poorly to existing chemotherapeutic drugs.
Over the last century, many studies have been carried out in order to identify differences 
between malignant and normal cells . Any biochemical characteristics that are unique to 
malignant cells can be exploited in the treatment of cancer. Although a number of 
metabolic differences between normal and malignant cells have been reported, few, if  
any, have proved to be either unique to cancer cells or useful in the development of
1
selective chemotherapeutic agents. Nevertheless, one such characteristic o f solid 
tumours which is thought to be useful in the treatment o f cancer is the presence of 
hypoxic cells.
Thomlinson and Gray3 first reported the presence of hypoxic cells in tumours in 1955. 
Analysis of the distribution of blood vessels, the viable tumour tissue and necrosis in 
human bronchogenic carcinoma in terms of the utilisation and distribution of molecular 
oxygen within the tissue revealed that the viable cells on the edge of the necrotic regions 
in these tumours were, in fact, severely hypoxic. Further evidence in support of this was 
provided by Moulder and Rockwell4'5 who reported that the majority of solid cancers 
contained hypoxic cells and that these often contributed about 10-20% of the total viable 
tumour cell population. Furthermore, hypoxic tumour cells have been reported to exist 
in an environment exhibiting oxygen concentrations from 0.01-5% O26.
In solid tumours, hypoxic cells develop as a result o f the unbalanced growth of the 
tumour cells and the vascular components that are required in order to provide an 
adequate blood supply6,7. As a result of this, cells are depleted of molecular oxygen and 
various other nutrients. At a distance of about 150 pm from a capillary, cells tend to be 
well-oxygenated. At greater distances, however, tissue oxygen tension decreases with 
distance from the capillary and eventually falls to a level which is insufficient for cell 
division to take place6,7. As a consequence, these oxygen-deprived cells die and this 
forms the necrotic region. Viable hypoxic cells tend to occur in the interface regions
• x  7
between the well-oxygenated tissue and the necrotic regions ’ .
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Figure 1: Diagramatic representation of a solid tumour
1.1 DIRECT AND INDIRECT MEASUREMENTS OF TUMOUR HYPOXIA
There are several methods that can be used in order to measure oxygen in tumours and 
tissues, which include vascular density measurements, the use of oxygen electrodes, 
redox-sensitive markers of hypoxia and metabolically activated chemical markers8.
Vascular Density
Poor vascularisation of tumours means that oxygen is poorly delivered to cells resulting 
in chronically hypoxic tumour cells. Indirect methods of measuring tumour hypoxia can 
be achieved by taking measurements of the density of the tumour vasculature. These 
measurements can be taken wherever a biopsy is obtained from a human tumour and 
histological sections made. However, this method is extremely time-consuming and, in 
addition, ignores the possibility of acutely hypoxic cells8.
Oxygen Electrodes
Oxygen electrodes have been used to directly measure oxygen concentrations in human 
tumours. Even though oxygen electrodes have been designed to be as accurate as
3
possible, they require the use o f very small diameter8. However, the smallest needle 
developed is still large in comparison to the diameter o f a tumour cell and, therefore, 
when inserted into a tumour, an oxygen electrode could be sampling a volume 
containing both hypoxic and well-oxygenated cells .
The Use of Spectroscopy in Redox-Sensitive Markers of Hypoxia
Near-infrared spectroscopic measurements of haemoglobin oxygenation have been used 
to provide non-invasive information on the oxygenation of the tissue but, because the 
reporter molecule is localised in the vasculature, it is unable to give information
o
regarding the status o f cells which are hypoxic . Furthermore, these redox-related 
changes are reversible upon reoxygenation on exposure to air and, therefore, cannot be 
used in biopsy material.
Metabolically Activated Chemical Markers
Nitro-aromatic compounds, such as misonidazole, can be metabolically reduced to the 
nitro radical anion, which, in aerobic cells, is reoxidised by molecular oxygen to inhibit
Q
further metabolism . However, under hypoxic conditions, reactive metabolites are 
generated and these effectively bind to cellular molecules, therefore labelling hypoxic 
cells. However, although the majority of nitro-aromatic compounds have been 
successful as probes for hypoxic cells in vitro, few have been successful in studies in 
vivo*.
Studies with isotopically-labelled 2-nitroimidazoles have also been used as hypoxia 
markers. However, the use o f large amounts of radioactivity for long periods o f time 
limits the clinical usefulness of this technique8. However, more recent studies have used 
2-nitroimidazoles with immunohistochemically detectable side chains, and the use of 
such compounds (for example NITP) has shown hypoxia-specific staining in 
experimental tumours8,9.
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1.2 THE MECHANISM OF ACTION OF RADIATION THERAPY
Over the last century, radiation therapy has been used in the treatment of human cancers. 
Radiotherapy involves the use o f X-rays or y-rays. Both o f these types of ionising 
radiation cause the ejection o f a fast-moving electron from the target molecule, resulting 
in the formation of an ion radical10. This species, in turn, reacts with other molecules, 
resulting in the formation o f ions and free radicals. It is the ions and free radicals that 
are produced from the interaction of radiation with water that interact with organic 
molecules such as DNA and RNA, thus resulting in cellular damage10. When oxygen is 
present, a wider range o f ions and free radicals are formed, hence more DNA damage 
occurs. When the DNA is damaged directly by radiation, radical cationic and anionic 
sites are produced. In the presence of oxygen, the oxygen molecules are capable of 
abstracting an electron from the radical anions resulting in radical cations that have a 
long enough life to cause DNA damage. In the absence of oxygen, however, the 
electron from the radical anion tends to combine with the radical cation, therefore no 
DNA damage occurs. In both o f the above cases, DNA damage is enhanced in the 
presence of oxygen10,11.
5
Radicals produced from radiation therapy:
H20  -» H20 + + e 
H20 + + H20  -> H30 + + OH" 
e‘ + H20  e' -> OH" + H* 
e + H30 + H20  + H*
20H* H20 2
2H" H2 + OH" H20  + H"
H20 2 + H" -» H20  + OH*
Reaction with 0 2:
H* + 0 2 -> H 02* ■» H20 2 + 0 2 
H 02 + e‘ -> H 02' + H+ -> H20  
Reaction with organic molecules:
X + OH* XOH*
X + OH* -> X* + H20  
X* + 0 2 X 0 2* X + o2*
x o 2* + x 1h -> x o 2h + x ‘
Figure 2: Illustrates the radicals generated during the interaction of radiation with water 
and the organic molecules DNA and RNA (these are represented by X)10
Oxygen, therefore, modifies the number and character of free radical reactions and thus 
increases the DNA damage produced by a given dose o f radiation. As a consequence of 
this, the cell-survival curve for aerobic cells is enhanced by a factor o f about three in 
comparison to that for severely hypoxic cells. Radiosensitisation can occur at relatively 
low concentrations o f oxygen, and a concentration of 0.25% oxygen effectively shifts 
the dose-response curve half-way towards the fully oxygenated cells1.
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1.3 RADIOSENSITISERS
As previously mentioned, the presence of hypoxic cells within tumours makes them 
extremely resistant to radiation therapy. In fact, mammalian cells that have been 
irradiated in air have slopes that are three times as steep as the radiation dose-response 
curves for cells that are irradiated under severely hypoxic conditions1. When a tumour is 
irradiated, the oxygenated radiosensitive cells are readily killed consequently, increasing 
the oxygen-diffusion path-length. As a result o f this, hypoxic cells are reoxygenated, 
and can, therefore, enter the cell cycle and allow the tumour to regrow1,7.
Hypoxic cell radiosensitisers are drugs that have been specifically designed to be given 
to patients with solid tumours, shortly before undergoing radiation therapy. These 
compounds are capable of interacting with short-lived free radicals that are produced 
during radiation, thus enhancing cell killing. Oxygen itself is known to be an effective 
radiosensitiser and hypoxic cell radiosensitisers act to restore (or at least to some extent) 
the radiosensitivity o f hypoxic tumour cells, which are otherwise resistant to cell killing 
by radiation therapy1,7. Radiosensitising drugs are therefore oxygen substitutes that are 
capable of diffusing into hypoxic tumour cells and sensitise them via a similar 
mechanism to oxygen1,7. However, the important difference is that these drugs are not 
rapidly metabolised when diffusing through the tumour cells. As a result o f this, they 
are able to penetrate further into the hypoxic regions o f tumour cells even those that are 
some distance away from the nearest microcapillary1,7. In normal tissues, the well- 
oxygenated cells are difficult to sensitise further therefore such drugs are effectively
1 7selective towards hypoxic cells ’ .
The notion that hypoxic cell radiosensitisers could be therapeutically useful first arose in 
1969, when Adams and Cooke12 observed that the more powerful oxidising agents were 
the most efficient sensitisers. The ability o f a compound to sensitise hypoxic cells 
towards the lethal effects of ionising radiation has been demonstrated to be dependant on 
the one-electron redox potential13. Hypoxic cell radiosensitisation occurs with the 
transfer of one electron at a radiation-induced lesion, resulting in fixation of the
7
chemical damage. Compounds that exhibit an Elj reduction potential in the range o f - 
300 to -500 mV have been found to be the most effective sensitisers. Compounds with 
reduction potentials outside this range have been found to be either too toxic or 
ineffective as radiosensitisers14,15. The aim in the development of hypoxic cell 
radiosensitisers is to design compounds that can be used at doses that produce maximum 
radiosensitisation o f the hypoxic cells. In addition, patient groups (or subgroups) that 
are likely to respond to hypoxic cell radiosensitisers or to other effects of improving 
tumour oxygenation need to be identified.
The earliest compounds that were evaluated as radiosensitisers were the class o f nitro- 
heterocyclic compounds. Although work was carried out on a number of compounds 
including nitroimidazoles1,7,14'16, nitrofiirans14,15,17, nitrobenzenes14 and nitrothiophenes18 
much of the attention focused on nitroimidazoles because they appeared to show 
increased selective toxicity towards hypoxic cells in comparison to the well-oxygenated 
cells.
From the various studies carried out, 2-nitroimidazoles were found to be the most 
effective radiosensitisers with reduction potentials in the range o f -250 to -400 mV. 
When the nitro group was changed from position 2 to position 5 or 4, the electron- 
affmity of the nitroimidazoles decreased14. This was demonstrated by Adams et a/14 
with nitroimidazoles RGW-601 (1), RGW-611 (2) and nimorazole (3).
Vv n o 2r={ 0 2N)= \
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4 5
R1 = (CH2)2NC4H8OA (where A = morphilino group) 
R2 = H
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One o f the first hypoxic cell radiosensitisers reported to enhance the lethal effects of  
radiation selectively to hypoxic cells was metronidazole (4). However, high 
concentrations o f this compound were required to sensitise the cells in vitro and, 
therefore, an alternative compound was sought7,19,20. Misonidazole (MDZ, 5) was the 
next imidazole compound to be developed and this was found to be superior to metro-
7  10 91nidazole both in vitro and in vivo studies ’ ' . Investigations carried out with mouse 
tumours revealed that the radiation response was increased significantly to single large
99doses of irradiation with MDZ . However, the clinical studies carried out with this 
compound have been disappointing. This was due to the neurotoxicity that was induced 
in patients that received the drug at therapeutic concentrations. The poor results that 
were observed have also been attributed to the fact that majority o f these clinical trials 
were performed on the heterogenous populations of tumours and therefore subgroups 
that may have shown an effect could have been masked by groups that were not 
affected. As a result of the neurotoxicity observed with MDZ, two analogues were 
developed; these were etanidazole (SR2508, 6) and pimonidazole (Ro-03-8799, 7)7,16. 
Etanidazole exhibited hydrophilic properties that would not allow the drug to cross the 
blood brain barrier and this was thought to make it less neurotoxic. Pimonidazole, on 
the other hand, was developed to be a more effective radiosensitiser and was achieved 
because the molecule was uncharged at acid pH; therefore, it was proposed that the drug 
would concentrate in the tumours. Both o f these compounds underwent clinical 
evaluation and proved to be promising, as tumour concentrations of both of these drugs 
have been achieved at five times greater than those which were achieved with MDZ. 
This increases the sensitizer enhancement ratio (SER) in a twenty-fraction radiotherapy 
regime of 1.1-1.2 for misonidazole to approximately 1.5 for each of the two analogues. 
However, this was still below the therapeutically required maximum of about 2.57,16,22.
The next compound to be developed was the DNA-targeted radiosensitiser RSU 1069 
(8). In the side chain o f RSU 1069 was incorporated an aziridine moiety that behaved as 
a monofunctional alkylating agent. This compound, therefore, had the potential to 
behave both as an alkylating agent and a radiosensitiser. Unfortunately, the drug failed
• 7  16clinically because of the reactivity of the aziridine group, which led to emesis ’ . In an
9
attempt to decrease the side-effect but retain its radiosensitising activity, the aziridine 
group was replaced by substituted acetohydroxamic acids23 and p-haloethylamines24. In 
the acetohydroxamic acids developed, KIH-802 (9) was found to be the most potent 
analog, displaying significant activity in vivo in SCCV11 tumours. However, studies
7 1 (\revealed that this compound caused neurotoxicity ’ . Work carried out with (3- 
haloethylamines resulted in two compounds, RB 6145 (10) and its derivative PD 130908 
(11). Both o f these compounds were found to be equal in radiosensitising activity to 
RSU 1069, but were less toxic7,16.
A number of non-nitro heterocyclic compounds have also been evaluated as hypoxic cell 




6  R = C H 2NHCO(CH2)2OH
7  R = C H 2CH(OH)CH2C5H5N
8 R = C H 2CH(OH)CH2N(CH2)2
9  R = (C H 2)CONHOK
10  R = (C H 2)CH(OH)CH2NH(CH2)2Br.HBr
11 R = (CH2)3NH(CH2)2Br.HBr
1.4 CHEMOSENSITISERS
Currently chemotherapeutic drugs that are in clinical use for the treatment o f cancer 
derive from the toxicity of the drugs to those cells, which are actively traversing the cell 
cycle. Unfortunately, the toxicity of such agents to proliferating cells o f normal tissues 
limits their use. Cycle-active agents are ineffective against quiescent tumour cells 
which, at the time o f treatment, may not be actively cycling but are capable of 
undergoing proliferation at a later stage, thus allowing the tumour to regrow1,6,7,19. The 
fact that hypoxic cells may have prolonged cell-cycle times or may be blocked in their 
progression through the Gi phase makes these cells relatively resistant to chemo­
10
therapeutic drugs that are directed towards proliferating cells1,6’7,19. Furthermore, 
pharmacodynamic considerations such as the drugs not diffusing into the tumour tissue, 
or that they are unstable or rapidly metabolised cause further complications in the 
treatment o f tumours. Because hypoxic cells are located in poorly vascularised regions 
makes drug accessibility very problematic, as these cells are usually located some 
distance away from the nearest microcapillary1,6,7,19. In some cases, molecular oxygen 
may be necessary for the energy requirement of a drug mechanism and, without it, the 
drug would be unable to exert its cytotoxic effect1,6,7,19. Furthermore, hypoxic cells tend 
to exist in an environment which is deficient in nutrients and is also relatively acidic. 
These differences in the cellular microenvironment o f hypoxic cells may further affect 
the proliferation patterns of such cells1,6,7,19.
The aim of chemotherapeutic drugs is to eradicate the tumour, with no or minimal toxic 
side effects to the host. In order to develop chemotherapeutic agents, various 
characteristics of tumours need to be considered such as whether the cells are 
proliferating, quiescent, clonogenic, non-clonogenic, well-oxygenated, slightly hypoxic 
or severely hypoxic1,6,7,19. In addition to this, both cellular and environmental factors 
need to be considered as they may contribute to the transition state of cells between 
subpopulations. Even though hypoxic cells are resistant to many chemotherapeutic 
agents, certain anticancer drugs have been found to be selectively toxic towards hypoxic 
cells. These include nitroimidazoles such as MDZ, RSU-1069, quinones such as 
mitomycin C (MMC, 12) and benzotriazine N-oxides such as SR 4233 (13).
c h 2o c o n h 2
OMe
NR2
12  R 1 = NH2i R2 = H
16  R 1 = NH2i R2 = Me




V N -C H 2CH(OH)CH2NH(CH2)2Br 
N 0 2
14  R = S  form
15  R = R  form
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MDZ was initially developed as a radiosensitiser but, in addition, showed chemo- 
sensitising properties. This drug and many other nitroimidazoles, were found to be 
selectively toxic towards hypoxic tumour cells1,19,26. Because hypoxic cells contain low 
oxygen concentrations, nitroimidazoles are capable of undergoing reductive metabolism 
to highly reactive electrophilic toxic agents1,6,7,19. The activation process is thought to 
be catalysed by flavoproteins such as NADPH cytochrome P450, NADPH cytochrome c 
reductase and xanthine oxidase. Therefore MDZ when activated by the reductase 
enzymes generates the first nitro-radical anion metabolite. This species under hypoxic 
conditions is reduced further to the nitroso, the hydoxylamine metabolite and eventually 
the amine. The reduction products that are formed during this process have been 
reported to bind to DNA, RNA and proteins, in addition to non-protein thiols such as 
glutathione26,27.
A number of biochemical alterations have also been reported to occur by MDZ 
intermediates including disturbances in electron transport pathways , reduction of non­
protein sulfhydryls29, inhibition of nucleotide uptake and DNA synthesis30, DNA single 
and double stranded breaks30, and increased cell-cycle times1.
In well-oxygenated cells, however, reductive metabolism of the drug leads to the 
formation of the nitro-radical anion. This species is veiy reactive towards oxygen, and 
under these conditions is oxidised back to the parent molecule.
MDZ has also been reported to sensitise mammalian cells to the cytotoxic effects of 
alkylating agents such as l-(2-chloroethyl)-3-cyclohexyll-nitrosourea (CCNU). It is 
thought that some of the chemosensitisation may be due to enhanced drug-induced 
cross-linking and also inhibition of CCNU metabolism by MDZ ‘ . In addition, the 
depletion o f cellular thiols by MDZ may also contribute to the chemopotentiation o f the 
alkylating agents34.
RSU-1069 has been reported to be about 80-fold more selectively toxic towards hypoxic 
cells than oxic cells35,36. This drug was found to be superior to MDZ and is also an
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effective radiosensitiser16. However, the high gastrointestinal toxicity observed in non- 
tumour-bearing mice limited the clinical usefulness o f this compound. The lower 
toxicity of RSU 1069 was achieved by using a prodrug of this compound, such as 
RB6145. RB 6145 is one of the most effective compounds in vivo that have been 
reported in this class. In the side-chain of RB 6145 is a P-carbon that exhibits chiral 
properties and so the compound can exist in two enantiomeric forms, which are PD- 
144871 (S) (14) and PD-144872 (R) (15). However, both o f these compounds have been 
found to be unsuitable for clinical use as they exhibited emesis side-effects37.
MMC is a bioreductive-alkylating agent which has been shown to be selectively toxic 
towards hypoxic cells1,19,38,39. Toxicity of this drug is induced with the formation of  
DNA-DNA cross-links and MMC monoadducts in DNA. This drug is biotransformed to 
the alkylating species via the one-electron reduction of the drug to a semiquinone, 
which, under hypoxic conditions, activates the C-l position o f the aziridine ring, 
resulting in the binding o f the drug to DNA1,19. After the initial covalent attachment of 
MMC to DNA at position N-2 o f guanine in DNA, the drug is thought to undergo further 
activation to produce a second alkylation site at the C-10 position. The bifunctionally 
alkylated MMC has recently been reported to fit snugly into the minor groove with 
minimal deformation of the helix and this feature is thought to make MMC cross-links 
difficult to recognize and repair in vivo40.
The activation of MMC is thought to be catalysed by several enzymes including 
xanthine oxidase and NADPH cytochrome P-450 reductase and toxicity o f this drug is 
observed following the one- or two-electron reduction product. In well-oxygenated 
cells, it appears that the oxygen prevents further reduction o f the MMC to the alkylating 
species by reacting with the one-electron reduction product to form both the parent 
compound and the superoxide radical1,6,7,19. The magnitude of the differential toxicity 
however, is dependant on the substrate specificities for the various reductases and on 
which reductive pathway occurs in the tumour cell line1,6,7,19.
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Under aerobic conditions, MMC has been shown to be activated chemically by mild 
acid. Under these conditions, the DNA adduct is formed at the N-7 of guanine which is 
different to that formed following reductive activation (N-2 of guanine). Similarly, 
studies carried out in cell culture have reported that the activity o f this drug is enhanced 
under acidic conditions and this leads to increased interstrand cross-linking by the 
drug1*7*41. This may prove to be significant with hypoxic tumour cells, because they may 
exist in an acidic environment and this feature o f such cells may be useful in enhancing 
the activity of the drug.
In this class of compounds, different toxicity is observed for compounds with different 
structures. For example, substitution at the aziridinyl nitrogen with a methyl group 
results in the analogue porfiromycin (16). This drug has been reported to exhibit greater 
selective toxicity to hypoxic cells than MMC. The cytotoxicity o f the drug is thought to 
be associated with the DNA cross-links that are formed42. Modification at position-7 of 
MMC, from the amino group to the amidine group results in compound BMY 25282 
(17), which shows increased selective toxicity towards aerobic cells in comparison to 
hypoxic cells43. This demonstrates that modification o f the structure o f MMC can alter 
the selectivity of these drugs.
The N-oxides such as the benzotriazine-N-oxide, tirapazamine (SR 4233), are also 
bioreductive alkylating agents that exhibit high selectivity for hypoxic cells. In fact, in 
some cases, differential toxicity ratios in some mouse cell lines are as high as 200-fold. 
These types o f compounds have an absolute requirement for one-electron reduction in 
order for toxicity to be expressed. The mechanism o f action is different to that reported 
for nitro compounds, in that it is the N-oxide radical anion species which causes toxicity 
by means of reacting directly with cellular macromolecules. It has been reported that 
hydrogen is abstracted from bases in DNA resulting in extensive single and double 
stranded breaks44,45.
In well-oxygenated cells, however, back-oxidation o f the nitroxide radical occurs, 
thereby reducing the number of toxic reactions that can occur. The enzymes involved in
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the bioreductive activation of tirapazamine are P450 reductase and P450 itself to give 
the toxic one-electron reduced product. The two-electron reductase DT diaphorase was 
also found to metabolise tirapazamine and it was thought that this constituted a 
detoxification reaction, as the toxic nitroxide radical is by-passed1,6.
1.5 BIOREDUCTIVE DRUGS
Another method of overcoming the resistance of hypoxic cells to both radiotherapy and 
chemotherapy is to eliminate the hypoxic cell population completely. This may be 
achieved by the use of bioreductive drugs. It has been proposed that bioreductive drugs 
would provide a bystander effect, by releasing a diffusible cytotoxin on activation by 
reductases, to utilise the hypoxic cells present in solid tumours. Bioreductive drugs can 
be divided into three domains that are the trigger, the effector and the linker. The trigger 
part of bioreductive compounds is responsible for activation o f the prodrug and is also 
required to inhibit the reduction by free oxygen when activated by reductases. If 
tumour-specific enzymes activate the drug, the trigger needs to be highly selective and if  
the drug is activated by radiation the trigger has to have potential as a reducing agent. 
Compounds that behave as triggers include nitro-aromatic compounds, quinones, 
aromatic N-oxides (as previously mentioned), nitrofuranyl prodrugs46 and transition 
metal complexes47,48.
Bioreductive drugs are prodrugs that are capable of distributing efficiently to the 
hypoxic regions of tumours, thereby undergoing selective metabolism in these areas to 
cytotoxic species. Prodrugs must therefore have minimal toxicity to aerobic cells, be 
able to withstand metabolism under these conditions and should possess good solubility 
characteristics47.
In order to improve aqueous solubility of a compound, basic functionalities (cationic 
charges) have been incorporated into a given drug. It was found that, in addition to 
providing solubilising potential, the basic functionalities also increased potency in cell 
cultures by inducing accumulation in cells. However, compounds that are positively
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charged (weak bases) have usually proved to be disappointing as bioreductive drugs in 
vivo47. Examples o f such compounds include NLA-1 (18), nitracine (19) and 5-NQ (20). 
It is thought that these compounds lack in vivo activity because the basic compounds 
may be sequestered into the low pH cellular organelles, such as lysosomes, or it may be 
due to the reversible binding to DNA that occurs with these types o f compounds. In 
both of these cases, the concentration of the free drug is lowered, thereby reducing the 
rates of passive diffusion through the tissue. A further problem, which may be 
encountered with these drugs, is that weak bases may be excluded from cells where the 
surrounding medium is at a low pH47.
The incorporation o f anionic groups (weak acids) to improve solubility characteristics 
has also been studied and it has been demonstrated that such compounds show 
preferential uptake in cells that exist in low external pH environments47. A recent study, 
which was carried out with 2,4-dinitrobenzamide mustards, demonstrated that the acid 
derivative (21) cytotoxicity was increased, by reducing the extracellular pH 
environment47.
2 N 0 2 NH (CH 2)3N M e2 N 0 2 NH(CH2)3N M e2 NO;
,C 0N H (C H 2)2C 0 2H
Bioreductive drugs can be activated by various enzyme activation systems. Most of the 
drugs that have been developed to date are activated by endogenous reducing enzymes, 
which are present in all cells. This process is common to nitro-aromatic compounds, 
transition metal complexes and to some quinone type compounds. In all of these cases, 
the mechanism of action results in the formation of a one-electron product, which can 
either be oxidised back to the parent compound in well-oxygenated cells, or can be 
reduced further to cytotoxic species in hypoxic cells. Recently, however, much of the
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attention has been focused on the activation of bioreductive drugs by endogenous 
tumour-specific enzymes. For example quinones such as MMC have been selectively 
activated by DT diaphorase, via the two-electron reduction, thereby passing the one- 
electron reduction product.
These studies have been extended to the use of tumour specific exogenous enzymes, 
which are capable o f activating bioreductive drugs, by deliberately introducing foreign 
enzymes into the cell population. One such approach is the antibody-directed enzyme- 
prodrug therapy (ADEPT)49, which uses tumour-specific antibodies in order to locate the 
foreign enzyme. A similar approach is the gene-directed enzyme-prodrug therapy 
(GDEPT)47, which involves the use of a foreign gene in order to generate the enzyme 
selectively.
Bioreductive drugs can also be activated by ionising radiation via the reducing species 
formed during the radiolysis of water. The advantage of this approach is that selectivity 
can be achieved by restricting the radiation field. This method o f drug activation results 
in the formation o f the one-electron reduced species and is independent of the expression
Anlevels of the reductive enzymes in tumour cells .
As previously mentioned, there is much evidence available to show that there are many 
compounds of diverse structure including the nitro aromatic compounds, quinones and 
N-oxides that can effectively kill mammalian hypoxic tumour cells. The similarity 
between all these compounds is that they all have to undergo enzyme-mediated 
reductive activation in order to express toxicity. Reductases that are involved in this 
process include xanthine oxidase, DT diaphorase, cytochrome P450 and NADPH- 
dependant cytochrome P450 reductase. The extent to which bioreduction of a drug will 
take place depends upon the ability of that drug to behave as a substrate for the 
intracellular reductase(s) and the expression levels o f these enzymes within a particular 
tumour cell type1,6,7,47. All these factors contribute to the differential cytotoxic 
efficiency observed in various cell lines and furthermore, they contribute to the extent of 
cytotoxicity observed between the oxic and hypoxic cells.
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Bioreductive drugs that are hypoxia-selective can also be combined with other 
treatments in therapy to target the surviving aerobic cell populations. The antitumour 
effectiveness of tirapazamine and RB6145 / RSU1069 has been demonstrated when 
these agents are used in combination with single high doses o f X-rays. Radiation 
therapy kills the well-oxygenated cells, whilst administration o f the bioreductive drug 
following irradiation reduces the number of hypoxic cells, thus improving tumour
1,6,7, 15,22response .
A further method for inducing tumour hypoxia and therefore increasing bioreductive 
drug activity is to inhibit the action o f the enzyme nitric oxide (NO) synthetase. Nitric 
oxide is the endogenous ’endothelial-relaxation' factor that is responsible for controlling 
or influencing the various processes involved in the function of normal endothelium50,51. 
It is thought that prodrugs that yield NOS inhibitors after hypoxia-mediated reductive 
activation maybe useful in the treatment of cancers .
Due to the assumption that hypoxic cells limit the effectiveness of both radiotherapy and 
chemotherapy, much of the earlier work was focused on designing experiments to 
eliminate hypoxic cells either by killing or by eliminating the selective protection of 
hypoxic cells7,53. Experiments involving irradiation schedules, minimising the 
importance of hypoxic cells have been proposed and tested1,7,54. Attempts to improve 
tumour oxygenation by the use o f radiotherapy combined with hyperbaric oxygen7,55,56, 
with oxygen and carbogen breathing57,58, and with oxygenated perfluorochemical 
emulsions59 have been developed. In addition, patients with low haemoglobin levels 
have been transfused prior to radiotherapy in order to improve tumour oxygenation60,61. 
An alternative approach reported that deliberate regional hypoxia was used to make the 
tumour and normal tissue equally hypoxic so that they were uniformly radioresistant62.
7  1AExperiments involving hypoxic cell radiosensitisers ’ have been reported, and high 
LET radiotherapy has also been developed . Many other approaches including
1 1 ^  77 •adjunctive therapy with bioreductive alkylating agents ’ ’ , mtroheterocyclic
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radiosensitisers16, and hypothermia64 have also been developed in order to exploit the 
selective toxicity of these agents to hypoxic cells.
The majority o f the studies that have been carried out over the last fifty years to target 
hypoxic regions of solid tumours have focused on the development of electron-affinic 
radiosensitisers and bioreductively activated cytotoxins.
Naylor et al65, in 1990, developed novel nitrofuran-carboxamides and -carboxylates as 
radiosensitisers and bioreductively activated cytotoxins. As previously mentioned, 
nitroheterocyclic compounds act as radiosensitisers. This is a fast free-radical process 
that is dependent upon the one-electron reduction potential. Furthermore, nitro 
compounds are capable o f undergoing reductive metabolism to form highly potent 
cytotoxins. This process tends to occur in hypoxic tissues therefore, it is thought that 
such compounds may be specific to poorly oxygenated solid tumours. Although 
radiosensitisation and bioreductive activation occurs via different mechanisms both 
effects are related to the compounds reduction potential. This to some extent provides a 
basis for selective cancer chemotherapy. A series of 5-nitrofuran-2- and -3- 
carboxamides with various alkylating side chains have been developed which have been 
found to be effective as radiosensitisers o f Chinese hamster cells (VI9) in vitro. 
However, these compounds were found to be ineffective against KHT sarcomas in C3H 
mice.
Jenkins et al24 in 1990 reported the development o f a prodrug o f RSU1069, which was 
the haloethylamine RB6145. This compound as previously mentioned was found to be 
superior to RSU1069, but less toxic and was able to act as both a radiosensitiser and a 
cytotoxin.
Similarly, Naylor et a f 6, in 1992, developed a series of 2-nitroimidazole compounds 
with various side chains containing aziridinyl and or oxiranyl groups to behave as both a 
radiosensitiser and a cytotoxin. Although some o f the compounds developed were o f  
similar activity to RSU1069, none were taken forward into clinical evaluation.
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More recently however, work has been carried out on indolequinone type compounds as
fslhypoxia selective cytotoxins and radiosensitisers .
From the various studies carried out, it can be seen that much work has been carried out 
to find the most therapeutically beneficial hypoxic cell radiosensitiser and cytotoxin. 
However, little attention has been focused on exploiting the physiological difference in 
oxygen concentration between the normal and hypoxic tumour tissues.
Sykes et a t 8’69, in 1995, carried out a number of studies on a bioreductively triggered 
system which was based on 2-nitroarylamides. It was demonstrated that, when 
activated, aminoaniline mustard alkylating agents were selectively released from the 2- 
nitroarylamide. Similarly, they reported the release o f N-hydroxylactam and an amine- 
bearing mustard via a cyclisation reaction when the nitroamide is activated.
Even more recently, Berry et al70 demonstrated the 5-nitrofuran-2-ylmethyl group as a 
bioreductively activated prodrug system. Similarly, Everett et al71 reported the release 
of aspirin and salicylic acid from the 2-nitroimidazol-5-methylene moiety. In both of 
the above cases, the release mechanism is very similar in that, following reduction, the 
nitro moiety is reduced to the amino group. The lone pair of electrons on the amino 
group allow fragmentation and the drug is selectively released. In the case of the 
nitroimidazole compounds, the drug is attached to the trigger moiety via the 5- 
ylmethylene group.
It was hypothesised that upon selective bioreduction in hypoxic tumour tissue, the 
trigger part of the prodrug would release therapeutic drugs only in that tissue. This was 
thought to greatly improve the selectivity of the biodistribution o f these types of 
compounds. Many studies have been carried out on 1-substituted 2-nitroimidazoles and 
it has been demonstrated that such agents are selectively bioreduced in poorly 
vascularised hypoxic tumour tissues72,73. In this study, 1-substituted 2-nitroimidazole 
compounds were selected as the bioreducible moiety because they tend to show greater
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metabolic stability in normal tissues and they also exhibit a wide range o f redox 
potentials. These types of compounds are widely used in medicines and many o f them 
have been found to be effective radiosensitisers and cytotoxins.
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2.0 POLY(ADP-RIBOSE) POLYMERASE
Poly(ADP-ribose) polymerase (PARP) (also known as poly(ADP-ribose) synthetase 
(PARS)) is a multifunctional homodimeric enzyme that is found in all eukaryotic 
cells ranging from protozoa to mammals74. 95% o f the enzyme is found in the 
nucleus, where it is tightly bound to chromatin. Each mammalian cell nucleus has 
been reported to contain approximately one million copies o f PARP. However, 
terminally differentiated cells, such as mature granulocytes, epidermal cells and 
intestinal cells, lack this enzyme. PARP was purified as early as 1977 from rat liver 
nuclei75.
Human PARP comprises o f a single polypeptide chain o f 1014 amino acid residues, 
o f molecular weight ~113 KDa. The location o f the gene encoding human PARP has 
been recently identified in chromosome Iq41-q4276. When PARP is activated, the 
enzyme catalyses the transfer o f ADP-ribose units from its substrate nicotinamide 
adenine dinucleotide (NAD*) to a number o f acceptor proteins. These may be 
nuclear proteins involved in chromatin architecture and DNA metabolism 
(heteromodification) or PARP itself (automodification)74. Despite all the research on 
PARP in the last 30 years, its precise biological role is not yet clear. However, it is 
known that PARP plays an important role in the repair o f DNA damage and it is this 
property o f PARP that has led researchers to target this enzyme by means o f  
chemosensitisers and radiosensitisers.
Interestingly, since PARP was discovered, it had been accepted that there was only 
one type o f PARP in each species. However, this view has now been challenged by 
the discovery of novel poly(ADP-ribosyl)ating enzymes77'79. These new PARPs 
have been classified into two subgroups according to their size. Type II PARPs are 
smaller than the generally accepted PARP and, in some cases, show nuclear
77localisation . These PARPs have been found to be present in organisms such as 
archaea79, plants77 and mammals80. Type ID PARPs, on the other hand, are large 
proteins containing ankyrin repeats and a PARP catalytic domain78. The only 
member o f this subgroup to be reported is the human protein tankyrase78. This is 
likely to be found in higher eukaryotes78. Currently, very little information is 
available on the new-found PARPs. At this moment, it is assumed that they
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contribute only modestly to the poly(ADP-ribosyl)ation potential o f higher 
eukaryotes. Their discovery has led to the concept that they maybe involved in 
specific nuclear functions requiring only limited levels o f poly(ADP-ribosyl)ation. 
Its thought that these new PARPs were not previously detected because their 
activities were masked by the very active and abundant PARP1. However, in this 
thesis, only the active abundant PARP1 o f 113 KDa will be discussed.
In 1984, Kameshita et identified the three functional domains o f PARP. These 
are the N-terminal DNA-binding domain, the central automodification domain and 
the C-terminal catalytic domain. These were separated from each other by limited 
proteolysis with a-chymotrypsin and papain. In short, cleaving the enzyme gave two 
fragments o f Mr 54 KDa and 66 KDa. The 54 KDa fragment was found to contain 
the substrate-binding site, as it was protected by the addition o f the substrate NAD+, 
or its analogue nicotinamide. The 66 KDa fragment was further cleaved into two 
fragments o f Mr 46 KDa and 22 KDa. The 46 KDa fragment was found to be bound 
to the DNA-cellulose column, with the 22 KDa fragment having little affinity for the 
DNA ligand. These results suggested that there were three domains, the first one 
being the NAD+-binding site, the second being the DNA-binding site and the third
O I
domain behaving as the site(s) for accepting poly(ADP-ribose) . Each o f the 
domains will now be discussed in detail.
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2.1.1 THE DNA BINDING DOMAIN (DBD)
The N-terminal DNA-binding domain o f Mr 46 KDa extends from methionine-1 to
O '}  O ' t  O A
threonine-373 in human PARP * . This domain contains two putative Zn fingers
O / 0*7 OO
in the N-terminal region and two helix-tum-helix motifs ’ . Furthermore, the 
DBD also contains a high proportion o f basic residues, which are thought to be 
involved in the interaction o f the enzyme with the DNA.
PARP is a metalloenzyme, in which each Zn is bonded to one histidine and three 
cysteine residues in the form of Cys-X2-Cys-28-30-His-X2-Cys. The first Zn finger 
(FI), beginning with Cys-21 and ending with Cys-56, consists o f  28 residues and is 
electrically neutral (three basic and three acidic residues). The second Zn finger (F2) 
starts at Cys-125 and ends at Cys-162. This finger comprises o f  30 residues and is 
basic overall (seven basic and five acidic residues).
PARP is activated by the presence o f DNA strand breaks. Footprinting 
experiments89 have shown that PARP prefers to bind symmetrically at DNA strand 
breaks, subsequently covering seven or eight nucleotide residues on each side o f the 
break. At the site o f a single stranded break (SSB), a V-shaped bend was observed 
when PARP (located at the kink) bound to the DNA break90. Many studies have 
been carried out in order to clarify the role of the two Zn fingers o f PARP84’86. 
Ikejima et a f x reported that both Zn fingers were required for PARP catalytic 
activity at SSBs, whereas activation by double stranded DNA breaks (DSBs) only 
required the first Zn finger. Therefore, FI is thought to be responsible for PARP 
activation whereas F2 is responsible for the detection o f DNA strand breaks. These 
results however, were in contrast to those o f de Murcia et a ? 1 who reported that F2 
was necessary for PARP catalytic activity in SSBs, whereas FI was responsible for 
the binding o f the enzyme to the breaks.
The DBD also contains a bipartite nuclear location signal (NLS), which is 
responsible for the transportation o f PARP into the nucleus. 95% o f the enzyme is 
found in the nucleus. The NLS is able to target proteins larger than 40 to 60 KDa to 
the cell nucleus. It is a short amino acid sequence rich in basic residues (207-226) o f
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the form KRK-Xn-KKKSKK. Site-directed mutagenesis93 revealed that the two 
basic clusters (D1 and D2) are both necessary for the transportation o f PARP.
A further feature present in the DBD region was the presence o f a 36 KDa fragment 
(derived from limited proteolysis)94 extending between amino acids 233 and 525. 
This domain contains the whole automodification domain and part o f the DBD80,82. 
Analysis o f this domain revealed the presence o f two helix-tum-helix motifs at 
residues ~ 200-220 and 280-285. It is thought that this helix-tum-helix motif is able 
to mediate strong interactions between DNA and proteins80.
2.1.2 THE AUTOMODIFICATION DOMAIN
This 22 KDa central automodification domain o f PARP is located between residues 
374 and 52582,83. Analysis o f this region revealed that this domain is basic and 
comprises o f most o f the 15 glutamic acid residues that are thought to be involved in
oa or Qf
PARP automodification ’ ’ . Interestingly, antibodies directed against this region 
were found to inhibit half o f the automodification reaction, thus confirming that at 
least half o f the residues that serve as acceptors are located in this domain.
The automodification reaction was initially thought to be intramolecular. This 
assumption suggested that the direction o f chain elongation would occur at the 
enzyme-proximal end. It was difficult however, to envisage a single polypeptide 
chain catalysing the simultaneous ADP-ribose chain elongation o f 15 to 28 units in 
an intramolecular mechanism96. However, Mendoza-Alvarez and Alvarez- 
Gonzalez96 reported that ADP-ribose chain elongation occurred at the protein-distal 
end o f the polymer. These results indicated that the automodification reaction was, 
in fact, intermolecular and the two monomeric units o f PARP function 
simultaneously as catalyst and acceptor molecules.
This domain also comprises o f a BRCT (BRCA1 C-terminus) domain that extends 
from amino acids 384 to 47997. This domain comprises o f about 95 (weakly 
conserved) amino acids found in proteins that have been shown to regulate cell-cycle
QA
checkpoints and DNA repair . These BRCT domains are thought to be protein- 
protein interactions that allow BRCT containing proteins to have strong and specific
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associations98. Recently BRCT-mediated interactions between the BRCT domain of 
ligase in  and the second (C-terminal) BRCT domain o f XRCC1 have been identified 
and found to be responsible for the formation o f a DNA-base-excision-repair (BER) 
complex99’100.
2.1.3 THE CATALYTIC DOMAIN
The 54 KDa catalytic domain is located in the C-terminal region o f the enzyme and 
extends from residues 526 to 1014 in human PARP82’83’101. The catalytic activity o f  
this domain is independent o f DNA strand breaks. The basal activity is the same as 
that o f full length PARP. This domain comprises the ‘minimal catalytic domain’ 
which catalyses the initiation, elongation and branching o f (ADP-ribose) polymers, 
in the absence o f DNA strand breaks. Simonin et alm  demonstrated that the loss of 
the last 45 amino acids in the C-terminal end o f this domain would abolish activity. 
In human PARP, residues 859-908 are conserved and comprise the area known as the 
‘PARP signature’.
The catalytic domain o f PARP appears to be very similar in structure to mono(ADP- 
ribosyl)ating enzymes. Studies o f both PARP and mono(ADP-ribosyl)transferases 
have suggested that residue Glu-988 is necessary for PARP activity. Mutation 
studies103 o f this residue resulted in a decrease o f the elongation o f the polymer 
2000-fold, and, in addition, reduced (although to a lesser extent) the initiation o f new 
chains o f ADP-ribose. The structure o f the catalytic domain o f chicken PARP 
complexed to an inhibitor has been elucidated by X-ray diffraction104. It was found 
that the active site appeared to consist o f a P-a-loop-p-a motif that was present also 
in mono(ADP-ribosyl)transferases and is thought to be responsible for NAD+ 
binding. Furthermore by photoinsertion105 o f a NAD+ analogue it was shown that 
NAD+ associates with Lys-893 and Trp-1014. However, Trp-1014 was not 
necessary for PARP activity, as was demonstrated in mutation studies80.
2.2.1 MECHANISM OF ACTION OF PARP
DNA damage by chemotherapy or radiotherapy results in the activation o f PARP80. 
In response to this damage, PARP catalyses the transfer o f ADP-ribose from its
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substrate NAD+ to nucleophilic acceptor sites on DNA-associated proteins74,80. This 
maybe PARP itself (automodification), histones (heteromodification), HMG 
proteins, topoisomerases, DNA polymerases and ligases74,80. This results in the 
release o f nicotinamide. PARP then transfers and links the ADP-ribose portion to 
the mono(ADP-ribosyl)ated protein via a ( l ”->2’) glycosidic bond to synthesise a 
straight chain74,80. Branching may occur at every 30-50 residues95,106 with a ribosyl 
( l ”’->2”) bond causing branch formation. PARP then appears to lose its affinity for 
DNA. The precise mechanism is not yet known but it has been suggested that 
electrostatic repulsions occur between the highly negatively charged poly(ADP- 
ribose) chains resulting in dissociation o f PARP from the DNA strands. The (ADP- 
ribose) polymers are broken down by the enzyme poly(ADP-ribose) glycohydrolase 
(PARG) to ADP-ribose units. These are removed from the protein by ADP-ribosyl 
protein lyase, subsequently returning PARP to its original form74,80.
2.2.2 MODIFICATION OF THE CHROMATIN STRUCTURE
The two enzymes PARP and PARG have been reported to modify the chromatin 
structure during DNA repair80. It has been proposed that, when DNA is damaged, 
PARP binds to the strand breaks resulting in the activation o f the enzyme. This in 
turn, results in the rapid shuttling o f PARP from DNA strand breaks. After the 
histones are modified (HI, H2B, H2A, H3 and H4) the chromatin structure opens. 
The enzyme PARG then enters the nucleus, resulting in a rapid turnover o f the 
polymer. The chromatin structure remains in a decondensed state. Finally, DNA 
damage is repaired; polymer levels are reduced due to the presence o f PARG and
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chromatin returns to its original conformation. Similarly, Althaus also postulated 
that a shuttle mechanism for chromatin exists in which relaxation o f its structure 
facilitates DNA BER.
2.3 POLY (ADP-RIBOSE) GLYCOHYDROLASE (PARG)
This is the most important enzyme required for the breakdown o f  poly(ADP-ribose) 
chains. It is a monomeric protein o f Mr 59 KDa80. It has been reported that PARG 
prefers to breakdown longer chains (>20 ADP-ribose residues) and that they are
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degraded rapidly, as opposed to smaller chains, which are degraded much less 
efficiently80’108.
2.4 MONO- AND POLY(ADP-RIBOSYL)ATION
Living organisms are able to modify their protein structures and functions by ADP- 
ribosylation reactions. The two main types o f ADP-ribosylation reactions that occur 
are mono(ADP-ribosyl)ation and poly(ADP-ribosyl)ation109.
Mono(ADP-ribosyl) transferases are enzymes that are able to transfer a single unit o f  
ADP-ribose from NAD+ to acceptor proteins. These enzymes have been found in 
both eukaryotes and procaryotes106,109. Bacterial toxins that are mono(ADP-ribosyl) 
transferases are capable o f modifying specific acceptor sites on their target proteins. 
Diphtheria toxin and pseudomonas exotoxin A 106,109 have been shown to mono(ADP- 
ribosyl)ate a modified histidine residue o f elongation factor 2. Cholera toxin A and 
Escherichia coli heat-labile toxin106,109 specifically modify an arginine residue o f a 
GTP-binding protein (GSa) and the pertussin toxin106,109 carries out mono(ADP- 
ribosyl)ation of a cysteine residue.
2.5 FUNCTIONS OF PARP
The physiological function o f PARP and poly(ADP-ribosyl)ation is still under heavy 
debate. However, with the use o f pharmacological inhibitors o f PARP, the enzyme 
has been shown to regulate various processes including cellular differentiation74,80, 
viral replication110, apoptosis80,111'115, inflammation and ischaemia reperfusion 
injuries80,116,117. The role o f PARP in some o f these processes will now be discussed.
2.5.1 ROLE OF PARP IN VIRAL REPLICATION
Gaken et alno established that inhibition o f PARP blocked the entrance of the 
infected retrovirus into mammalian cells. From the various methods used to inhibit 
PARP, it was demonstrated that inhibition occurred in the step in which the retroviral 
DNA is introduced into the host genome110 It seems that PARP acts with the virus-
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encoded integrase protein (IN) in order to incorporate the viral genome into the host 
genome.
2.5.2 ROLE OF PARP IN APOPTOSIS
Apoptosis is an active form o f cell death that occurs in both normal and tumour cells. 
It can be triggered physiologically and pathologically when the cells are under mild 
stress80. It is different to the passive cell death that results from high doses o f  
damage to the cell, known as necrosis. When under mild stress, apoptosis can be 
blocked by inhibitors, subsequently increasing cell survival80,111. Apoptosis is 
thought by many scientists to be a mechanism useful in the process o f eliminating 
potentially mutant cells that have been sub-lethally hit by a DNA-damaging agent. It 
is thought that PARP may then translate this DNA damage into a message o f cell 
suicide. In general, apoptosis has attracted a lot o f interest. This is because it is 
thought that dysregulation o f apoptosis may lead to diseases such as cancer, arthritis 
and diabetes. Unfortunately, the exact events involved in apoptosis are not yet fully 
known80,111.
It is, however, known that, for the apoptosis process to be completed, it requires 
^Tp80112-1 is When genotoxic agents damage DNA, PARP is activated. As PARP 
uses its substrate NAD+ in poly(ADP-ribosyl)ation reactions, these levels are 
significantly reduced, thus depleting the ATP levels in cells and the dGTP levels. As 
a result those cells which are in the apoptotic stages cannot complete their course o f  
action due to the lack o f ATP, resulting in the apoptotic cells switching to the 
necrotic pathway. Necrotic cells have been found to be the main cause o f cellular 
damage associated with ischaemia and inflammation80,116,117. Because o f these 
effects, apoptosis is the favoured means o f cell death. Interestingly, it has been 
demonstrated that, even in cases o f little cellular damage, PARP still uses large 
amounts o f NAD+, thus depleting the levels o f ATP drastically.
Recently, there has been evidence80,115 put forward suggesting that eukaryotic cells 
have developed a mechanism to protect themselves from switching over to the 
necrotic pathway. It was shown that about 30 min after the induction o f apoptosis, 
death proteases known as caspases cleave PARP in its bipartite NLS (DEVD214 /
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G215) to give a 24 KDa DNA-binding fragment and an 89 KDa catalytic 
fragment80,115. This inactivates the catalytic activity o f PARP, thus preventing the 
apoptotic cells turning necrotic. This mechanism, however only appears to function 
in the presence o f moderate levels o f DNA damage.
Many studies112,113,116 have demonstrated that reactive free radical species and 
peroxynitrite induce apoptosis in various cell types. It seems that sudden exposure to 
high concentrations cause cell necrosis, whereas sustained exposure or low levels o f  
peroxynitrite induce apoptosis. Nitric oxide, a precursor o f  peroxynitrite, in low 
concentrations has been shown to inhibit apoptosis, whereas exposure to high levels 
o f NO has been reported to cause apoptosis.
From the various experiments118,119 carried out with PARP inhibitors, the results 
appear to be conflicting. The PARP inhibitors 3-aminobenzamide (3-AB) and 
nicotinamide have been shown to reduce NO-induced apoptosis. However, in the 
case o f  raw murine macrophages, these inhibitors were reported to be ineffective in 
blocking apoptosis118,119. It is thought that the reason for this maybe because NO- 
induced apoptosis is mediated through a mechanism which is different to that of  
potent DNA single-strand-breaking agents, such as peroxynitrite.
2.5.3 ROLE OF PARP IN INFLAMMATION
Peroxynitrite and hydroxyl radicals are also known to induce various forms of 
inflammation116,117. As previously mentioned, they are potent DNA strand-breaking 
reagents that activate PARP. In response to DNA damage, PARP depletes the 
concentration o f its substrate NAD+, which, in turn, depletes ATP levels and dGTP 
levels, subsequently slowing down glycolysis, electron-transport and ATP formation. 
As a consequence o f this cell necrosis and cell dysfunction are known to occur. In 
addition to this, PARP also appears to modulate the course o f  inflammation by 
regulating the expression o f a number o f genes, which includes collagenase and the 
inducible nitric oxide synthase116,117. PARP inhibitors are therefore thought to be 
useful by protecting against cell death under these conditions116,117.
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Experiments116,117 in vivo have demonstrated that PARP inhibition by 3-AB delayed 
the onset o f streptozotocin- and alloxan-induced diabetes. Similarly, with the use o f
■I
the nicotinamide inhibitor, the extent o f obesity-associated diabetes was reduced . 
Inhibition with 3-AB has also been shown to reduce oedema formation, and suppress
191 1 9 9the development o f rheumatoid arthritis m rodent models ’ .
2.5.4 ROLE OF PARP IN ISCHAEMIA-REPERFUSION INJURY
The fact that hydroxyl radicals and peroxynitrite trigger PARP activation has also 
been well established in the pathogenesis o f ischaemia-reperfusion injury. For
1 91
example, peroxynitrite generation has been demonstrated in the reperfused heart , 
kidney124, brain125, and lung126. In such cases, inhibition o f peroxynitrite generation 
by inhibiting NO biosynthesis has been shown to reduce reperfusion injury, 
modestly125. Even though these reactive species are exerting cytotoxic effects, the 
activation of PARP appears to result in major cellular injury.
Recently, a number o f studies127'129 have shown that inhibition o f PARP results in 
protective effects in animal models o f stroke127, myocardial ischaemia-reperfusion128
1 90and splanchnic ischaemia-reperfusion .
However, it is also known that severe haemorrhage and resuscitation leads to organ 
ischaemia. Oxygen-derived free-radicals are generated upon reperfusion leading to 
DNA strand breaks and subsequently PARP activation. 3-AB has previously been 
shown to reduce the circularatory effect and the organ dysfunction / injury by 
inhibition o f PARP130,131. Due to the solubility problems encountered with 3-AB, an 
alternative PARP inhibitor was required. Recently, McDonald et alU2 reported that 
5-aminoisoquinolinone (5-AIQ, a potent PARP inhibitor) abolished the multiple 
organ injury caused by severe haemorrhage and resuscitation. Following this work, 
McDonald and co-workers extended their studies to the effect o f 5-AIQ on cardiac 
myoblasts. They found that inhibition o f PARP in cardiac myoblasts resulted in the 
reduction o f the myocardial infarct size in rats, in vivo. These results highlight the 
potential o f such inhibitors in conditions associated with myocardial ischaemia and 
reperfusion (C. Thiemermann and M. D. Threadgill, personal communication).
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2.5.5 ROLE OF PARP IN DNA REPAIR
In living cells, DNA repair is known to occur via several mechanisms. Although the 
enzyme PARP is known to be involved in DNA BER , its precise mechanism 
remains to be elucidated. However, previous studies have demonstrated that 
poly(ADP-ribosylation) is not involved in the excision o f  the damaged bases80,134 nor
oa  i i r
in the resynthesis o f DNA after excision ’ . Some models have been proposed to
explain PARP’s role in DNA repair:
(1) The Recruiting Model
As PARP is one o f the first enzymes to be aware o f DNA damage, it is thought to be 
in the perfect position to recruit the DNA (base excision) repair enzymes to the sites 
o f damage. This theory has been supported by several authors who have identified a 
BER complex comprising o f PARP, XRCC1, DNA ligase IE and DNA polymerase 
p80,99,ioo,i36 xRCCl has been poly(ADP-ribosyl)ated in vitro, it is plausible that 
PARP may regulate the activity o f the complex by modifying XRCCl activity in 
vivo'00’'36. This would subsequently prevent it from reacting with other components 
o f the complex. It is not known whether other components o f the complex are 
poly(ADP-ribosyl)ated. The stoichiometry for this complex is thought important for 
regulation o f PARP activity. When XRCCl and DNA ligase HI are in excess over
QA
PARP, they were shown to inhibit PARP activity, in vitro . DNA ligase IE is 
thought to inhibit via a competitive mechanism as both enzymes share similar zinc 
fingers. It has been proposed that DNA repair factors maybe recruited by PARP 
through modification o f the chromatin proteins. As a result o f this, the long chains o f  
poly(ADP-ribose) would be able to target repair enzymes to DNA damaged sites 
much faster than if  they had to find their own way. The recruiting model implies that 
PARP acts before / and or after the excision o f damaged bases80.
(2) The Anti-Recombination Model
1 77This model was proposed by Satoh and Lindahl , who reported that PARP inhibits 
DNA repair, thus preventing DNA recombination. The poly(ADP-ribosyl)ation of 
neighbouring proteins and PARPs association with DNA breaks would allow PARP
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to protect DNA ends from nuclease / and or DNA strand exchange activities 
necessary for recombination. This theory was supported in PARP' ' double-knockout 
animals, which revealed that recombination was stimulated in the absence o f PARP,
11Rresulting in increased incidence o f lymphomas .
Recently, PARP was found to be present in a multi-protein complex that is able to 
perform DNA recombination activities80,139. Interestingly, three o f the components 
of this complex including numatrin/B23140, nucleolin/C23141 and PARP itself have 
been shown to be modified by poly(ADP-ribosyl)ation. It has been proposed that, by 
poly(ADP-ribosyl)ating its components, the enzyme may be able to regulate the 
activity o f the complex.
(3) The Chromatin-Dependent Model
The fact that histones are poly(ADP-ribosyl)ated in response to DNA damage 
suggested that PARP plays an important role in the repair o f DNA, when the DNA is 
structured in chromatin80,142,143. When PARP is activated by DNA damage, the 
chromatin structure opens because o f poly(ADP-ribosyl)ation o f histones resulting in 
the disruption o f the chromatin structure, which is necessary for the repair o f highly 
condensed chromatin. This is consistent with the fact that, in the absence o f PARP, 
DNA repair in the condensed chromatin structure is less efficient than the repair in
o n
the open chromatin structure . This is because DNA proteins and transcription 
factors are able to access the site o f damage. In a similar fashion, PARP would be 
able to facilitate DNA repair by alleviating steric congestion caused by packed 
chromatin, subsequently allowing DNA repair factors access.
(4) The Signalling Model
It has been reported that PARP could stimulate DNA repair and ensure genomic 
stability by signalling the presence o f DNA lesions to effectors downstream involved 
in co-ordinating the cellular responses to DNA damage80,144,145. It’s thought that the 
modification o f PARP and histones at sites o f DNA damage could act as a strong 
signal activating signalling molecules and or repair machinery. This model was 
proposed following the observation that poly(ADP-ribosyl)ation reactions are
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involved in p53 regulatory functions. It has been reported that PARP inhibition
OA
suppressed the accumulation o f p53, in response to ionising radiation . p53 is 
known to be a key factor o f Gi arrest and is also involved, to a lesser extent, in G2 
arrest. In the absence o f PARP activity, lesions may remain undetected before DNA 
replication, resulting in further damage during the S phase, subsequently arresting at 
the G2 phase. It is thought that induction o f the p5 3-induced cell cycle by poly(ADP-
on
nbosyl)ation may allow the necessary time required for these lesions to be repaired .
However, it is not yet known how PARP regulates p53. It is thought that, as p53 is 
able to interact strongly and non-covalently with ADP-ribose polymers, it is 
plausible that poly(ADP-ribosyl)ation reactions at DNA damaged sites may provide 
a strong signal to direct signalling factors or p53 to the sites o f damage in the 
nucleus80. The breakdown o f these poly(ADP-ribose) polymers by the enzyme 
PARG would allow p53 to perform efficiently its signalling functions at the site o f  
damage. PARP is also known to directly interact with p53 and it has been proposed 
that this interaction may regulate p53, either by modification o f its functional 
properties or by recruiting them to the sites o f DNA damage80.
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1A INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE
With the discovery that poly(ADP-ribose) polymerase appears to be involved in 
DNA excision repair, came the notion that inhibitors o f  PARP may be capable o f  
potentiating the cytotoxicity o f both DNA-damaging agents and radiotherapy. Such 
compounds are o f particular interest because they are prime targets for the design of 
chemosensitisers and radiosensitisers in the treatment o f  cancer.
Many studies have been reported that have used either monofunctional alkylating 
agents or ionising radiation to determine PARP’s involvement in the repair o f DNA 
damage74-146.
3.1.1 CHEMOSENSITISATION
Chemosensitisers are compounds that sensitise tumour cells to the cytotoxic effects 
o f DNA-damaging drugs. Thus, inhibitors o f PARP are thought to be useful in 
chemotherapy.
Durkacz et alu l, in 1980, demonstrated, with the use o f 3-AB, that PARP inhibition 
potentiated cytotoxicity o f the alkylating agent dimethyl sulfate (DMS) in L1210 
mouse leukaemia lymphoblast cells. Similar results were also reported by other 
studies74,146,147 using alkylating agents such as DMS and N-methyl-N-nitrosourea to 
potentiate DNA damage in various cell lines. More recent studies include that o f  
Weltin et a /148, who reported that 6(5H)-phenanthridinone, in combination with the 
alkylating agent N,N-bis(2-chloroethyl)methylamine (HN2) significantly reduced the 
proliferation o f RDM4 murine lymphoma cells. This demonstrates the involvement 
o f PARP in the proliferation o f lymphoma cells.
Griffin et a/149, in 1998, enhanced the cytotoxicity o f the alkylating agent 5-(3- 
methyltriazen-l-yl)imidazole-4-carboxamide (MTIC) 3.5-fold against L1210 murine 
leukaemia cells by inhibition o f PARP. This was achieved by the novel 8-hydroxy-
2-methylquinazolin-4-one (NU 1025) inhibitor. The cytotoxicity o f the alkylating
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agent was potentiated in a concentration-dependant manner and the PARP inhibitor 
was found to be 50-fold more potent as a chemopotentiator than 3-AB.
More recently White et a l150 found that, in vitro, the novel compound 2-(4- 
hydroxyphenyl)-lH-benzimidazole-4-carboxamide was able to potentiate the 
cytotoxicity o f both temozolomide (TM) and topotecan (TP) against A2780 cells 2.8 
and 2.9 fold, respectively. These results have proved promising in the use o f such 
compounds as chemosensitisers. Following this work, Delaney et al151 extended 
these studies to human tumour cell lines (lung, colon, ovary and breast cancer). It 
was reported that both compounds NU 1025 and NU 1085 were able to enhance the 
cytotoxicity o f TM and TP in the various tumour cell lines and furthermore they 
were used at concentrations, which were not toxic to the cell.
Although these recent in vitro studies seem promising, activities in vivo remain to be 
seen. The problem with many o f these compounds is that they lack specificity and, 
consequently, when inhibitors are used in vivo studies, they tend to cause other 
cellular disruptions146. This makes it difficult to determine if  the sensitisation 
observed is due to PARP inhibition or to other cellular defects. For example, 3-AB 
has been used in vivo to potentiate the cytotoxicity against Erhlich ascites tumour for 
bleomycin and cisplatin146,152,153. At the doses which have been used, it is not known 
whether the cytotoxicity is due to PARP inhibition or whether it is the hypothermic 
effect observed when such doses o f inhibitors are used.
3.1.2 RADIOSENSITISATION
Radiosensitisers are compounds that sensitise tumour cells to radiotherapy by 
inhibiting PARP. Currently, the problem with radiotherapy is that it involves the use 
of daily low X-ray doses to minimise the normal tissue damage and also to allow 
tumour reoxygenation between doses. This has proved problematic, because 
extensive repair has been known to occur between X-ray doses. Inhibitors o f PARP 
are therefore thought to be useful as radiosensitisers, because o f their ability to 
inhibit the DNA repair mechanism.
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As in the case o f chemosensitisers, many studies have been carried out in order to 
potentiate the cytotoxicity o f cells to X-ray and y-radiation74,146,149,154. Earlier studies 
used nicotinamide and 3-AB to enhance DNA damage. Both o f these inhibitors have 
been shown to potentiate damage in plateau V79 Chinese hamster cells but not in log 
phase cells146. However, earlier studies involving PARP inhibitors only reported a 
slight increase in cell killing, or in some cases none at all111,74,146. This was thought to 
be due to the insufficient time allowed for the inhibitor to be taken up by the cells, or 
the low concentrations o f the inhibitors used11,74,146. Furthermore, it was found that 
following irradiation the effect o f the inhibitor should be measured within two hours, 
as this was the time when PARP was thought to be most active11,146. Following these 
observations, studies were carried out using higher inhibitor concentrations, for 
shorter periods o f time and consequently, these were found to be more 
successful11,146.
More recently, Griffin et al149 reported that the resistance modifying agent NU 1025 
enhanced the cytotoxicity o f 5-(3-methyltriazen-l-yl)imidazole-4-carboxamide 1.4 
fold, against L1210 murine leukaemia cells, following y-radiation. This compound 
was found to be an effective radiopotentiator as well as being an effective 
chemopotentiator.
Sebolt-Leopold and Scavone155 and Elliot et al156 reported that, in vivo, the PARP 
inhibitor 3,4-dihydro-5-methylisoquinolin-l-one (PD128763), in combination with 
radiotherapy, produced a 1.4-1.6 increase in cell kill in SCC7, RIF-1 and KHT 
murine tumours, thus increasing growth delay by 10-15 days. This combination o f  
radiation therapy and a PARP inhibitor resulted in tumour regressions, whereas 
radiotherapy alone was reported to result in only a minor growth delay. This 
emphasised the importance o f such compounds in the treatment o f  radiotherapy.
From the various studies carried out on PARP inhibitors, it can be seen that they 
have been developed with two main aims: The first one is to understand the enzymes 
physiological role in DNA-repair but, more importantly, the second aim is to 
potentiate the cytotoxic effects o f both radiotherapy and chemotherapy. However, 
this has proved difficult because a PARP inhibitor targeted specifically to the 
enzyme is yet to be achieved. Current PARP inhibitors tend to lack tissue-selectivity
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and possess poor solubility characteristics. These factors will be discussed with 
respect to known inhibitors o f PARP.
3.2 PARP INHIBITORS DEVELOPED TO DATE
Most PARP inhibitors that have been developed to date are competitive, reversible 
inhibitors that bind to the NAD+ binding-site o f the enzyme. As previously 
mentioned, when activated, the enzyme catalyses the cleavage o f the ribose- 
nicotinamide bond in NAD+, with the initial transfer o f the ADP-ribosyl fragment to 
a nucleophilic centre on a protein acceptor, which may be PARP itself 
(automodification) or target proteins such as histones (heteromodification)146. 
Cleavage o f the ribose-nicotinamide in NAD+ bond results in the formation o f an 
oxonium ion, facilitated by the lone pair o f electrons on the adjacent oxygen. 
Following initiation, the process can be repeated through elongation (via 
combination o f the 2 ’-OH o f ribose (attached to adenine) with the 1-position o f the 
ribose attached to nicotinamide)146. Branching can occur every thirty to fifty 
residues (via combination o f ribose 1-position initially attached to nicotinamide, with 
the 2 ’-OH o f another ADP-ribose polymer)146.
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Scheme 1: Schematic representation o f poly(ADP-ribosyl)ation146
Nicotinamide (22) was the first compound that was found to inhibit PARP, not 
surprisingly. Unfortunately, there were many problems associated with the use of 
nicotinamide as a PARP inhibitor. As well as being a weak inhibitor o f the enzyme, 
it was only slightly soluble, lacked specificity and behaved as a substrate for NAD+- 
metabolising enzymes.
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Consequently an alternative compound was required. Interestingly, most of the 
inhibitors that have been developed are mimics o f the nicotinamide unit. The next 
compound to be analysed as a PARP inhibitor was benzamide. Benzamide (23) is 
structurally very similar to nicotinamide. It was first shown by Shall157 in 1975 to be 
an effective inhibitor o f PARP. Furthermore, it lacked a ring nitrogen and was 
unable to undergo metabolism. Unfortunately, due to its poor solubility 
characteristics, this compound could not be used as a PARP inhibitor.
By introducing polar substituent onto the aromatic ring o f benzamide, Purnell and 
Whish158 hoped to increase the aqueous solubility o f the compound. It was found 
that substitution at the 3-position o f the ring improved solubility o f the compound, 
without affecting its activity against the enzyme. Subsequently, 3-amino- (24), 3- 
hydroxy (25) and 3-methoxybenzamide (26) were found to be potent inhibitors o f  
PARP with relatively good solubility characteristics. Compounds (24) and (26) were 
found to be competitive inhibitors o f PARP, exhibiting Kj values o f less than 2pM. 
Interestingly, alkylation o f the carboxamide group or substitution with a carboxylic 
acid reduced significantly or abolished enzymic activity. However, acylation o f the
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In 1982, Sims et al159 evaluated the PARP inhibitory activity in a number of 
compounds including the nicotinamide and benzamide derivatives. It was 
demonstrated that the presence o f a carbamoyl group was necessary for significant 
activity, although the position o f this substituent was found to be less important. 
Both picolinamide (27) and isonicotinamide (28) were found to have similar enzymic 
activities to nicotinamide. When an additional ring nitrogen was introduced this 
appeared to be tolerated and, subsequently, pyrazinamide (29) was found to be only 
slightly less potent than nicotinamide. However, alkylation o f the ring nitrogen (30),
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Sestilli et a /160,161 and Cantoni et al162 provided further information on the structure 
and activity relationships o f the benzamide series. They reported that, when the 
carbamoyl substituent was modified, this had a crucial effect on the activity. 
Subsequently, the alkylamide (32), sulfonamide (33) and thioamide (34) analogues 
appeared to be much less active than benzamide, whereas benzoic acid and 3- 
aminobenzoic acid were found to be inactive. However, it was found that reduction 
of the aryl ring to give cyclohexanecarboxamide (35) abolished activity. 
Interestingly, although alkylation o f the 3-amino group o f  (24) had little effect on 
inhibitory activity, acylation o f the amino group enhanced inhibitory activity 
significantly; subsequently 3-acetamido- (36) and 3-propanamidobenzamide (37) 
were found to be potent inhibitors o f PARP. In support o f this evidence was Purnell 
and Whish158 who had previously reported that 3-acetamidobenzamide and its 
analogue, 3-succinylaminobenzamide (38), were excellent inhibitors o f the porcine 
thymus enzyme. However, the introduction o f a halogen abolished activity, thus 
chloroacetylbenzamide (39) was found to be inactive.
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1Banasik et al evaluated over one hundred and fifty compounds o f various
structures for activity against calf thymus PARP and mono(ADP-ribose)transferases.
They reported that 3-hydroxybenzamide was found to be the most potent PARP
inhibitor o f the benzamide series, which was in contrast to the report o f Purnell and 
1Whish . It was suggested that this discrepancy may have been due to differences in 
the assay conditions employed, such as the substrate concentration and the enzyme 
preparation. Nevertheless, the most important observation made during these studies 
was again the presence o f a carbamoyl substituent incorporated within a ring system. 
This appeared to be very important for PARP activity and subsequently 1,8- 
naphthalimide derivatives (40, 41), 5-hydroxyisoquinolin-l-one (42),
phenanthridinone (43) and quinazolinone (44) were found to be very potent 
inhibitors o f PARP. These results provided essential structure-activity relationship 
(SAR) information necessary for PARP inhibitors. It was found that a 6-membered 
aryl or heteroaryl ring was necessary for activity. Any modifications made resulted 
in inactivity as was observed for nipecotamide (31), and cyclohexanecarboxamide 
(35) and claimed for thiophene-3-carboxamide (45). However, it was suggested that 
polyaromatic heterocyclic systems such as phenanthrene, isoquinoline and 
quinazoline may be associated with potent inhibitory activity. In addition, a carbonyl 
group conjugated to the arene appeared to be essential for activity. On this basis and 
the fact that a carboxamide group in the benzamide and nicotinamide series is 
essential for activity, it was deduced that these compounds were occupying the 
nicotinamide binding site o f PARP and that the 3-substituent was situated within the 
ribose nucleoside-binding domain. These compounds were able to serve as 
competitive inhibitors as they are unable to undergo C-N bond cleavage. It was also 
observed that, in the benzamide series, the only compounds that appeared to be 
active were those that contained an unsubstituted carbamoyl NH2 group. This 
indicated that they may be making important hydrogen-bond interactions with an 
amino-acid donor within the enzyme’s active site.
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In 1991, Suto et al164 provided evidence supporting this hypothesis, by designing 
compounds that constrained the carbamoyl group into either the ‘syn’ or ‘anti’ 
conformation. This was achieved via two ways: In the first case, ‘rigid’ benzamide 
analogues were prepared in which the orientation o f the carboxamide group was 
constrained into a ring system -  (dihydro)isoquinolin-l-ones. The second approach 
involved introducing substituents at the 2-position o f the ring -  2,3-disubstituted 
benzamides. In was found that, the 5-substituted (dihydro)isoquinolin-l-one 
compounds, where the carboxamide was constrained in the ‘anti’ conformation, 
resulted in highly potent compounds, thus confirming this to be the biologically 
active conformation. Also, positioning o f the substituent on the aromatic ring proved 
crucial for activity. When the substituent was placed on the 6-, 7- or 8-positions o f  
the ring, inhibitory activity was lost, indicating that the 5-position was important for 
activity. Of this series, 5-methoxy- (46, IC50 0.42 pM), 5-hydroxy- (47, IC50 0.10 
pM) and 5-aminodihydroisoquinolinone (48, IC50 0.4 lpM) were found to be potent 
PARP inhibitors. Similarly, 5-methoxy- (49, IC50 0.58 pM), 5-hydroxy- (50, IC50 
0.15 pM), and 5-aminoisoquinolinone (51, IC50 0.28 pM) were also found to be 
potent inhibitors o f PARP. In the second approach, the 2,3-disubstituted analogues 
were found to be completely inactive, because the biologically inactive ‘syn’ 
conformation predominated in these compounds.
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Following these studies, Griffin et a / 165 extended this work to benzoxazole-4- 
carboxamide compounds, on the basis that intramolecular hydrogen-bond 
interactions resulting between the amide NH and the oxazole nitrogen in the 
electron-rich heterocycle would afford a good donor carbonyl group constrained in 
the biologically active ‘anti’ conformation for association with the NAD+-binding 
site. This theory was reported to be achieved in the benzoxazole-4-carboxamides 
(52) and (54), which proved to be potent inhibitors o f PARP, exhibiting IC50 values 
of 9.5 pM and 2.1 pM, respectively. These results highlight the fact that the intra­
molecular hydrogen-bond between the carboxamide and the oxazole nitrogen in (52) 
and (54) constrained the carboxamide in the biologically active conformation and, 
furthermore, the compounds possessed good donor properties due to the electron rich 
heterocycle. In the case o f compound (53), the methyl group was occupying a site 
where a second hydrogen-bond to PARP was required, hence the compound was 
inactive. It was also noted that the presence o f a phenyl group next to the oxazole 
oxygen appeared to enhance inhibitory activity significantly. In the quinazolinone 
series, 8-hydroxy-2-methylquinazolinone (55) was found to be the most potent PARP 
inhibitor, exhibiting an IC50 value o f 0.44 pM. These results were similar to those o f  
Suto et a/ 164 who reported that the active conformation was the ‘anti’ conformation.
0 0  o
Me Ph
52  R = NH2 5 4  55
53  R = NHMe
Following this work in 1998, Griffin et al149 reported the activity o f various 
quinazolin-4-one inhibitors. The 8 -methyl (56) and 8 -hydroxy (57) substituents were 
reported to enhance inhibitory activity in comparison to the 8 -methoxy group (58). 
The 2-phenylquinazolinones were found to be slightly less potent than the 2- 
methylquinazolinones, however, the introduction o f an electron-donating or electron- 
with-drawing group on the 4 ’-substituent appeared to increase potency significantly. 
This was particularly evident in the 8 -methylquinazolinone series, where compounds 





5 6  R = M e
5 7  R = OH
5 8  R = OM e
59 R = N02, X = Me
60 R = CN, X = Me
61 R = OMe, X = Me
62 R = NH2, X = Me
63 R = OH, X = Me
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Recent studies104,149,166 have shed light onto the crystal structures o f  PD128763 (64) 
and NU 1025 (55) bound to the catalytic domain o f PARP. From the crystal 
structures, it can be seen that all the inhibitors bind in the same ‘anti’ orientation and 
complexes are formed between the two hydrogen bonds occurring between the 
carbonyl and NH (or NH2) groups and the peptide backbone o f Gly-863146. The third 
hydrogen bond occurs between the carbonyl group o f the inhibitor and the side chain 
o f Ser-904. In the case o f N U 1025, a further hydrogen bond interaction was evident 
between the 8-hydroxyl substituent and the hydroxyl group o f Tyr-907.
White et a /150, in 2000, expanded these studies to the development o f benzimidazole-
4-carboxamides as PARP inhibitors. 2-Phenyl-lH-benzimidazole-4-carboxamide 
(65) was found to be a potent PARP inhibitor, exhibiting a Kj  value o f 15nM. 
Derivatives o f this compound were developed with various substituents on the 
phenyl ring. From the analysis o f these compounds they found that many o f them 
exhibited Kj values for PARP inhibitory activity <10 nM, with 2-(4- 
hydroxymethylphenyl)-lH-benzimidazole-4-carboxamide (66) exhibiting a Kj value 




6 6  R 1 = CH2OH
6 7  R2 = OCH3
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The structure-activity relationships were also studied using the complex formed 
between 2-(3-methoxyphenyl)-lH-benzimidazole-4-carboxamide (67, Kj = 6 nM) 
and the catalytic fragment o f chicken PARP150. It was found that the carboxamide 
group o f compound (67) formed three important hydrogen bonds. It was observed 
that the carbonyl oxygen on the inhibitor accepted two hydrogen bonds, one from the 
Gly 863 polypeptide amide NH and the other from the side chain oxygen o f Ser 904. 
The amide NH o f  compound (67) on the same side o f the carbonyl group formed a 
hydrogen bond donor to the Gly-863 carbonyl oxygen. The benzimidazole part of  
compound (67) appeared to lie in a deep pocket formed by residues Phe 897, Ala 
898, Lys 903 and Glu 988. The benzimidazole was reported to be buried between 
two tyrosine residues-Tyr 896 and 907. Tyr 907 appeared to be coplanar with the 
benzimidazole, whereas Tyr 896 was rotated about 37° from coplanarity150. The 2- 
(3-methoxyphenyl) group was found to be located above a large, solvent-containing 
part o f the enzyme and was, therefore, not bound to the enzyme’s active site. Both 
faces o f the 2-phenyl ring appeared to be exposed to the solvent. The 3-methoxy 
group was also found to be exposed to the solvent but appeared to be partially 
shielded from the solvent by the presence o f a Gin 763 side chain. The 3-methoxy 
and 4-carboxamide groups appeared to be centred over the enzyme cavity. The 
unsubstituted 4- and 5- positions were oriented towards the surface o f the enzyme 
cavity. The 3-methoxy position and 4-position appeared to have space available 
around them, which was much less for positions 6, 7 and 8150.
Other compounds that have been of interest as PARP inhibitors are thymidine and 
thymidine analogues167 and thiophenecarboxamide compounds168. In the case o f  
thiophenecarboxamides, Shinkwin et alm  reported that the benzene ring o f the 
benzamide compounds could be replaced by a heterocyclic thiophene ring without 
significantly affecting PARP inhibitory activity.
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4.0 CURCUMIN
Scientists for many years have been aware that the onset o f cancer is a gradual, 
stepwise process that may unfold over the course o f several years. Carcinogenesis is 
the result o f a prolonged accumulation o f injuries at various biological levels, and 
includes both genetic and biochemical changes in cells. At each o f the biological 
levels, there is an opportunity to prevent, slow down or stop the healthy cells from 
becoming malignant. Chemoprevention is therefore an attempt to intervene in the 
early stages o f carcinogenesis by using natural and / or synthetic compounds.
The concept o f chemoprevention first arose in the 1960s and 1970s when 
Wattenberg169 demonstrated that compounds, particularly those associated with fruits 
and vegetables such as indoles and isothiocyanates, could inhibit tumours induced in 
animals. In the mid 1970’s this phenomenon was termed “cancer chemoprevention”. 
Since then, many scientists all over the world have contributed to this concept as a 
strategy for reducing human tumours. Chemoprevention is therefore the process o f  
inhibiting, delaying or reversing carcinogenesis by the use o f natural or non-toxic
1 7 0synthetic compounds .
To date, over six hundred compounds can be considered as chemopreventive agents, 
including inhibitors o f the initiation process, such as phenols, aromatic 
isothiocyanates, flavones and glutathione and inhibitors o f  the post-initiation stages, 
such as p-carotene, tamoxifen, retinoids, protease inhibitors, terpenes and 
prostaglandin inhibitors. These agents can either be natural or synthetic compounds.
In order for a compound to be classed as a chemopreventive agent, it has to meet 
several criteria including, (1) availability (the compound has to be available in large 
quantities either naturally or synthetically). (2) Cheap (the compound has to be 
relatively cheap as it may be consumed daily over a long period o f time). (3) Oral 
administration (the compound should be in a form, which is easy to administer 
orally). (4) Non-toxic (the compound should be non-toxic, or have very little side 
effects, and (5) a known mechanism o f action (the compounds mechanism o f action 
should be known so that it can be targeted specifically to the problem area). In
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general, natural compounds are preferred over synthetic compounds because they
171have been used over many decades and have little known side-effects .
In order to understand how chemopreventive agents exert their activity, it is 
important to appreciate the steps involved in epithelial carcinogenesis. 
Carcinogenesis occurs in three stages: the first one being the initiation stage, the 
second is the promotion stage and the third is the progression stage. In the case o f 
initiation, this process is rapid and involves the direct binding o f the carcinogen to 
the DNA, resulting in DNA damage. The mutation that results is irreversible. In the 
second stage o f the process, promotion occurs which involves the clonal expansion 
of the initiated cells. These cells are induced by agents acting as mitogens and this 
stage is usually reversible. Following promotion, the final progression stage occurs. 
This is generally an extension o f the promotion stage and results from it, as the 
cellular damage is further enhanced172. Following this stage genotypically and 
phenotypically altered cells result. Both o f  the promotion and progression stages o f  
carcinogenesis are prolonged. Depending on which stage the chemopreventive agent 
affects, they can be divided into tumour ‘blocking* agents or tumour ‘suppressing* 
agents. Tumour ‘blocking’ agents usually interfere with the initiation stage of  
carcinogenesis so that it can counteract the cancer172. These agents generally, tend to 
reduce the accumulation o f initiating mutations. Tumour ‘suppressing’ agents tend 
to act on both the promotion and progression stages o f carcinogenesis and work to 
suppress the development o f the initiated cell to a full-blown tumour. This can be 
achieved by scavenging free-radicals thereby behaving as antioxidants, inhibiting 
arachidonic acid metabolism, hormone and growth factor activity and oncogene 
activity. These agents are also known to suppress the tumour by modulating the
177cellular transduction pathways .
A class o f dietary compounds that have been evaluated as chemopreventive and 
chemoprotective agents are the polyphenols. One such member o f this class which is 
under intense investigation, is curcumin. Curcumin is the major constituent o f the 
spice turmeric. Turmeric is prepared from the dried rhizomes o f Curcuma longa L, 
which tends to be found in the tropical regions o f Asia. Turmeric has long been used 
as a spice in foods and gives the characteristic yellow colour. More importantly, 
however, it has been used in herbal medicines in countries such as China, India and
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Indonesia to combat cancer, inflammation, alleviate fever and to treat sprains and 
bruises.
Three major phenolic diarylheptanoids have been isolated from Curcuma longa L, 
including curcumin (68), demethoxycurcumin (69) and bisdemethoxycurcumin (70). 
However, recently, a further compound (71) has been reported to be isolated from 
this naturally occurring herb. Compound (71) was isolated and identified by
171Satyanarayana and Ravindranath .
0  0  o o
68  R1 = R2 = O M e 71
69  R1 = H, R2 = O M e
70  R1 = R2 = H
Figure 4. Constituents o f Curcuma longa L173
Curcumin (diferuloylmethane) is the yellow pigment in turmeric and has had
widespread use in the food, cosmetic and pharmaceutical industries. It was first
isolated in 1870 but its structure was not elucidated until as late as 1910. Curcumin
has been reported to possess strong anticarcinogenic effects in various tissues o f
animals. It was reported to possess anti(tumour promoting) activity by Huang et
alm , who demonstrated that curcumin applied topically to the skin o f mice inhibited
tumour promotion. Subsequently, further investigations carried out reported that
175curcumin was able to inhibit benzo[a]pyrene-induced forestomach tumours ,
176azoxymethane-induced crypts in rat colon and DMBA-induced hyperplastic
1 7 7  •nodules in cultured rat mammary gland tissue . As well as possessing antitumour
activity, curcumin also exhibits antiflammatory activity178. Recently, curcumin has 
also been shown to be a modest inhibitor o f HIV-1 and HIV-2 proteases179. In 
addition, interestingly curcumin has also been reported to be an inhibitor o f  
PARP171. Its inhibitory activity was found to be similar to that o f 3-AB. As PARP 
is known to play an important role in DNA repair, curcumin may be useful in the 
treatment o f radiotherapy and chemotherapy. However, currently curcumin is o f
48
great interest as a chemopreventive agent for cancer, and in particular carcinoma o f  
the colon172,180'182.
111 i fin i fi1)In the western countries, colorectal cancer is the major cause o f  deaths ’ ' .
However, epidemiological data have suggested that modification o f the diet may 
reduce these deaths by up to 90%. At the biochemical level, curcumin has been 
shown to inhibit cyclooxgenase 2 (COX2) activity, indirectly. This was achieved 
through the inhibition o f phosphorylation o f IkB, inhibition o f  N FkB activation and 
inhibition o f the COX2 expression.
COX2, an inducible isoform o f prostaglandin H synthase (PGHS), is known to 
mediate prostaglandin synthesis during inflammation, and in colon tumours is known 
to be overexpressed. COX2 is therefore thought to play an important role in colon 
carcinogenesis. Experiments involving the pharmacological inhibition, or genetic 
knock-out o f COX2 have been shown to protect against development o f colonic 
tumours in rats exposed to the colon carcinogen azoxymethane, or mice harbouring a 
germline knockout mutation o f the adenomatous polyposis coli (APC) tumour 
suppressor gene183,184. In colonic epithelial cells, overexpression o f COX2 is thought 
to promote tumour development by causing cellular alterations and also by resisting 
apoptosis. However, non-steroidal antiflammatory agents have been used to inhibit 
COX2 activity and this has been shown to reduce the risk o f sporadic colon
i o i
cancer . Unfortunately, due to the senous side-effects that are known to occur with 
such agents, this means that they cannot be used to suppress human tumours.
Recently, Plummer et a /182 reported that in human colon epithelial cells, curcumin 
was successful in inhibiting COX2 induction by the colon tumour promoters, tumour 
necrosis factor a, or fecapentaene-12. It was found that COX2 induction by 
oxidative stress or inflammatory cytokines could be mediated by the nuclear factor 
kappa B (NF-kB). In addition to curcumin inhibiting NF-kB activation, it was also 
found to prevent phosphorylation o f  IkB by inhibiting the activity o f the IKKs. This 
feature makes curcumin an attractive candidate for the prevention o f colon cancer.
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The concentrations that have been used in order to bring about the pharmacological 
effects o f curcumin in vitro have been reported182 to be in the range o f 10-100 pM. 
However, it has been demonstrated that the bioavailability o f curcumin in rodents, 
following oral administration, is poor. This suggested that maybe one or more o f the 
metabolites o f curcumin are involved in its pharmacological activity.
Although the metabolism o f curcumin in humans is unknown, a number o f
185 186studies ’ have addressed the absorption, metabolism and tissue distribution o f  
curcumin, following oral administration o f 400, 80 and 10 mg o f [3H]-curcumin in
187rats . Measurements o f the radioactivity in the plasma levels have shown that 
curcumin was poorly absorbed from the gut. These studies therefore suggested that 
curcumin was transformed during absorption from the intestines. It was reported that 
the transformed product(s), which was found to be more polar than curcumin entered 
the serosal side. Holder et aln i in 1978 reported that, following i.v. administration 
o f 50 mg Kg'1 [3H]-curcumin in rats, most o f the radioactivity present in the bile was 
found in the form o f  glucuronide conjugates o f tetrahydrocurcumin (THC) and 
hexahydrocurcumin (HHC), although some curcumin was found in the bile.
Following this work, the biotransformation o f  curcumin in mice was reported by Pan 
et a lm . It was reported that, following i.p. administration o f curcumin (O.lg Kg'1) to 
mice, approximately 2.25 pg mL"1 o f curcumin was found in the plasma in the first 
15 minutes. One hour later, curcumin was found to be present in the intestines, 
spleen, liver and kidneys (177.04, 26.06, 26.90 and 7.51 pg g'1)188. Analysis o f the 
metabolites indicated that when administered, the curcumin was reduced by UDP- 
glucuronosyl transferases, subsequently giving curcumin-glucuronoside, 
dihydrocurcumin-glucuronoside, THC-glucuronoside and THC. As THC was found 
to be one o f the major metabolites o f curcumin, studies have been carried out to 
elucidate its biological function. Sugiyama et alm  recently reported it to be a 
stronger antioxidant than curcumin in vitro. If this is the case it is thought that THC 
may show similar pharmacological activities as curcumin, therefore may itself be 
useful as a chemopreventive agent.
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As previously mentioned, the absorption and metabolism o f curcumin is not yet 
known in humans. However, an ongoing collaborative study on the uptake o f this 
compound with [14C]-labelled curcumin is currently underway.
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5.0 AIMS AND OBJECTIVES
HYPOXIA SELECTIVE PRODRUGS
The aim of this project was to build on the earlier studies, in order to exploit the lower 
oxygen concentration in solid tumours, by developing a prodrug system which when 
activated under hypoxic conditions will release inhibitors of PARP, selectively in solid 
tumours. Prodrugs that selectively release therapeutic drugs in hypoxic tumour tissues 
would, therefore, behave as tumour-selective radiosensitisers.
Inhibitors of PARP that were selected in this project were 5-bromo- and 5- 
aminoisoquinolinone. From the previous studies carried out, it is known that 5-bromo- 
and 5-aminoisoquinolinone are particularly active70,164 and, consequently, were chosen 
as the drugs for delivery. Isoquinolinone has previously been shown to be released from 
the nitrofuranylmethyl derivative when activated chemically. Other inhibitors that were 
thought to be useful as PARP inhibitors were quinoline-8-carboxamide N-oxides.
From the previous studies carried out on PARP inhibitors, the structural activity 
requirements (SAR) necessary for PARP inhibitory activity have been reported.
o 






Figure 5. SAR necessary in the development of PARP inhibitors146
• It is essential that the conformation of the amide be in the ‘anti’ orientation. It 
consists of a secondary arene-carboxamide that has an absolute requirement for the 
N-H to be ‘syn’ to the C=0 bond.
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•  At the 3 and 4 positions of the isoquinoline-1-one ring, a bulky substituent is 
permitted.
• The R group cannot be an electron withdrawing group.
• At the 6, 7 and 8 positions of the isoquinoline-1-one ring no substituent is permitted.
In this study l-substituted-2-nitroimidazole was selected as the bioreducible moiety 
because, as previously mentioned, these compounds show greater metabolic stability in 
normal tissues and they exhibit a wide range of redox potentials. From the literature 








Figure 6. SAR necessary for the bioreducible nitroimidazole moiety7
• The nitro group in the 2-position of the imidazole ring largely determines the 
electron affinity, hence the radiosensitising properties. In general, the more negative 
the reduction potential, the less electron affinic the compound. As the nitro group is 
changed from position 2 to 5 to 4, the electron-affinity of the nitroimidazoles 
decreases.
• The side chain R determines the solubility characteristics in water and lipids, hence 
the pharmacokinetics. The prodrug must be highly soluble in water and lipids so that 
it is able to diffuse through a nonvascularised cell mass in order to reach the hypoxic 
cells, which can be located as far as 200 pm from the nearest capillary.
• Nitroimidazole type compounds show metabolic stability in normal tissues and can 
have a wide range of redox potentials. Previous studies1,7,13'15 have suggested that a 
redox potential between -250 mV to -400 mV is required for effective 




It is proposed that, in hypoxic tumour tissue, the nitroimidazole will be metabolically 
reduced by cellular reductases to the aminoimidazole. The available lone pair of 
electrons on the nitrogen will then promote fragmentation to release the drug selectively 
in the tumour tissue. This is demonstrated schematically below.
Bioreduction
7 4  7 5  7 2
Scheme 2. Proposed mechanism of bioreductively triggered release o f drugs from 
general nitroimidazole prodrug.
However, in aerobic cells, the nitroimidazole will only be reduced by the cellular 
reductases to the initial nitro radical anion metabolite. This species is very reactive 
towards oxygen and, in oxygenated cells, will be oxidised back to the parent compound.
The aim of this project was therefore to (i) synthesise 2-nitroimidazolyl-5-methyl 
derivatives o f isoquinolinone compounds, in addition to other PARP inhibiting drugs,
(ii) to optimise the solubility characteristics of the 2-niroimidazolyl-5-methyl moiety,
(iii) to optimise release characteristics o f the 2-niroimidazolyl-5-methyl moiety, (iv) to 





Figure 7. Illustrates the general structure o f tumour hypoxia selective prodrugs.
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CURCUMIN
As previously mentioned, curcumin is of particular interest as a chemopreventive agent 
in the treatment o f various forms of cancer. However, the metabolism of this compound 
following administration in humans is unknown. Nevertheless, studies carried out with 
mice have reported that bioavailability of curcumin, following oral administration, is 
poor. The aim of this part of the project was to synthesise 14C-labelled curcumin (235) 
so that, in an ongoing collaborative study, its biodistribution and pharmacology, could 
be evaluated.
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6.0 RESULTS AND DISCUSSION
The first synthetic target was the (nitroimidazolylmethyl)isoquinolinone (119). This 
carries the 2-nitroimidazol-5-ylmethyl trigger unit linked to the potent PARP 
inhibitor 5-bromoisoquinolin-l-one70,164. In this first target, the N 1 nitrogen o f the 
imidazole is masked with a simple methyl group; in later targets, this nitrogen 
substituent could be modified to incorporate other functions, such as water- 
solubilising groups.
As a synthetic target, the molecule can be divided conveniently into two parts.
70Alkylations o f the anions derived from isoquinolinones have been reported to be 
efficient in introducing alkyl and aralkyl groups at the heterocyclic nitrogen. Indeed, 
5-bromoisoquinolin-l-one has been alkylated70 with 4-methoxybenzyl chloride in the
7 0presence o f base to give 5-bromo-2-(4-methoxybenzyl)isoquinoline-l-one . For the 
present target, this reaction represents a very good point for retrosynthetic 
disconnection, as it would lead to two similar-sized fragments and thus the forward 
synthesis would be convergent. Thus the synthetic problem becomes the synthesis of 
two fragments, a 2-nitro-5-(halomethyl)imidazole (or an analogous electrophile) and 
5-bromoisoquinolin-1 -one.
Although these structurally simple compounds appear easy to synthesise they have 
proved difficult for the chemist. Direct nitration o f  imidazole and its derivatives 
introduces the nitro group into either the 4- or 5-positions o f the ring, when they are 
free190. However, even if  the 4- and 5-positions are occupied, electrophilic 
substitution does not take place at the 2-position190.
Synthetic strategies have been reported in which 2-nitroimidazoles can be obtained 
from the corresponding 2-aminoimidazoles190. In literature studies190, there are only 
few examples o f the oxidation o f an amino group at the 2-position. These include 
oxidation with peroxytrifluoroacetic acid and microbial oxidation. Alternatively, the 
amino group can be replaced with nitro by diazotisation, followed by a Gattermann 
reaction with sodium nitrite in the presence o f copper190’192.
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It was Lancini et a/191 in 1969 who first reported the synthesis o f a number o f 1,5- 
disubstituted-2-nitroimidazoles by diazotisation and Gattermann reaction on the 
corresponding 2-aminoimidazoles. The aminoimidazoles were prepared from either 
amino acetals or lactones. In the first reported route191, hydrolysis o f alkylamino 
acetals (prepared from the treatment o f a-bromo acetals with monoalkylamines or a- 
amino acetals with bromo esters) followed by condensation o f the aminoaldehyde 
with cyanamide afforded the aminoimidazole compound. In the second route, 
Akabori reduction191 o f a-alkylaminolactones (prepared from bromolactones), 
followed by condensation with cyanamide also gave the required aminoimidazole. 
However, the reported procedures acquired the use o f expensive chemicals, tedious 
work-up requirements and afforded low yields. As a result, an alternative route was 
preferred.
NH R1
R 2 ^ 0 ^ 0
N H R 1 
*  RC H C H O  *
NH R1
R 3CH CH (O C2H5)2






R 1 = R2 = alkyl group  
8 0
Scheme 3. Reported synthesis o f 2-nitroimidazoles191.
In 1972, Cavalleri et a?92 reported a synthetic route to l-methyl-2-nitro-5- 
hydroxymethylimidazole (94). Their synthetic procedure started from ethyl 2- 
amino-l-methylimidazole-5-carboxylate which undergoes diazotisation in tetra- 
fluoroboric acid at low temperatures, followed by reaction o f the diazonium salt with 
nitrite in the presence o f copper (by the procedure reported by Lancini et a/191), 
which resulted in the corresponding l-methyl-2-nitroimidazole-5-carboxylate (92). 
Selective reduction o f the ester o f (92) with lithium borohydride was reported to give 
the 5-hydroxymethyl derivative.
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As compound (94) was recognised as a key intermediate in the synthesis o f 5- 
chloromethyl-l-methyl-2-nitroimidazole (101), this was the preferred route. 
Furthermore, this procedure involved the use o f readily available starting materials.
1 O ')However, low yields were reported in Cavalleri’s procedure for compounds (92) 
and (94). In attempts to optimise the reported yields, the experimental procedures 
were evaluated and optimised in order to bring forth a good yield o f the key 
compound (101) for elaboration with the PARP inhibitory isoquinolinones.
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Scheme 4. Synthesis o f l-methyl-2-nitroimidazoles. Reagents: i, EtOH / SOCI2 , ii, 
K2CO3 , iii, A c20 / N a0 2CH, iv, NaOEt / EtOCHO, v, EtOCHO / NEt3 / di-^-butyl 
dicarbonate, vi, EtOH / HC1, vii, aq. HC1 / cyanamide, viii, H2O / HBF4 /  NaN0 2  /  
Cu, ix, LiBH4 (solid) / THF, x, SOCI2 , xi, dry pyridine /  MeS0 2 Cl, xii, dry pyridine / 
TsCl, xiii, LiBH4  (solution), xiv, dry DMF / Br2 /  PPh3.
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6.1 CRITICAL 2-NITROIMIDAZOLE INTERMEDIATES
Sarcosine (81) was converted to its ethyl ester (82) using thionyl chloride and 
ethanol. In the next step o f the reaction, it was essential to protect the nitrogen, to 
ensure that formylation would take place at the methylene o f  compound (82) and not 
at the nitrogen. Compound (82) was protected as the formamide. In initial 
experiments, following a common procedure for protection, the free base o f the ester 
was extracted and was treated with ethyl formate in the presence o f base. Although 
the reaction was successful, N-formylsarcosine ethyl ester (84) was obtained in a 
poor yield o f 25%. The low yield was attributed to the fact that the majority o f the 
free base was lost in the aqueous layer. However, treatment o f  compound (83) with 
the electrophile appeared to go to completion, according to TLC analysis.
As a result, the reaction was repeated but without initially extracting the free base. 
However, in this procedure, compound (84) was obtained in a lower yield o f 11%. 
At this stage, it was thought that perhaps it was due to the presence of solvent 
(ethanol) that was causing problems by diluting the reaction mixture, consequently 
slowing down the rate o f  reaction. As a result, the reaction was repeated but without 
the use o f solvent. This led to compound (84) being obtained in a yield o f 18%. 
Although this procedure improved the yield slightly, it was still extremely low 
yielding and inefficient. The low yields obtained questioned the reactivity o f the 
electrophile in use. Schmidt and Geiger193 reported the synthesis o f compound (84) 
by treatment o f the ester hydrochloride salt (82) with the more reactive electrophilic 
formylating reagent acetic formic anhydride. This reaction gave compound (84) in a 
much-improved yield o f 70%.
Due to the delocalisation o f the lone pair o f electrons on nitrogen into the carbonyl o f  
the amide, there is partial double bond character in the C-N amide bond, leading to 
restricted rotation. Correspondingly, signals for the cis and trans rotamers o f (84) 
were observed in the !H NMR spectrum at 25°C. This was particularly evident in the 
signals for the NMe and NCH2 protons. The two rotamers existed in a 1:2 ratio. As 
the sample is heated, the rate o f rotation about this bond should increase and become 
rapid on the NMR time-scale. The signals should then coalesce. However, at 90°C 
the rotameric signals appeared to get closer together and even more so at 120°C, but
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the signals did not merge, indicating a high energy barrier to rotation. In addition to 
the protective function o f the formyl group, its presence also enhances the next 
formylation step at the methylene o f compound (84). This is due to the electron- 
withdrawing effect o f the formyl group on the nitrogen resulting in a shift of electron 
density and a slightly electropositive nitrogen.
Alternative Boc protection o f the nitrogen o f (82) was also investigated. Initially, the 
free base was extracted and allowed to react with di-f-butyl dicarbonate to give N- 
Boc-sarcosine ethyl ester (85) in 97% yield. However, the one-pot reaction between 
the hydrochloride (82) and di-/-butyl dicarbonate, in the presence o f excess tertiary 
amine base, went to completion and gave compound (85) in 97% yield. For this N- 
Boc compound, the NMR spectrum showed the presence o f  rotamers in a 1:1 ratio, 
reflecting the greater bulk o f the BurO group, compared to that o f the H for the 
formyl compound.
With the nitrogen o f (84) protected with formyl, the methylene was deprotonated 
with sodium ethoxide; the anion reacted with ethyl formate to give ethyl 2-(N- 
formyl-N-methylamino)-3-oxopropanoate as its sodium enolate salt. The newly 
introduced aldehyde was protected as the diethyl acetal by prolonged treatment at 
reflux with ethanol saturated with HC1. These conditions also served to remove the 
N-formyl group by ethanolysis. The driving force for the cleavage o f the formamide 
was the formation o f the salt o f the product amine. The ethyl 3,3-diethoxy-2- 
methylaminopropanoate (87) was obtained in 41% yield.
During the optimisation o f this procedure, the method reported in the literature191 
was investigated. In this, the N-formyl enolate salt (8 6 ) was merely stirred with 
ethanolic HC1 at ambient temperature. NMR indicated the presence o f two 
product compounds. Compound (87) was present in addition to the formylated acetal 
(8 8 ), suggesting that complete removal o f the formyl group with HC1 had been 
unsuccessful. Attempts to separate the two by column chromatography failed as the 
crude mixture decomposed on silica gel.
The aldehyde was unmasked using aqueous hydrochloric acid and the amino­
imidazole (91) was formed by condensation with cyanamide. In the initial
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experiment, the literature procedure192 was followed. It was reported that unmasking 
of the aldehyde by 10% hydrochloric acid at 60°C could be achieved after 2 h. 
However, this was not the case and it was not known whether the hydrolysis or the 
condensation step was unsuccessful but *H NMR indicated that a large amount o f the 
acetal was present. Furthermore, during the reaction it was found that (90) could not 
be monitored via TLC as it had a similar Rf value to the starting compound (87). In 
order to overcome the hydrolysis problem, compound (87) was treated with 
hydrochloric acid at 60°C for a longer period o f 12 h. Although it was known that, if  
the mixture was left heating for a prolonged period, this may have resulted in the 
hydrolysis o f the ester. Despite this, the reaction was treated with aqueous 
hydrochloric acid for 12 h at 60°C and, following very slow recrystallisation from 
aqueous propan-2-ol, the aminoimidazole (91) was obtained in 55% yield. NMR 
confirmed the presence o f this compound, as the imidazole ring proton was observed 
at 57.76 as a singlet. Furthermore, a broad peak was observed at 58.26 
corresponding to the amino group. In D2O, the imidazole 4-H remained, whereas the 
amino group protons were exchanged.
Kirby194 reported an alternative synthetic route to 2-aminoimidazoles which involved 
the treatment o f the acetal with S-methylisothiuronium sulfate, followed by 
unmasking o f the aldehyde with 1 0 % hydrochloric acid and a condensation reaction 
to give the aminoimidazole. However, treatment o f the acetal (87) with S- 
methylisothiuronium sulfate failed to give compound (89), as !H NMR indicated that 
the compound had decomposed. Treatment o f the acetal (87) with cyanamide was 
also tried in an attempt to form the intermediate compound (89). However, again the 
reaction was unsuccessful and only decomposed material was recovered.
In the next stage o f the reaction, the amino group was diazotised and a copper- 
catalysed Gattermann reaction introduced the required 2-nitro group in ethyl-1- 
methyl-2-nitroimidazole-5-carboxylate (92). In this reaction, a suspension o f the 
diazonium tetrafluoroborate in aqueous sodium nitrite was treated with copper 
powder. The solution was made acidic by treating with aqueous hydrochloric acid in 
order to retain any starting aminoimidazole compound (91). The 2-nitro compound 
(92) was extracted with ethyl acetate. !H NMR indicated the presence o f two 
compounds, which included the desired ethyl-l-methyl-2-nitroimidazole-5-
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carboxylate (92) and the side product ethyl-l-methyl-2-chloroimidazole-5- 
carboxylate (93), obtained in 48% and 18% yields, respectively. This latter 2-chloro 
compound (93) was thought to have been formed during the work-up procedure in 
which the nucleophilic chloride ions substitute the nitro group. In subsequent 
reactions, aqueous sulfuric acid was used in place o f the hydrochloric acid to prevent 
this nucleophile substitution from occurring, as the sulfate ions are much less 
nucleophilic than the chloride ions. Under these reaction conditions, compound (92) 
was obtained in a higher yield o f 63% and the 2-chloro compound (93) was obtained 
in only 4% yield.
Compound (92) in tetrahydrofuran was reduced by addition o f solid lithium 
borohydride to its solution in tetrahydrofuran. The excess lithium borohydride was 
decomposed by addition o f aqueous hydrochloric acid. This resulted in formation o f  
two compounds, the first being the desired l-methyl-2-nitro-5- 
hydroxymethylimidazole (94), obtained in 36% yield, and the side compound 1- 
methyl-2-chloro-5-hydroxymethylimidazole (95) was obtained as a crude mixture. 
Compound (94) was obtained pure following column chromatography. However, 
column chromatography and recrystallisation failed to purify compound (95). The 2- 
chloro analogue was thought to have occurred due to the chloride ions in aqueous 
hydrochloric acid being nucleophilic resulting in the substitution o f the nitro group. 
To prevent this from occurring, in subsequent reactions, glacial acetic acid was used 
to decompose the excess lithium borohydride, as the acetic acid is a much weaker 
acid than hydrochloric acid. In !H NMR, the peaks for the chloro analogue (95) were 
slightly more upheld than those observed for compound (94). This was due to the 
less deshielding effect o f the chloro substituent. Under these reaction conditions, 
compound (94) was obtained in a higher yield o f 60%.
Interestingly, the reaction was repeated with commercial solution o f lithium 
borohydride in tetrahydrofuran and it was found that over-reduction occurred, which 
resulted in the cleavage o f the nitro group. This is the first report o f the reductive 
removal o f the nitro group with lithium borohydride. NMR provided evidence for 
the formation o f compound (96), which was obtained in 91% yield. The two 
imidazole ring protons were observed at 86.76 and 87.53 as singlets, each integrating
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for one proton. The imidazole 2-H was assigned to the signal at 57.53, i.e. downfield 
due to the electron-withdrawing effect o f the heteroaromatic ring nitrogen.
Attempts to substitute the hydroxy o f compound (94) selectively using thionyl 
chloride failed. However, the novel compound 2-chloro-5-chloromethyl-l- 
methylimidazole (97) was obtained. As the hydroxide ion is a poor leaving group, it 
cannot be displaced by nucleophiles in Sn2 reactions. However, reaction o f the 
alcohol with thionyl chloride converts the hydroxy into a much better leaving group 
which is substituted by nucleophilic attack o f the chloride ion. The nucleophilic 
chloride ions in solution also substitute the nitro group at the 2 -position o f the 
imidazole ring. Compound (97) was oxidized in air to the aldehyde compound (98). 
No further reactions were carried out with thionyl chloride as this reagent was found 
to be too reactive for the nitroimidazole type compounds. !H NMR provided 
evidence for the formation o f compound (98) as the CH2 previously observed at 
54.55 was absent. Furthermore, the appearance o f an aldehyde peak at 59.65 further 
supported this assignment.
Compound (94) was treated with methanesulfonyl chloride, following a common 
procedure195 to form compound (99). However, this failed but provided the equally 
equivalent useful electrophile 5-chloromethyl-l-methyl-2-nitroimidazole (101) in 
70% yield. It was thought that the mesylate (99) was formed initially but was then 
substituted by chloride. Use o f methanesulfonic anhydride would have avoided the 
formation o f the chloromethyl compound but was not investigated, as the 
chloromethylimidazole (1 0 1 ) proved to be a suitable electrophile for further 
synthesis. Similar treatment o f (94) with / 7-toluenesulfonyl chloride also afforded 
compound (101) but in a lower yield o f 31%.
Larger halogens, such as bromine, are better leaving groups. If problems were 
encountered with the chloro group when attaching the drug to the imidazole, an 
alternative leaving group, such as the bromide in (102), would be considered. 5- 
Bromomethyl-l-methyl-2-nitroimidazole (102) was synthesised by treatment of 
compound (94) with bromine and triphenylphosphine196. Compound (102) was 
obtained in 17% yield. The reaction proceeds via a Mitsunobu-like mechanism. 
Initially, the triphenylphosphine attacks the bromine molecule and forms a
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bromotriphenylphosphinium adduct. The nucleophilic oxygen attacks the electro­
positive phosphorus and eliminates the bromide ion. The nucleophilic bromide ion 
in turn attacks the electropositive carbon, hence eliminating the triphenylphosphine 
oxide group.
Having achieved the first part o f the synthetic target, the potent PARP inhibitor 5- 
bromoisoquinolin-l-one was synthesised.
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6.2 CRITICAL 5-BROMOISOQUINOLIN-l-ONE INTERMEDIATES
5-Substituted isoquinolin-1 -ones have been reported70,164 to be potent PARP 
inhibitors. As previously mentioned, PARP is an enzyme which plays an important 
role in initiating the excision repair o f DNA following damage induced by radiation 
therapy and / or chemotherapeutic drugs. O f the reported compounds, 5-bromo- 
isoquinolin-l-one was found to be particularly active70,164 and was, therefore, chosen 
as the first drug for delivery.
7 0Synthesis o f 5-bromoisoquinolin-l-one has previously been reported by Berry et al . 
The reported synthetic strategy initially involved the formation o f the bromo- 
cinnamic acid (104), which was prepared from 2-bromoiodobenzene (103) in an 
iodine-selective Heck reaction. 2 ,-Bromocinnamic acid was converted into the acid 
chloride (105) and then to the acid azide (106) by reaction with sodium azide. 
Curtius rearrangement o f the acid azide at >260°C, with subsequent cyclisation, was 
reported to furnish 5-bromoisoquinolin-l-one in 10% yield. As a consequence o f  the 
poor yield, new routes were developed for the synthesis o f 5-bromoisoquinolin-l-one 
(108).
COCI
Scheme 5. Reported synthesis o f 5-bromoisoquinolin-l-one70. Reagents: i, 
H2C=CHC02H / Pd(OAc) 2 /  NEt3 /  EtCN, ii, SOCl2 /  DMF, iii, NaN3 / H20  / 1,4- 
dioxane, iv, heat, Ph20 .
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Masanori et al197 recently reported a simple synthetic route to 5-aminoisocoumarin. 
In our laboratory, it was proposed that diazotisation o f 5-aminoisocoumarin with 
sulfuric acid and sodium nitrite and treatment with copper (I) bromide / potassium 
bromide, followed by treatment with ammonia and 2 -methoxyethanol would afford 
5-bromoisoquinolin-l-one. The new synthetic route employed for the formation o f
5-bromoisoquinolin-l-one is outlined below.
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Scheme 6 . Synthesis o f 5-bromoisoquinolin-l-one and prodrug (118). Reagents: i, 
MeOH / SOCl2, ii, DMF / DMFDMA, iii, THF / aq. HC1 / Pd/C / H, iv, H20  / 
N aN02 /  aq. H2SC>4 / CuBr / KBr, v, 2-methoxyethanol / NH3 , vi, DMF / lithium 
bis(trimethylsilyl)amide / 5-chloromethyl-l-methyl-2-nitroimidazole / Nal, vii, 2- 
methoxyethanol / 4-methoxybenzylamine.
2-Methyl-3-nitrobenzoic acid (109) was converted to its methyl ester (110) using 
thionyl chloride and methanol. Compound (110) was condensed with 
dimethylformamide dimethylacetal in boiling DMF. Evaporation gave crude (111).
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In the !H NMR, the N(CH3)2  was observed as a singlet at 82.83. The two alkenic 
protons were each observed as doublets at 86.34 and 85.66. The alkene proton 
adjacent to the aromatic ring was observed further upheld than the adjacent alkenic 
proton because the enamine electrons push into this proton. The alkene is shown to 
exist as the ^-stereoisomer because the coupling constant ( /  = 13.6 Hz) is typical o f a 
trans isomer.
Cyclisation o f the enamine (111) on silica gave compound (112) in 39% yield. 
Further elution gave (113) in 10% yield. Initially, the enamine tautomerises to give 
the iminium compound. Nucleophilic oxygen o f water attacks at the electropositive 
carbon o f the iminium and pushes electrons into the electropositive nitrogen to give a 
hemiaminal type compound. Proton transfer and delocalisation o f the hydroxy group 
results in the aldehyde. Tautomerism to the enol, followed by transesterification / 
cyclisation gave 5-nitroisocoumarin. However, in the case o f compound (113) it is 
thought that the nucleophilic oxygen o f methanol attacks at the aldehyde 
electropositive carbon, resulting in the hemiacetal compound. Transesterification 
now gives the side product compound (113).
In subsequent runs to compound (112), the enamine (111) was left to cyclise 
overnight on silica. Column chromatography and recrystallisation gave (112) in 60% 
yield. In ]H NMR, the 4-H proton was split into a double doublet by the adjacent 3- 
proton and the 8 -proton. A small coupling constant o f  0.5 Hz was evident between 
the 4 and 8  protons. Here a five-bond coupling is observed which is unusual; 
however, everything is in plane and the coupling is W-like. The 3-H was split into a 
doublet by the adjacent 4 proton and was observed at 87.44. The 8 -H was observed 
as a double double doublet due to ortho coupling being observed between the 7- 
proton, meta coupling being observed between the 6  proton and a five bond W-like 
coupling being observed between the 4 proton. The signal was observed further 
downfield at 88.65, due to the deshielding effect o f the adjacent carbonyl group.
Evidence for the formation o f compound (113) was obtained by the presence o f the 
OCH3 group in !H NMR, which was observed as a singlet at 83.54. The methylene 
protons at position 4 o f the aromatic ring were observed as a doublet at 83.59. The
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methine proton was split into a triplet by the methylene protons and observed at 
85.52. The methylene and methine protons have a vicinal coupling constant o f 3.3 
Hz.
Generally, it is known that nitroaromatic compounds can be reduced by catalytic 
hydrogenation (palladium/carbon, hydrogen). Treatment o f 5-nitroisocoumarin (112) 
with palladium/carbon and hydrogen for 6 hours gave 5-aminoisocoumarin (114) in 
99% yield. However, in some runs, catalytic hydrogenation resulted in over 
reduction. This was due to exposure o f 5-nitroisocoumarin (112) to hydrogen for a 
longer period o f time (12 h), which consequently reduced the double bond o f the
isocoumarin ring to give 5-amino-3,4-dihydroisocoumarin (115) in 91% yield.
108However, Bellamy and Ou reported the use o f an alternative reducmg agent (tin(D) 
chloride) which was selective and would not reduce the double bonds. Although 
reduction was achieved, compound (114) was obtained in a lower yield o f 77%. 
Evidence for the formation o f compound (114) was provided by !H NMR whereby a 
broad singlet was observed at 83.90 corresponding to the amino group. Furthermore, 
the 6-proton adjacent to the amino group becomes more upfield due to the shielding 
effect o f the amino group in comparison to 5-nitroisocoumarin (112) where the 6- 
proton was deshielded and was evident at 88.30 due to the adjacent electron- 
withdrawing nitro group. In the case o f compound (115) the 3 -H2 and 4 -H2 were 
each observed as triplets at 84.46 and 82.74.
Diazotisation o f compound (114) with aqueous sulfuric acid, sodium nitrite, followed 
by treatment with copper bromide and potassium bromide gave 5-bromoisocoumarin 
(116) in 35% yield. The aromatic amine is thought to undergo reaction with cold 
nitrous acid in sufuric acid solution to give the aryl diazonium sulfate species. The 
nitrous acid is generated in situ by reaction o f the sodium nitrite with the acid. The 
resulting diazonium salt is very reactive and can be displaced by nucleophilic 
bromide ions. Such substitution reactions are thought to proceed via an aryl cation 
typically through an SnI mechanism. This is known as the Sandmeyer reaction. 
However, it has also been reported that some reactions proceed via a free-radical 
mechanism199. In *H NMR the disappearance o f the broad NH2 peak provided 
evidence for the formation o f compound (116). Furthermore, the isocoumarin 6-H
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was shifted further downfield due to the negative inductive effect o f the bromide 
substituent and consequently the signal is evident at 87.95. MS data provided further 
evidence for the formation o f this compound, whereby the molecular ion in the FAB+ 
spectrum was evident at 227/225. 5-Bromoisocoumarin (116) was converted to 5- 
bromoisoquinolin-l-one (108) in a one-pot process by treatment with ammonia in 
boiling 2-methoxyethanol. Recrystallisation furnished compound (108) in 71% 
yield. The JH NMR spectrum was consistent with that reported in the literature70, in 
which the N-H was observed at 811.55 as a broad singlet integrating for 1 H.
Berry et al10 reported that deprotonation o f 5-bromoisoquinolin-l-one (108) with 
lithium bis(trimethylsilyl)amide, followed by alkylation with l-chloromethyl-4- 
methoxybenzene gave 5-bromo-2-(4-methoxyphenylmethyl)isoquinolin-l-one (117). 
In the present work, this compound was also formed by condensation o f 5-bromo- 
isocoumarin (116) with 4-methoxybenzylamine, demonstrating the generality o f this 
method o f formation o f isoquinolinones.
In the present work, 5-bromoisoquinolin-l-one (108) was deprotonated with lithium 
bis(trimethylsilyl)amide and the anion was allowed to react with 5-chloromethyl-l- 
methyl-2-nitroimidazole (101) to give the first target prodrug 5-bromo-2-((l-methyl- 
2-nitroimidazol-5-yl)methyl)isoquinolin-l-one (118) in 85% yield. In the !H NMR 
the spectrum, the CH2 peak was shifted slightly further downfield at 85.23 
(previously observed at 84.55 in (101) due to the deshielding effect o f the 
isoquinoline ring nitrogen. The 4-H was observed as a double doublet at 86.93 due 
to coupling being observed between the 4- and 8-protons. The isoquinoline 3-H was 
split into a doublet by the adjacent 4-H and was observed at 87.14. The imidazole 4- 
H was evident as a singlet at 87.23. The 7-H was split into a triplet by the 6- and 8- 
protons and was observed at 87.38. The 6-H was evident as a double doublet at 
87.93 due to coupling being observed between the adjacent ortho 7-H and the met a 
8-H. The 8-H was split into a double double doublet by the adjacent ortho 7-H, the 
meta 6-H and the para 4-H and was observed at 88.39.
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Similarly, the anion derived from 5-bromoisoquinolin-l-one (108) was treated with 
5-bromomethyl-l-methyl-2-nitroimidazole (102). The target prodrug (118) was 
obtained in a lower yield o f 65%.
The routes described above allow the synthesis o f (118) in excellent overall yields 
through convergent sequences. Interestingly, the corresponding nitrofuranylmethyl-
7 0isoquinolinone reported by Berry et al had to be assembled stepwise, with 
alkylation o f isoquinoline-1-one with chloromethylfuran, followed by a difficult 
regioselective nitration.
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6.3 REDUCTIVELY TRIGGERED RELEASE FROM PRODRUG (118)
A number o f experiments were conducted to reduce the nitroimidazole prodrug (118) 
to the aminoimidazole (119), to study the release o f the potent PARP inhibitor 5- 
bromoisoquinolin-l-one (108). The mechanism by which this is predicted to occur is 
outlined below.
Scheme 7. Reductively activated release o f 5-bromoisoquinolin-l-one (108). i, 
NH4CI / MeOH / H20  / Zn dust or NaBRj / Pd/C / Pr'OH / H20 .
There are several ways in which a nitro group can be reduced selectively to the 
amino compound70,71,197,198,200. Everett et a f x demonstrated the use o f y-radiolysis 
and pulse radiolysis which selectively reduce nitro compounds to nitro radical 
anions. Other methods include the use o f hydrogen and catalyst. However, such 
agents are not particularly selective and are known to cleave at benzylic positions, 
such as the imidazole-CH2-N unit. However, tin (II) chloride and titanium
7 0  107  1 ORtrichloride have been reported to be selective for nitro compounds ’ ’ . In
addition, sodium borohydride and palladium / carbon have also been reported to be 
selective for aromatic compounds. Berry et al10 reported the reduction o f  
nitrofuranylmethylderivatives using a mild method for selective chemical reduction 
of the nitro group. Sodium borohydride in the presence o f palladium / carbon and tin 
(II) chloride reducing systems were reported to selectively release the drug through
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the intermediate aminofuran. Reduction o f the nitro o f the prodrug 5-nitrofuran-2- 
ylmethyl iV-[3-(l,2-dicarba-c/as'o-dodecarboran-(12)-yl)propyl] carbamate was
selectively reduced by tin (II) chloride; carboranylpropylamine was obtained in 40% 
yield. As these systems proved successful and selectively reduced the nitro group of 
the nitrofuran moiety, these systems were investigated for the selective reduction of 
the nitro o f prodrug (118).
Treatment o f the prodrug (118) in aqueous propan-2-ol with excess sodium 
borohydride and palladium on carbon resulted in the complete consumption o f the 
prodrug within 10 min, as demonstrated by HPLC. A peak representing the 5- 
bromoisoquinolin-l-one was observed at a retention time o f 5.5 min. However, in 
addition, two further peaks were observed with retention times o f 4.5 min and 4.9 
min. Control experiments were carried out, in which 5-bromoisoquinolin-l-one in 
propan-2-ol was treated with sodium borohydride / palladium / carbon system. From 
HPLC analysis it appeared that the peak corresponding to the 5-bromoisoquinolin-l- 
one had been completely converted to the peak exhibiting a retention time o f 4.9 
min. This suggested that this compound was, in fact, a product o f the delivered drug. 
Analysis o f this compound by HPLC, *H NMR, and MS provided evidence that this 
compound was the 5-unsubstituted isoquinoline-1-one compound (120). This 
suggested that hydrogenolysis o f the aryl bromide was taking place with the 
palladium / carbon and sodium borohydride reducing agents. These reducing 
systems were reported to be selective to nitro compounds and hydrogenolysis with 
such reagents has not previously been reported. However, recently Madani has 
shown reduction o f an alkyne with this reagent system. This, therefore, demonstrates 
that the reported reductants are not as selective as originally reported. Evidence for 
the formation o f (120) was provided by !H NMR whereby; the 5-H was observed as 
a multiplet at 57.48. The 6- and 7-protons were also observed as a multiplet at 57.68.
Treatment o f the prodrug (118) with palladium / carbon in aqueous propan-2-ol also 
afforded the debrominated product. This may have been due to hydrogen being 
adsorbed onto the metal surface o f the compound during manufacture. Other 
possibility by which it is thought that the 5-unsubstituted isoquinoline-1-one (120) 
may have formed, is that either the 5-bromoisoquinolin-l-one (108) was initially 
released from the prodrug and further degradation o f (108) gave the unsubstituted
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analogue (1 2 0 ), or that initially the bromine o f the prodrug (118) was cleaved, and 
then releases the unsubstituted analogue (1 2 0 ).
The nitro group o f the prodrug (118) was also reduced by treatment with tin (II) 
chloride. From HPLC analysis it appeared that the nitro group o f the prodrug 
appeared to be reduced completely in less than 5 min. Following reaction times o f 1 
h and 2 h, a number o f peaks were observed. However, no peak was observed for 5- 
bromoisoquinolin-l-one. Therefore, a control experiment was carried out in which 
5-bromoisoquinolin-l-one was treated with tin (II) chloride. Analysis o f HPLC data 
indicated that the tin (II) chloride had no effect on the drug. These results suggested 
that the peaks observed may have been due to the amino or intermediate 
hydroxylaminoimidazole species. It was thought that failure o f tin (II) chloride to 
release the drug (108) may have been due to the tin complexing as a Lewis acid to 
the amine which made it no longer an electron-donor.
Other reducing systems, which were considered were sodium dithionite and 
diisobutylaluminium hydride (DIBAL). However, treatment o f the prodrug with 
sodium dithionite failed to release the drug. It was thought that the reducing agent 
may have reacted with the compound as the prodrug was consumed but the products 
could not be identified. In the case o f DIBAL, solubility problems o f the prodrug in 
toluene prevented the use o f this reagent.
Varghese and Whitmore202 demonstrated selective reduction o f the nitro group in 
misonidazole by treatment with zinc dust in aqueous ammonium chloride. This 
system was, therefore, thought appropriate for reduction o f the nitro group. Initially, 
control experiments were carried out with the prodrug (118), 5-bromoisoquinolin-l- 
one (108), l-methyl-2-nitro-5-hydroxymethylimidazole (94) and both zinc and 
ammonium chloride individually. The results indicated that none o f the compounds 
were affected by either o f the reagents alone. However, treatment o f the prodrug 
with both zinc and ammonium chloride in propan-2-ol afforded the slow release o f 5- 
bromoisoquinolin-l-one. In addition, a small peak for the 5-unsubstituted 
isoquinolin-l-one was observed. A small number o f other peaks were also evident in 
the chromatogram, which were thought to be the reduction products o f the 
nitroimidazole species.
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It was noted that under these reducing conditions the prodrug was completely 
consumed after 20 min. At this stage of the reaction, only a small peak was observed 
for the delivered drug 5-bromoisoquinolin-l-one. However, at shorter time periods, 
major peaks were observed in the HPLC chromatogram. These were thought to be 
the reduction products of the nitro group of the prodrug.
After a period of 1 h, the peak corresponding to 5-bromoisoquinolin-l-one had 
increased significantly. After 1 and 2 days, the 5-bromoisoquinolin-l-one (108) and 
the 5-unsubstituted isoquinolinone (120) peaks were strongly present in addition to 







HPLC retention time (min)
Figure 8 . Typical HPLC chromatograms from the reductively triggered drug release 
study. A. Synthetic standards; B. 118 + Zn / aq. NH4C1 (24 h).
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6.4 SYNTHESIS OF PRODRUG (127)
McDonald et alU2 recently reported that 5-aminoisoquinolin-l-one (124) (previously 
shown to be a potent PARP inhibitor by Suto et a/164) was successful in abolishing 
the multiple organ injury caused by severe haemorrhage and resuscitation. However, 
even more recently, they demonstrated203,204 that inhibition o f PARP by 5- 
aminoisoquinolin-l-one reduces myocardial infarct size in rats. Furthermore, (124) 
has been shown to be effective in the kidney205. As 5-aminoisoquinolin-l-one was 
proving to be extremely useful as a PARP inhibitor, this was the next drug that 
would be considered in the attachment to 5-hydroxymethyl-l-methyl-2- 
nitroimidazole trigger moiety. The synthetic route employed for this compound is 
outlined below.
o
1 2 5  X
O o O \  o




N H B oc N H B oc
1 2 2  1 2 6  1 2 7
Scheme 8 . Synthesis o f 5-amino-2-((l-methyl-2-nitroimidazol-5-
yl)methyl)isoquinolin-l-one. Reagents: i, CHCI3 / dw-butyl dicarbonate, ii, 2- 
methoxyethanol / NH3 , iii, TFA / CHCI3 /  HC1, iv, dry DMF / lithium 
bistrimethylsilylamide / l-methyl-2-nitro-5-chloromethylimidaole /N al, v, TFA.
5-Aminoisocoumarin (114) was treated with 3.0 equivalents o f di-f-butyl dicarbonate 
in the presence o f base for 4 d. Interestingly, these conditions led to the introduction 
o f two Boc groups on the exocyclic nitrogen. Compound (121) was obtained in 58%
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yield. The !H NMR spectrum was consistent with this structure in that the two t- 
butyl groups were observed at 51.83 as a singlet.
When 5-aminoisocoumarin (114) was treated with a lower excess o f di-^-butyl 
dicarbonate (1.5 equivalents) for 4 d, it gave the mono-Boc compound (122) in 56% 
yield. Now the NMR spectrum showed only one f-butyl group at 51.45. 
Furthermore, the NH was observed at 56.50 as a broad singlet. The mass spectrum 
gave a molecular ion at 262, some 100 Da less than that o f (121).
For the synthesis o f 5-aminoisoquinolin-l-one (123), it was not necessary which 
route was taken in order to obtain the desired compound. Both compounds (121) and
(122) were converted to the isoquinolinone compound (123) following treatment 
with 2-methoxyethanol and ammonia. Both procedures afforded (123) in a yield o f  
71% and 76%, respectively. In !H NMR the presence o f the NH next to the Boc 
group was evident as a broad singlet at 56.61, and the NH adjacent to the carbonyl 
was observed as a broad singlet at 510.60.
Deprotection o f (123) with trifluoroacetic acid followed by treatment with 
chloroform and HC1 gave 5-aminoisoquinolin-l-one hydrochloride (125) in 79% 
yield. Evidence for the formation o f (125) was provided by ]H NMR whereby a 
broad singlet was observed at 54.02 corresponding to the three amino protons o f the 
salt.
Having achieved the key intermediates (123) for the second target, alkylation o f
(123) at the heterocyclic nitrogen o f the isoquinoline ring was achieved following 
treatment with base and (101). Although there was a possibility that the imidazole 
trigger could attach at the NH adjacent to the Boc group, it was thought that steric 
hindrance would prevent this. 5-(l,l-Dimethylethoxycarbonylamino)-2-((l-methyl- 
2-nitroimidazol-5-yl)methyl)isoquinolin-l-one (126) was obtained in 54% yield. In 
the *H NMR spectrum the f-Bu group was observed as a singlet at 51.53. The NCH3 
o f the imidazole was observed as a singlet at 54.05. The CH2 attached to the N-2 o f  
the isoquinoline ring was observed as a singlet at 55.29 further downfield than when
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it was attached to the chloro group 84.63 in (101). This was due to the deshielding 
effect o f the heteroaromatic ring nitrogen.
Removal o f the Boc group was achieved by treatment with trifluoroacetic acid. 
Extraction o f the free base gave compound (127) in 80% yield. Evidence for the 
formation o f (127) was provided by *H NMR, whereby the NH2 was evident as a 
broad singlet at 81.58. Furthermore, the peak for the Boc group that was previously 
present at 81.53 was no longer evident.
5-Aminoisoquinolin-l-one is a potent PARP inhibitor shown to be useful in 
haemorrhagic shock and renal dysfunctions ’ ' . This was attached to the 2-
nitroimadzole trigger (1 0 1 ) with the aim that when reductively activated it will 
release the potent PARP inhibitor 5-aminoisoquinolin-l-one selectively in the 
hypoxic tumour tissue. Incorporation o f the 5-aminoisoquinolin-l-one drug 
furthermore enhanced the aqueous solubility o f the prodrug, which is essential in 
hypoxic tumour tissues because o f the poorly vascularised blood capillary network. 
Compound (127) will be evaluated in vitro and in vivo as a prodrug o f 5- 
aminoisoquinolin- 1 -one.
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6.5 ATTEMPTED SYNTHESIS OF PRODRUG (129)
Several authors have reported by using a variety o f models and ab initio calculations 
that the carboxamide moiety in the anti conformation is essential for PARP 
inhibitory activity and furthermore the carboxamide can be restricted into the anti 
conformation in heterocyclic aromatic compounds. One group o f heteroaromatic 
compounds that are currently o f interest are the quinazolin-4-ones. Griffin et al146 
recently reported the synthesis o f a number o f quinazolinones and found them to be 
extremely potent PARP inhibitors. Of this series, 8-hydroxy-2-methylquinazolin-4- 
one exhibited an IC50 o f 0.4 pM and was found to enhance the cytotoxicity o f 5-(3- 
methyltriazen-l-yl)imidazole-4-carboxamide (MTIC, a metabolite o f dacabazine and 
of temozolomide) and y-radiation 3.5- and 1.4-fold, respectively, against L1210 cells.
Miyashita et al206 reported the synthesis o f 4-(arylmethyloxy)quinazolines using 4- 
chloroquinazoline and an arylmethanol. Formation o f the arylquinazolines was 
thought to involve a nucleophilic substitution reaction between the aryl methoxide 
ion and 4-chloroquinazoline. Although the alcohol used by Miyashita et al was 
different to that used in the present work, it was proposed that treatment o f 4-chloro- 
2-phenylquinazoline (128) with 5-hydroxymethyl-l-methyl-2-nitroimidazole (84) 
may give prodrug (129). The reaction mechanism was thought to proceed via a 
nucleophilic substitution reaction between the aryl methoxide ion o f (84) and 2- 
phenylquinazoline (128), linking the 2 -phenylquinazoline to the nitroimidazole via 
an ether linkage.
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Scheme 9. Synthesis o f quinazolin-1-one. Reagents: i, NaH.
Attempts to synthesise prodrug (129) by treatment o f 4-chloro-2-phenylquinazoline 
(128) with l-methyl-2-nitro-5-hydroxymethylimidazole (94) in the presence o f base 
(sodium hydride) failed. However, ]H NMR showed that 2-phenylquinazolin-l-one 
(130) had formed via a hydrolysis reaction. Although, the reaction was performed 
under dry conditions and under argon it was thought that maybe the starting 
quinazoline (128) was wet. However, repetition o f this reaction with dry quinazoline 
also failed and again (130) was observed in *H NMR. Interestingly, the starting 
nitroimidazole compound (94) was absent in the *H NMR spectrum, suggesting that 
it may have decomposed under the reaction conditions.
Treatment o f the quinazoline (128) with the 2-nitroimidazole (94) in the presence o f  
lithium bis(trimethysilyl)amide also failed, as ]H NMR indicated only the presence 
of 2-phenylquinazolin-l-one. Evidence for the formation o f (130) was provided by 
*H NMR, whereby the NH o f the quinazolinone ring was observed at 510.20 as a 
broad singlet. No peaks corresponding to the starting nitroimidazole compound (94) 
were evident in ]H NMR.
6.6 ANALOGUES OF PRODRUG (118)
In the first target, the N 1 nitrogen of the imidazole was masked with a simple methyl 
group. However, in this advanced target, the nitrogen substituent was modified to 
incorporate a methyl ester to provide a site for elaboration to enhance aqueous 
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Scheme 10. Attempted synthesis of analogue (141). Reagents: i, EtOH / SOCI2 , ii, 
AC2 O / Na02CH, iii, NaOEt / EtOCHO, iv, aq. HC1, v, cyanamide.
Iminodiacetic acid (131) was converted to its diethyl ester (132) quantitatively by 
treatment with thionyl chloride and ethanol. The nitrogen of compound (132) was 
protected as the formamide, as before, using acetic formic anhydride, to give diethyl 
N-formyliminodiacetate (134) in 86% yield.
The methylene of compound (134) was deprotonated with sodium ethoxide and the 
anion reacted with ethyl formate to give the sodium enolate salt (135). The aldehyde 
was protected as the diethyl acetal by prolonged treatment at reflux with boiling
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ethanol saturated with HC1. The acetal (136) was obtained in 62% yield. In the lH 
NMR spectrum the ethyl ether groups are magnetically nonequivalent, with the 
methyl resonances at 81.17 and 81.20. The ester CH3 groups were observed slightly 
further downfield at 81.24 and 81.27. The protons o f the CH2 o f the ether groups 
show geminal coupling as well as vicinal couplings, demonstrating that the two 
protons o f these methylenes are also magnetically inequivalent. The CH2 protons 
were observed as double quartets at 83.54, 83.55, 83.71 and 83.72. The CH2 o f the 
CHCO2CH2 group also showed both geminal and vicinal couplings and were each 
observed as double quartets at 84.12 and 84.19. The CH2 o f the other ester 
CH2CO2CH2CH3 was split into a quartet by the adjacent CH3 group and was 
observed at 84.15. Geminal couplings were also observed for the inequivalent NCH2 
protons, which were observed as doublets at 83.39 and 83.47.
The aldehyde was unmasked by treatment with aqueous hydrochloric acid and the 
aminoimidazole (138) was formed by condensation with cyanamide. However, it 
was not possible to isolate compound (138). Attempted recrystallisation from 
propan-2-ol gave a material identifiable as a trans esterification product. However, 
accurate mass spectrum data o f the crude material confirmed the presence o f  
compound (138) as a peak o f molecular weight 242 corresponded to the molecular 
ion o f (138).
Since the aminoimidazole may be highly polar and / or unstable under the isolation 
conditions, attempts were made to mask the exocyclic amine. The crude mixture was 
treated with benzyl chloroformate and, separately, with di-f-butyl dicarbonate. TLC 
indicated that the protected compounds (139) and (140) had formed but they were 
unstable to silica during column chromatography.
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6.7 OTHER ROUTES TO l,5-DISUBSTITUTED-2-NITROIMIDAZOLES
Davis et al reported a novel synthetic strategy for 1 -unsubstituted-2-
nitroimidazoles. A synthetic route to the key compound 2-nitroimidazole-4-
methanol (150) involved 8  steps. Although there may be a problem by attaching the 
alkylating agent to the hydroxy group, it can be directed towards the adjacent 
nitrogen. This was predicted to occur by the selective fimctionalisation o f (150) at 
the N -l position, which would give access to the bioreducible masking agent (151). 
The scheme adapted for the synthesis o f compound (150) is outlined overleaf.
83





















h o h 2c
y ~ \






/  153 \




/ = \  / = \  
N y N - C P h 3
N02
B uM e^iO H ^ 
N -C P h 3
V=\










h o h 2c
V=\
N y N - H
NO,
151 150
Scheme 11. Attempted synthesis of 2-nitroimidazole-5-methanol. Reagents: i, 
Ac20  / heat / H20 , ii, EtOH / SOCl2 or EtOH / H2S 0 4, iii, NEt3 / 
chlorotriphenylmethane, iv, LiAlH4, v, DMF / TBDMSC1, imidazole, vi, 1,2- 
dimethoxyethane / BuLi / D20 .
The strategy towards the 1-unsubstituted analogue (150) was markedly different to 
that for l,5-disubstituted-2-nitroimidazoles. Imidazole-4,5-dicarboxylic acid (142)
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was decarboxylated by heating with acetic anhydride and water to give the 
intermediate tricycle (143). This was hydrolysed with water to give imidazole-4- 
carboxylic acid (144) in 49% yield. !H NMR showed a single peak at 57.70 
(integrating for 1-H) and a single peak at 58.50 (integrating for 1-H) corresponding 
to the 5-H and 2-H, respectively, of the imidazole ring. Esterification o f compound 
(144) was achieved by treatment with ethanol and thionyl chloride or with ethanol 
and concentrated H2SO4 to give ethyl imidazole-4-carboxylate.
The imidazole N-H was masked prior to the critical lithiation at the 2-position o f the 
ring; this was achieved by tritylating the less sterically hindered nitrogen to yield 
ethyl l-tritylimidazole-4-carboxylate (146). Reduction o f  compound (146) with 
lithium aluminium hydride gave l-tritylimidazole-4-methanol (147) in 93% yield.
Davis et al207 reported that treatment o f compound (147) with two equivalents o f  
butyllithium in tetrahydrofuran at -78°C formed the alkoxide in the side chain and 
introduced lithium at position 2 o f the imidazole ring. Furthermore, it was reported 
that quenching with propyl nitrate and detritylation gave the nitroimidaole (150) in 
29% yield.
It was known that the formed anion was easily quenched by moisture, therefore the 
reaction was carried out under nitrogen or argon. As the nitration step was 
unsuccessful, a number o f reasons for failure were considered. It was noted that 
butyllithium may be decomposing in tetrahydrofuran, hence the solvent 1 ,2 - 
dimethoxyethane was used.
Due to the problems encountered with the lithiation o f compound (147), it was 
proposed that masking o f the hydroxy group at position 4 o f the ring by silylation 
may enhance lithiation at the C-2 position. A procedure for the silylation step 
reported by Bond et a / 208 was followed and compound (153) was obtained in 99% 
yield. However, attempts to nitrate compound (153) by treatment with butyllithium 
and propyl nitrate failed, as only starting materials were recovered as shown in lH 
NMR.
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Attempts were carried out to lithiate the silylated imidazole (153) with butyllithium 
at -79°C, followed by quenching with various agents, including the electrophile 4- 
methoxybenzaldehyde and D2O, to give compounds (155) and (156). However, the 
reactions failed and only starting materials were evident in the NMR spectra.
Most lithiation reactions take place at low temperature conditions (-79°C) and Davis 
et al201 reported that the lithiation o f the imidazole (147) was achieved at -79°C. In 
contrast to these conditions, Bond et a / 208 reported that lithiation at the 2-position of 
the imidazole ring required heating at 40°C for 4 h. Failure to achieve lithiation at
7 0 o
-79°C led to the employment o f the reaction conditions reported by Bond et al , 
even though Bond nitrated different nitroimidazole compounds to those in the 
present work. Consequently, the reaction mixture containing compound (147), 1,2- 
dimethoxyethane and butyllithium was heated to 45°C for 4 h under argon. 
Quenching with D 2O gave crude (152). The NMR spectrum indicated that the 
intensity o f the proton at 87.30 corresponding to the 2-H proton o f the imidazole ring 
had decreased by half, indicating that at least 50% lithiation had taken place. 
Accurate MS data confirmed that compound (152) was present, as a molecular ion at 
341 was evident.
Although the lithiation reaction reported by Davis et al207 used mild ambient 
conditions, it was found during these studies that harsh conditions were required to 
lithiate at the 2- position o f the imidazole ring. This was demonstrated in the 
reaction between the imidazole (147) and butyllithium in which the reaction mixture 
was heated at 45°C for 4 h. Quenching with D2O gave crude (152). !H NMR 
spectrum indicated that at least 50% lithiation had taken place as the intensity o f the 
2 -proton had decreased.
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6.8 CRITICAL 2-NITROTHIOPHENE INTERMEDIATES
Recently, there has been widespread interest in the use o f nitrothiophene type 
compounds as radiosensitisers, bioreductively activated cytotoxins and inhibitors o f  
PARP18,168. A number o f authors18,168 have previously reported the synthesis o f a 
variety o f nitrothiophene compounds with various allkylating agents that have been 
shown to be effective as radiosensitisers. Therefore, the next synthetic target was the 
nitrothienylmethylisoquinolin-l-one (161). This consists o f the 2-nitrothiophene-5- 
ylmethyl trigger unit linked to the (masked) potent PARP inhibitor 5- 
aminoisoquinolin-l-one (124). Attachment o f 5-chloromethyl-2-nitrothiophene 
(160) to a quinazolin-l-one was also attempted to synthesise prodrug (162). The 
route investigated for the synthesis o f the prodrugs (161) and (162) is outlined below.
NHBoc
Scheme 12. Attempted synthesis o f prodrugs (161), (162) and (163). Reagents: i, 
THF/NaBH 4 , ii, SOCl2.
2-Nitrothiophene-5-carboxaldehyde (158) is a readily available and cheap starting 
material and is the starting point in the synthesis o f the key intermediate 5- 
chloromethyl-2-nitrothiophene. Reduction o f compound (158) with sodium 
borohydride gave 5-hydroxymethyl-2-nitrothiophene (159) in excellent yield. 
Reaction o f compound (159) by treatment with thionyl chloride gave 5-
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chloromethyl-2-nitrothiophene (160) in very high yield. In the !H NMR spectrum, 
the CH2 was split into a doublet by long-range coupling to the 4-H.
Alkylation o f the isoquinolinone (123) was attempted with 5-chloromethyl-2- 
nitrothiophene (160) in dimethylformamide. As no reaction occurred at 20°C, the 
mixture was heated to 50°C for 12 h and boiled under reflux for 5 h. *11 NMR 
analysis indicated only the presence o f the starting material (123) and no peaks were 
evident for the nitrothiophene compound. This suggested that the nitrothiophene 
compound may have decomposed under the harsh conditions employed.
Synthesis o f prodrug (162) was also attempted by treatment o f 2 -phenylquinazolin-l- 
one (128) with 5-chloromethyl-2-nitrothiophene (160) in the presence o f lithium 
bis(trimethysilyl)amide. No reaction occurred at 20°C, consequently, the mixture 
was heated to 50°C for 48 h and at 70°C for 24 h. !H NMR only indicated the 
presence o f quinazolin-l-one (130).
As mentioned earlier, Miyashita et al reported a synthetic route to 4- 
(arylmethyloxy)quinazolines using 4-chloroquinazoline and aryl methanol in the 
presence o f base. Following the reported procedure, attempts were made in order to 
synthesise prodrug (163) using 4-chloro-2-phenylquinazoline (128) and 5- 
hydroxymethyl-2-nitrothiophene (159). However, the reaction was unsuccessful and 
only quinazolin-l-one (130) was obtained via the hydrolysis reaction. In the !H 
NMR spectrum, no signals were evident for 5-hydroxymethyl-2-nitrothiophene 
suggesting that the compound had decomposed.
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6.9 QUINOLINE-8 -CARBOXAMIDES AND QUINOLINE N-OXIDES
As mentioned in the introductory chapter, N-oxides, such as SR 4233, have been 
shown to be bioreductive agents that exhibit high selective toxicity for hypoxic cells. 
These types o f compound have an absolute requirement for one-electron reduction in 
order for toxicity to be expressed. The mechanism o f action is thought to be 
different to that reported for the nitroaromatic compounds in that it is the N-oxide 
radical species that causes toxicity by means o f reacting directly with cellular 
macromolecules. This is thought to be achieved by hydrogen being abstracted from 
bases in DNA, which results in extensive DNA single and double stranded breaks.
It was proposed that rather than having a nitroimidazole based prodrug, we can have 
an N-oxide type prodrug. Previous studies have shown for example, that SR4233 
(13)6'37 and AQ4N (171)209 are bioreduced. As the N-oxides can be bioreduced, a 
prodrug was designed based on N-oxide bioreduction.
OH O  NH(CH2)2N(CH3)2
OH O  NH(CH2)2N(CH 3)2 
171 O
Sims et al159 found that the carboxamide function was critical for PARP inhibition. 
Furthermore, it was shown that the carboxamide function could be incorporated into 
a heteroaromatic ring without affecting its activity against the enzyme.
Banasik et al163 substantiated this evidence by synthesising compounds in which the 
carbamoyl substituent is incorporated within a ring system. This resulted in highly 
potent PARP inhibitors and 1,8-naphthalimide derivatives, 5-hydroxyisoquinolin-l-
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one, phenanthridinone and quinazolin-4-one compounds were all found to be active. 
Based on the above and the fact that a carboxamide group in the benzamide and 
nicotinamide series is essential for activity, it was thought that such compounds were 
occupying the nicotinamide binding site o f PARP and that the 3-substituent was 
incorporated in the ribose nucleoside-binding domain. Furthermore, it was observed 
in the benzamide series that the active compounds were those that contained a 
primary amide. This indicated that important hydrogen bond interactions were 
occurring with an amino acid donor within the enzyme’s active site.
In fact, recent studies104,149,150,166 have shed light onto the crystal structures o f  
PD128763 and NU1025 bound to the catalytic domain o f PARP. From the crystal 
structures it can be seen that all the inhibitors bind in the same ‘anti’ orientation and 
complexes are formed between the two hydrogen bonds occurring between the 
carbonyl and NH (or NH2) groups and the peptide backbone o f Gly-863. The third 
hydrogen bond is thought to occur between the carbonyl group o f the inhibitor and 
the side chain o f Ser-904.
Suto et al164 demonstrated the ‘anti’ theory by using 2,3-disubstituted benzamides 
and 5-substituted dihydroisoquinolinone compounds. In the former case, the 
analogues were found to be completely inactive as the ‘syn’ conformation was 
adopted. However, in the case o f dihydroisoquinolinones where the carboxamide 
was constrained in the ‘anti’ conformation, the compounds were found to be 
extremely potent.
Griffin et a l165 extended these studies to benzoxazole-4-carboxamide compounds. It 
was reported that intramolecular hydrogen bond interactions occurred between the 
amide NH and the oxazole nitrogen. This afforded a donor carbonyl group 
constrained in the biologically active ‘anti’ conformation. However, even more 
recently, White et a l150 extended these studies to the benzimidazole-4-carboxamides 
and found 2-phenyl-lH-benzimidazole-4-carboxamide (65, Ki 15nM) to be 
particularly active against PARP. A number o f analogues were developed with 
various substituents on the phenyl ring. Many o f them exhibited Ki values for PARP 
inhibitory activity <10 nM, with 2-(4-hydroxymethylphenyl)-lH-benzimidazole-4- 
carboxamide (6 6 ) exhibiting a Ki value of 1.6 nM and being the most potent inhibitor
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of PARP reported to date. The concept was similar to that o f the benzoxazole-4- 
carboxamide compounds in that the carboxamide group was restricted via an 
intramolecular hydrogen bond150,164.
These studies demonstrate that the ‘anti’ /  ‘syn’ conformation can be controlled by 
either constraining the carboxamide within a heteroaromatic ring system or by 
constraining the carboxamide via an intramolecular hydrogen bond. In both 
benzoxazole-4-carboxamides and benzimidazole-4-carboxamide the design is similar 
in that they consist o f a 6  /  5 fused ring. However, the compounds that were 
synthesised in our laboratory were 6 / 6  fused rings. Based on the above studies, it 
was postulated that a quinoline-N-oxide compound would demonstrate this concept 
as it was thought that in the presence o f the N-oxide group the carboxamide would be 
tipped out o f plane where as in the absence o f the oxygen the compound would be in 
plane. The carbonyl twisted out o f plane destroys the pharmacophore and with 




Figure 9. Demonstrates the structure o f the carboxamide when it is ‘in-plane’ and 
when twisted ‘out-of-plane’.
To establish whether this postulated H-bond is real and whether the substituents at 
the N -l position would twist the carboxamides out o f plane, a number o f quinoline 
and quinoline N-oxide compounds were synthesised.
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Naphthalene-1-carboxylic acid (174) was converted to its acid chloride (175) 
following treatment with thionyl chloride. Treatment o f (175) with ammonia and 
chloroform gave naphthalene-1-carboxamide (176) in 87% yield. An alternative 
route for synthesis, involved initially converting the acid (174) to its methyl ester 
(177) by treatment with thionyl chloride and methanol. Treatment with methanol / 
conc. ammonia gave the carboxamide (176) in a lower yield o f 53%.
CONH
c o 2c h 3
1 7 7
Scheme 13. Synthesis o f naphthalene-1 -carboxamide. Reagents: i, SOCI2, ii, 
MeOH / SOCI2 , iii, CHCI3 / NH3, iv, MeOH / conc. NH3.
Quinoline-8 -carboxylic acid (178) was converted to its acid chloride (179) by 
treatment with thionyl chloride. Treatment o f the acid chloride (179) with 
chloroform and ammonia gave quinoline-8 -carboxamide (180) in 90% yield. An 
alternative route for synthesis involved initially converting the acid (178) to its 
methyl ester (181) and subsequent reaction with ammonia to give the carboxamide 
(180) in a slightly lower yield.
c o 2h  c o c i  c o n h 2
c o 2c h 3
181
Scheme 14. Synthesis o f quinoline-8 -carboxamide. Reagents: i, SOCI2 , ii, MeOH / 
SOCI2 , iii, CHC13 /  NH3, iv, MeOH / conc. NH3.
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In the NMR spectrum o f naphthalene-8 -carboxamide, one N-H was observed at 
87.56 and the other at 87.99. The NH2 signals are close together. However, in 
quinoline-8 -carboxamide, one o f the N-H signals was evident at 86.04 whereas the 
other N-H was observed much further downfield at 810.94. This study demonstrates 
that the carboxamide has a very restricted conformation and that the N-H at 810.94 is 
tightly hydrogen-bonded.
A number o f strategies were employed to approach the synthesis o f quinoline-8 - 




Scheme 15. Attempted synthesis o f 8 -bromoquinoline N-oxide. Reagents: i/ii, 
SOCI2 or TsCl, iii, EtOH / NaOH / H20 2, iv, AcOH, H20 2, v, (CH3C 02)2Hg / NaCl, 
vi, H2O / Br2 / KBr, vii, THF / BuLi / trimethylsilyl isocyanate.
Attempts to oxidise (180) directly to the quinoline-8 -carboxamide N-oxide (182) 
with w-chloroperoxybenzoic acid also failed and only the starting compound and
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decomposed material were recovered. It was thought that failure o f the reaction may 













Scheme 16. Proposed mechanism for the synthesis o f quinoline-8 -carboxamide N- 
oxide by directed oxidation / hydrolysis.
It is generally known that nitriles are formed following dehydration o f corresponding 
amides. It was thought that, as direct oxidation o f quinoline-8 -carboxamide (180) 
was unsuccessful, it may be possible to carry out a directed oxidation whereby 8 - 
cyanoquinoline (183) undergoes treatment with hydrogen peroxide. Treatment o f  
quinoline-8 -carboxamide with thionyl chloride gave 8 -cyanoquinoline (183) in 80% 
yield. Similar treatment with /?-toluenesulfonyl chloride gave (183) in a higher yield 
of 97% and with less decomposed material. Direct oxidation o f 8 -cyanoquinoline
(183) with concomitant hydrolysis by treatment with sodium hydroxide and 
hydrogen peroxide failed, giving only quinoline-8 -carboxamide (180). Failure o f  
this reaction was thought to be due to the wrong conformation being adopted, hence 
preventing the reaction from occurring. The proposed mechanism is outlined above.
The results obtained demonstrate that a direct oxidation o f quinoline-8 -carboxamide 
(180) was unsuccessful in yielding the carboxamide N-oxide (182). Furthermore, 
directing oxidation o f the cyanoquinoline (183) to the N-oxide compound (182) also
*71A 01 1 91 1failed. Consequently, an alternative route was proposed ’ . Brzezinski claimed
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that 8 -bromoquinoline N-oxide could be converted to its Grignard reagent; reaction 
with formaldehyde introduced a 1-carbon unit to give 8 -hydroxymethylquinoline N- 
oxide. Similarly, it was proposed that formation o f the Grignard reagent and 
treatment with trimethylsilyl isocyanate would give the N-oxide (182) directly from 
(187).
Quinoline (184) was oxidised to the N-oxide (185) by treatment with hydrogen 
peroxide and acetic acid, in very high yield. In the NMR spectrum of quinoline
(184) the 8 -proton was evident at 57.70 where as in the N-oxide (185) the 8 -proton 
moved sharply downfield to 58.76. This was due to the deshielding effect o f the 
adjacent oxygen. However, when making the N-oxide the 2-proton shifts slightly 
upfield from 58.93 in (184) to 58.55 in (185).
Mercuration at the 8 -position by treatment with mercuric (II) acetate and sodium 
chloride gave the chloromercuri compound (186) in 83% yield. Electrophilic 
replacement o f the chloromercuri group by bromine gave 8 -bromoquinoline N-oxide 
(187) in 29% yield. In the !H NMR spectrum the 2-H was observed downfield at 
58.75 due to the deshielding effect o f the adjacent N-oxide group. Further evidence 
to support the formation o f (187) was provided by MS data whereby the molecular 
ion was evident at 224/226 and loss of hydrogen bromide gave an ion at 144. 
Treatment o f 8 -bromoquinoline N-oxide (187) in ether with magnesium and 
trimethylsilyl isocyanate failed to give the N-oxide (182) and !H NMR only 
indicated the presence o f the starting materials, suggesting that the Grignard reagent 
(RMgBr) had not formed. Furthermore, solubility problems were encountered with 
the use o f diethyl ether as the solvent and this factor may have contributed to the 
failure o f the reaction.
An alternative route212 to incorporate the carboxamide group into the 8 -position 
without affecting the N-oxide moiety was considered. It was proposed that 
halogen-> lithium exchange and treatment with trimethylsilyl isocyanate may afford 
the desired compound (182). Initially, the hypothesis was tested with 8 - 
bromoquinoline (191). Treatment o f (191) with butyllithium followed by quenching 
with trimethylsilyl isocyanate gave quinoline-8 -carboxamide in 79% yield.
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However, treatment o f 8 -bromoquinoline N-oxide (187) with butyllithium and 
quenching with trimethylsilyl isocyanate failed to give the N-oxide (182), but 
furnished quinoline-8 -carboxamide in 77% yield. It was thought that the reason for 
failure was partly due to the fact that 8 -bromoquinoline N-oxide (187) is hygroscopic 
and therefore picks water easily from the atmosphere, consequently making the 
lithiation reaction more difficult. Furthermore, the use o f the base butyllithium 
appeared to cleave the oxygen o f the N-oxide group, suggesting that such compounds 
may be unstable under these basic conditions.
Nakashima and Suzuki reported the direct oxidation o f 8 -methylquinoline with 
hydrogen peroxide and acetic acid. It was reported that 3-hydroxy-8-
methylquinoline and 8 -methylquinoline N-oxide were obtained in 14% and 8 % yield. 
It was proposed that similarly, it may be possible to oxidise 8 -bromoquinoline 
directly with hydrogen peroxide and acetic acid to give the N-oxide (187). However, 
following treatment with hydrogen peroxide and acetic acid, ]H NMR indicated the 
presence o f only 8-bromo-3-hydroxyquinoline (192), which was obtained in 8 6 % 
yield. Evidence for the formation o f (192) was provided by the fact that the 3-proton 
was no longer evident in *H NMR. However, Hamm and Philipsbom214 reported the 
use o f an alternative oxidising agent. It was reported that 8 -methylquinoline was 
oxidised to 8 -methylquinoline N-oxide in 54% yield by treatment with 
peroxybenzoic acid. However, in subsequent runs, attempts to oxidise 8 - 
bromoquinoline (191) with m-chloroperoxybenzoic acid failed and ]H NMR only 
indicated the presence o f the starting material and decomposed material.
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Scheme 17. Attempted synthesis o f quinoline-8 -carboxamide and 2-phenyl- 
quinoline-8 -carboxamide. Reagents: i, AcOH / H2O2 , ii, CHCI3 /  SeC>2, iii, CHCI3 / 
/72-CPBA, iv, CCI4 /  NBS / dibenzoyl peroxide, v, THF / PhMgBr / NH4 CI / Pb0 2  / 
CfcH^ , vi, EtOH / NaOH / H2O2 , vii, SOCI2 or oxalyl chloride, viii, CHCI3 / NH3 .
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As it was proving difficult to synthesise the desired quinoline-8 -carboxamide N- 
oxide (182) by the above synthetic routes, an alternative route was sought. This was 
to oxidise an 8 -methyl unit in the N-oxide ring system. It was proposed that 
oxidation o f 8 -methylquinoline to the N-oxide, followed by oxidation o f the methyl 
group to an acid and subsequent formation o f the amide would provide a route for the 
synthesis of quinoline-8 -carboxamide N-oxide (182). Attempts to oxidise 8 - 
methylquinoline (198) directly to the N-oxide (199) by hydrogen peroxide in acetic 
acid failed to give the N-oxide but gave 8-methyl-3-hydroxyquinoline (200) in 93% 
yield. Evidence for the formation o f (200) was provided by NMR whereby the 3- 
H was no longer present and coupling was observed between the 2 and 4 protons. 
Furthermore, the OH signal was evident at 510.25. However, treatment o f (198) with 
/w-chloroperoxybenzoic acid afforded 8 -methylquinoline N-oxide (199) in 95% yield. 
This represents a major advance on the reported 54% using peroxybenzoic acid214. 
In the !H NMR spectrum o f 8 -methylquinoline (198), the Me group was evident at 
52.83. However, in the N-oxide (199) the Me group moves downfield to 53.19 due 
to the deshielding effect o f the adjacent oxygen. Also evident in the spectrum is that 
the 2-proton moves slightly upfield going from 8 -methylquinoline (198) at 58.97 to 
58.39 in the N-oxide (199). This is consistent with the data obtained for quinoline N- 
oxide (185) where the 2-proton similarly shifted upfield going from quinoline (184) 
to the N-oxide (185).
Having achieved the synthesis o f 8 -methylquinoline N-oxide (199), attempts were 
made to oxidise the 8 -methyl group to the aldehyde with selenium dioxide. 
Oxidation o f 8 -methylquinoline (198) with selenium dioxide failed to give the 
aldehyde but gave 8-methylquinolin-4-one (201) in 82% yield. The *H NMR 
spectrum of the crude product mixture also indicated a trace amount o f 8 - 
methylquinoline (198). This demonstrates that either the N-oxide (199) is thermally 
unstable or that selenium dioxide is behaving as a reducing agent. !H NMR was 
consistent with compound (201) as the 4-H was no longer evident. Oxidation o f  
(199) with potassium permanganate also failed to oxidise the methyl group and only 
decomposed material was evident in the !H NMR spectrum. Therefore, an 
alternative route was sought.
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Aromatic compounds can be brominated under free radical conditions by treatment 
with N-bromosuccinimide and a radical initiation. This was proposed to provide a 
route to quinoline-8 -carboxamide N-oxide. However, treatment o f (199) with N- 
bromosuccinimide gave mainly the starting material. Nevertheless, MS data 
revealed trace amounts o f the desired compound (2 0 2 ).
©M gBrCH3 O
Scheme 18. Schematic representation o f the attack o f the Grignard reagent on 8 - 
methylquinoline N-oxide. Reagents: i, THF / PhMgBr / / PbC>4 .
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In 1980, Colonna et al reported a synthetic route to 2-phenylquinoline N-oxides in 
that treatment o f  8 -methylquinoline N-oxide with phenylmagnesium bromide results 
in nucleophilic attack at the C-2 position to give the corresponding 2- 
phenylquinoline N-oxide. The analogue 2-phenylquinoline-8-carboxamide N-oxide 
was o f interest in !H NMR studies because the 2-phenyl would occupy the region o f  
space as the 2-aryl substituent in the benzimidazole-4-carboxamide147. Furthermore, 
the phenyl group was proposed to improve the potency o f the compound. Treatment 
with Grignard gives (213). However, the intermediate can be oxidized in situ with 
lead (IV) dioxide to give the N-oxide (204). Column chromatography gave 8 - 
methyl-2-phenylquinoline (203) in 48% yield and the desired novel 8-methy-2- 
phenylquinoline N-oxide (204) in 29% yield. In the !H NMR spectrum of 8 -methyl- 
2-phenylquinoline (203), the Me group was evident at 82.89; however, the signal 
moves further downfield in the N-oxide (204) to 83.21 due to the deshielding effect 
of the adjacent oxygen attached to the heteroaromatic ring nitrogen. Also evident in 
the !H NMR spectrum was that the 2- and 6 -protons o f the phenyl group at position 2
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o f the heteroaromatic ring in (203) were at 58.23 but in the N-oxide (204) they had 
shifted slightly upfield to 57.84. The data for compounds (203) / (204) are consistent 
with that reported for 8 -methylquinoline / 8 -methylquinoline N-oxide in that the 8 - 
methyl group is shifted downfield in the N-oxide compounds. Similarly, in the 13C 
NMR spectrum, the CH3 o f (203) was observed at 5c 18.36, whereas the CH3 o f (204) 
with the N-oxide was observed further downfield at 5c25.51. Evidence for the 
formation o f the N-oxide compound was further substantiated by MS in which the 
molecular ion was observed at 236.
Direct oxidation o f 8-methyl-2-phenylquinoline (203) with m-chloroperoxybenzoic 
acid to introduce the N-oxide into the compound failed and NMR only indicated 
the presence o f the starting compound. It was thought that steric hindrance from the 
C-2 phenyl group may have prevented the oxidation from taking place.
Attempts to oxidise the CH3 o f the N-oxide (204) with selenium dioxide to the 
aldehyde compound (205) also failed. Column chromatography o f the crude 
indicated the presence o f a number o f compounds. Analysis o f the NMR 
spectrum found them to be 8-methyl-2-phenylquinoline (203) in 16% yield, followed 
by the novel 2-phenylquinoline-8-carboxaldehyde (206) obtained in 40% yield and 
2-phenylquinoline-8-carboxylic acid (207) obtained in 29% yield. It was thought 
that in the reaction the selenium dioxide was converting to selenium metal, which 
was thought to be responsible for reducing the compound. Evidence for the 
formation o f the aldehyde (206) was provided by !H NMR, whereby the CH3 peak 
had disappeared and a CHO peak was observed at 511.67, which was very low field 
for an aldehyde. This indicates that the aldehyde is in-plane and deshielded. 
Furthermore, the 7-H was shifted downfield to 58.34 due to the electron-withdrawing 
effect o f the aldehyde. Evidence for the formation o f the acid (207) was obtained by 
the fact that no CHO signal was observed in !H NMR and furthermore, the acid 
signal was evident at 517.00 as a broad singlet, the very pronounced deshielding 
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Scheme 19. Schematic representation o f the attack o f hydrogen peroxide on 
quinoline-2 -phenylcarboxaldehyde.
It was proposed that it may be possible to form the N-oxide compound by a directed 
oxidation o f the aldehyde (206) with hydrogen peroxide. However, treatment with 
the above reagents failed to give the N-oxide (205). It was thought that the reaction 
may have failed due to the wrong conformation being adopted, or that the 
heteroaromatic ring nitrogen is not nucleophilic enough hence preventing the 
oxidation from taking place. This was demonstrated earlier with 8 -cyanoquinoline.
Treatment o f the aldehyde (206) with sodium hydroxide and hydrogen peroxide in 
acetone also failed to give the N-oxide compound (205) and instead gave the novel 
compound (211) in 83% yield, in an aldol reaction with the solvent. However, it is 
an interesting compound to have for comparison with the carboxamide compounds.
Since the acid compound (207) was obtained, it was thought that the 2- 
phenylquinoline-8 -carboxamide may be useful in !H NMR studies. Consequently, 
(207) was converted into the acid chloride (208) by treatment with thionyl chloride. 
The acid chloride was then treated with ammonia. Two compounds were evident in 
the ]H NMR spectrum. One was the desired 2-phenylquinoline-8-carboxamide 
(209), whereas the other appeared to be missing the quinoline 3-H. Recrystallisation 
gave (210) in 20% yield and (209) in 65% yield. It was found that thionyl chloride
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gave an unexpected oxidation, chlorinating at an unusual position. Evidence for the 
formation o f compound (209) was obtained by *H NMR whereby one o f the N-H 
groups was observed at 56.36 and the other N-H was evident further downfield at 
511.18. This was consistent with quinoline-8 -carboxamide where similar chemical 
shifts were observed for the N-H2 protons. This study demonstrates that the 
carboxamide has a very restricted conformation and that the N-H observed at 511.18 
is hydrogen bonded. In compound (210) the 4 proton was evident as a singlet at 
58.42. Further evidence was provided by MS data, whereby the molecular ion was 
observed at 285/283. In subsequent runs, to prevent the formation o f the chloro 
analogue, compound (207) was treated with the less oxidative oxalyl chloride. 
Treatment o f the acid chloride with ammonia gave 2-phenylquinoline-8-carboxamide 
(209) in 94% yield.
In this section o f  the project, although the synthesis o f the target was not achieved, 
several advances in quinoline chemistry were made. It was found that 8 -methyl­
quinoline N-oxide could be obtained in excellent yield by treatment with m- 
chloroperoxybenzoic acid. In addition, the synthesis o f the analogue 8-methyl-2- 
phenylquinoline N-oxide was found to highly sterically hinder the N-oxide. 
Formation o f 2-phenylquinoline-8-carboxamide by treatment o f the acid (207) with 
thionyl chloride gave unexpected oxidation at the 3-position. During these studies 
the intramolecular hydrogen-bond in quinoline-8 -carboxamide and 2 -phenyl- 
quinoline-8 -carboxamide was demonstrated. lH NMR studies showed that when the 
carboxamide was in plane, one o f the N-H were found to be hydrogen-bonded 
resulting in the signal being very low field. Although the attempted directed 
oxidations with 8 -cyanoquinoline and 2 -phenylquinoline-8 -carboxaldehyde failed to 
give the N-oxide compounds, it was thought that this may have been due to the 
reacting materials participating in the intramolecular hydrogen-bond, which 
prevented the formation o f the N-oxide compounds.
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7.0 SYNTHESIS OF I4C-LABELLED CURCUMIN (235)
Curcumin is currently o f interest as a chemopreventive and chemoprotective agent 
against cancer. Studies carried out with mice have demonstrated that curcumin is 
poorly adsorbed from the gut185*188. In an attempt to elucidate its metabolism, 
biodistribution and pharmacological activity in human trials, 14C-labelled curcumin 
was required so that the compound may be monitored in the urine by isotope ratio 
mass spectroscopy.
The isotopic label was incorporated into the heptatriene core o f curcumin, which was 
thought to ensure its retention during metabolic processes. The majority of the 
synthetic routes published in the synthesis o f unlabelled curcumin have involved the 
condensation o f 4-hydroxy-3-methoxybenzaldehyde (223) with pentane-2,4-dione 
under acidic or basic conditions216'220. It was proposed that the isotope be located in 
the aldehyde component o f compound (223) as opposed to incorporating it in the 
pentane-2,4-dione moiety, because the required intermediate could be synthesised 
from a one-carbon unit. Furthermore, the labelled intermediates 4-hydroxy-3- 
methoxybenz-[2H]-aldehyde and 4-hydroxy-3-methoxybenz-[14C]-aldehyde may be 
o f use in biochemical studies.
The procedure followed to synthesise unlabelled curcumin was that reported by Babu 
and Rajasekharan219. This was the chosen route for synthesis as the route allowed for 
the incorporation o f the isotope in the heptatriene core o f curcumin. The synthetic 
route employed is outlined on the following page.
103
a OCHi B K ^ 0 C H 2OH k A ii/iiiOH XX
2 1 8 2 1 9 2 2 0  R = S i(C H 3)2Bu* 
2 2 7  R  = CH CH 3OEt





H02a ^ O C H 3
X X _O Si(CH 3)2Bu'
2 2 4
VI
H02C 1 ^ ^ 0 C H 3XX,‘OH
2 2 5
R2Y ^ och3
^ ^ O R 1
2 2 2  R 1 = S i(C H 3)2Bu( 
R2 = CHO
2 2 9  R 1 = CH CH 3OEt 
R 2 = CHO
2 3 0  R 1 = CHCH3OEt 
R 2 = C2HO
2 3 2  R 1 = CHCH3OEt 
R2 = 14CHO
XX,OH
2 2 3  R = CHO  
231 R = C2HO 
2 3 3  R = 14CHO
V II
v U . i o c h 3
OH
IV
LK>^ ? v n ^OCH3XX,‘O R
2 21 R = Si(C H 3)2B uf 
2 2 8  R = CHCH3OEt
6 8  R = 1H 
X = 12C
2 3 4  R = 2H 
X = 12C
2 3 5  R = 1H 
X = 14C
Scheme 20. Synthesis o f 14C-labelled curcumin. Reagents: i, CHCI3 /  Br2, ii, DMF 
/  TBDMSC1 / imidazole, iii, CHCI3 / ethoxyethene / pyridinium4-methylbenzene 
sulfonate, iv, THF / BuLi, v, DMF or DCON(CD3) 2 or H 14CON(CH3)2, vi, aq. H2 S 0 4 
/ TBAF or aq. HC1, vii, DMF / pentane-2,4-dione / B2C>3 / AcOH / 1,2,3,4- 
tetrahydroquinoline.
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Treatment o f 2-methoxyphenol (218) with bromine and chloroform by the procedure 
reported by Mabic and Lepoittevin221, gave 4-bromo-2-methoxyphenol (219) in 98% 
yield.
•j
Although synthesis o f regiospecifically ring [ H]-labelled vanillins have been 
reported222'224, whereby the 2-H was incorporated either by direct lH->2H exchange 
or by replacement o f a halogen, it was preferred to carry out a halogen-lithium 
exchange on an oxygen-protected 4-bromo-2-methoxyphenol followed by quenching 
with anhydrous (labelled) dimethylformamide.
In earlier reactions, the oxygen o f compound (219) was protected as its OSiM^Bu* 
derivative. This was achieved following treatment o f compound (219) with t- 



































































































Table 1. Optimisation studies for the synthesis o f (223).
Treatment o f compound (220) with butyllithium, unlabelled dry dimethylformamide, 
followed by acid hydrolysis and deprotection with /e/rabutylammonium fluoride 
gave 3-methoxy-4-hydroxybenzaldehyde (vanillin) (223). However, many problems 
were encountered during the synthesis o f (223).
Initially, it was thought that 0.9 / 1.0 equivalents o f butyllithium was sufficient for 
complete lithiation to take place. However, this was not the case and treatment of  
compound (220) with butyllithium (0.9 equivalents) in the presence o f excess 
dimethylformamide only gave compound (223) in 21% yield. Repetition o f the 
above reaction but with the more reactive /-butyllithium and using similar ratios of 
reacting agents gave the benzaldehyde (223) in 51% yield. However, it was noted 
with the use o f the more reactive /-butyllithium that a number o f further compounds 
were evident on TLC. In subsequent runs a further compound (225) was identified in 
*H NMR. It was thought that use o f aqueous sulfuric acid was oxidising the 
aldehyde to the acid and crude (225) was obtained. To prevent the formation of the 
acid derivative (225), in further reactions, aqueous hydrochloric acid was used during 
the work-up procedure.
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Due to the very low yields obtained it was needed to be determined whether the 
compound was lithiating efficiently or whether the lithio compound reacted. This 
was tested by carrying out a bromine->lithium exchange o f compound (2 2 0 ) with the 
/-butyllithium (fixed at 1 . 0  equivalents), followed by quenching with benzaldehyde. 
Aliquots were taken out every hour to see whether the compound was lithiating. 
However, no lithiation occurred, as determined by TLC and *H NMR. This 
suggested that the bromine-> lithium exchange was not taking place with ratio o f  
base used.
In an attempt to increase the yield o f compound (223), the temperature conditions for 
lithiation were investigated and found that the optimum lithiation temperature with t- 
butyllithium was -79°C. An alternative lithiating reagent was also investigated. 
Treatment o f compound (220) with methyllithium (1.0 equivalents) at -79°C and 
DMF (1.0 equivalents) failed and only starting material was recovered.
Another problem that was encountered during the synthesis o f (223) was separating 
the starting compound from the intermediate silylated compound (222). This was 
due to both compounds having very similar R f values. However, although time- 
consuming, this problem was overcome by the use o f column chromatography 
carried out under gravity. With the silylated compound (220), the acid used (aqueous 
hydrochloric acid / aqueous sulfuric acid) was unsuccessful in removing the 
protecting group completely, therefore the crude had to be treated with tetra- 
butylammonium fluoride. It was noted that to incorporate the isotope into the 
aldehyde from a one-carbon unit, it was important to optimise the yield based on 
dimethyformamide as opposed to the bromoarene. Hence, the problems encountered 
with the use o f the starting silylated compound (2 2 0 ) suggested that an alternative 
protecting group was required.
Recently, Ralph et al225 reported the synthesis o f 4-hydroxy-3-[12C, 2H3]methoxy- 
benzaldehyde from the starting 4 -bromo-2 -[2H3]methoxyphenol which was protected 
as an acetal. This reaction was reported to give the isotopically labelled 
benzaldehyde in a yield o f 78%. The reaction employed the use o f butyllithium (3.0
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equivalents) and dimethylformamide (3.0 equivalents). Treatment o f compound 
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Table 2. Optimisation studies for the synthesis o f (223).
4-Bromo-2-methoxyphenol (219) was protected as the acetal by 
ethoxyethene and pyridinium-4-methylbenzenesulfonate. 




Bromine->lithium exchange with butyllithium at -79°C gave the anion (228) and 
quenching with unlabelled dimethylformamide gave compound (229). Acid 
hydrolysis (aqueous hydrochloric acid) cleaved both the intermediate iminium and 
the protecting acetal to give the desired benzaldehyde (223).
An optimisation study was carried out with the acetal (227). Initially, (227) was 
treated with 1.5 equivalents o f butyllithium and quenched with 1.5 equivalents o f  
anhydrous DMF. However, the reaction was unsuccessful and lH NMR indicated 
the presence o f starting material only. This study demonstrated that higher base and 
formamide ratios were required in order for the reaction to be successful.
In subsequent runs, compound (227) was treated with 3.0 equivalents o f butyllithium 
and a 2.0 equivalents o f anhydrous DMF. Compound (223) was obtained in 55% 
yield. As the compound was only lithiated for 1 h at -79°C, it was proposed that this 
lithiating time period may be insufficient for complete lithiation to take place. 
Consequently, reactions were carried out with the butyllithium fixed at 3.0 
equivalents and the dimethylformamide fixed at 2 . 0  equivalents and the lithiating 
reaction times were varied from 2 to 4 h. Lithiating the mixture for 2 h at -79°C gave 
(223) in 64% yield. However, increasing the lithiation time to 4 h resulted in a lower 
yield o f 45%. Therefore, the optimum lithiation time was in fact 2 h and it was 
thought that at longer lithiating periods the reaction was slowly being quenched.
Increasing the ratio o f dimethylformamide enhanced the yield o f compound (223). 
Treatment o f compound (227) with butyllithium (3.0 equivalents) and 
dimethylfomamide (3.0 equivalents) gave the aldehyde (223) in 70% yield.
Based on these optimisation studies it was observed that an excess o f the alkyl 
lithium was required. With the butyllithium fixed at 3.0 equivalents, it was found 
that by varying the amount o f the dimethylformamide (from 2.0 to 3.0 equivalents) 
afforded a higher yield based on compound (227). However, dimethylformamide 
fixed at 2 . 0  equivalents afforded the potentially more isotopically efficient yield 
based on dimethylformamide. Furthermore, it was established that the optimum time 
for bromine-> lithium exchange was 2 h at -79°C resulting in a maximum yield o f
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32% o f 4-hydroxy-3-methoxybenzaldehyde (223) based on dimethylformamide and 
64% based on the bromoarene.
Application o f the optimised lithiation conditions and quenching with 
0 2HCN(C2H3 )2  (2.0 equivalence ratio) afforded 4-hydroxy-3-methoxybenz-[2H]- 
aldehyde (231) in 55% yield based on the bromoarene and 27% based on the 
dimethylformamide. *H NMR spectroscopy further confirmed the formation o f the 
2H-compound (231), as no aldehyde peak was evident in *H NMR. 13C NMR also 
provided further evidence for the formation o f (231), whereby the C HO was 
observed as a triplet at 8190.64, with a coupling constant o f  ^c-d 26.4 Hz (2H has 
sp in /=  1 ).
Similarly, treatment o f compound (227) with butyllithium (3.0 equivalents), followed 
by quenching with OH14CNMe2 and hydrolysis o f the intermediate (232) gave 4- 
hydroxy-3-methoxybenz-[14C]-aldehyde (233) in 45% yield and 8.1% radiochemical 
yield. The lower efficiency o f isotopic incorporation was due to problems 
encountered in the delivery o f OH14CNMe2 from the container in which it was 
purchased to the reaction mixture.
In the condensation o f unlabelled 4-hydroxy-3-methoxybenzaldehyde (223) with 
pentane-2,4-dione it was important that the bis-enol(ate) o f the P-diketone was 
formed, in order to prevent the reaction from taking place at the central CH2 . In 
attempts to avoid this, a number o f studies have complexed the dione with boric acid 
(H3BO3 )217,219 or with borate esters (B(OR)3)216,226. The procedure reported by Babu 
and Rajasekharan219 was adapted. It was a simple procedure and was reported to 
afford unlabelled compound (6 8 ) in a yield o f 78%.
In initial experiments, unlabelled 4-hydroxy-3-methoxybenzaldehyde (223) was 
treated with pentane-2,4-dione and boric acid. Decomplexation with aqueous acetic 
acid gave E,E-l,7-di(4-hydroxy-3-methoxyphenyl)-3-hydroxyhepta-l,3,6-trien-5-one 
(curcumin) (6 8 ) in 57% yield. It was thought that the yield maybe further enhanced 
by initially forming the complex between the boric acid and pentane-2,4-dione, 
followed by addition o f the benzaldehyde (223). However, in subsequent runs, 
compound (6 8 ) was obtained in a lower yield o f 40%. Although, it was reported in
1 1 0
• *7 1 Qthe literature that boric acid was more reactive than boron oxide, studies were also 
carried out with boron oxide. It was found that complexation o f boron oxide with 
pentane-2,4-dione, followed by addition o f compound (223) gave compound (6 8 ) in 
a higher yield o f 77%. The heptatriene 4 proton was observed as a singlet at 86.06. 
The heptatriene alkenic 2 and 6  protons were observed as a doublet at 86.76 due to 
coupling being observed between the adjacent 1 and 7 protons. The coupling 
constant was large (J =  15.6Hz) which was indicative o f a trans stereoisomer. The 1- 
and 7-alkenic heptatriene protons were observed at 87.56 as a doublet due to 
coupling to the adjacent 2- and 6 -protons. These protons were shifted slightly further 
downfield in comparison to the alkenic 2 - and 6 -protons because o f the deshielding 
effect o f the aromatic ring. The two OH signals were observed as a broad singlet at 
89.70.
Application o f the optimised conditions in the reaction o f the isotopically labelled 
compound (231) gave is,is-l,7-di(4-hydroxy-3-methoxyphenyl)-3-hydroxy-l,7-di- 
[2H]-hepta-l,3,6-trien-5-one (234) in 43% yield. !H NMR provided evidence for the 
formation o f (234), as the heptatriene 1 and 7 protons were no longer evident in the 
spectrum. Further evidence for the formation o f compound (234) was obtained by 
MS in which (FAB+) m/z 372 corresponded to the weight o f the dideuterated 
compound.
Treatment o f the radiolabelled 4-hydroxy-3-methoxybenz-[14C]-aldehyde (233) with 
the boron oxide and pentane-2,4-dione complex, followed by treatment with 1,2,3,4- 
tetrahydroquinoline and acetic acid, gave the radiolabelled compound (235) in 81% 
yield. It was thought that the prolonged reaction time o f 24 h at 110°C attributed to 
the high radiochemical yield obtained.
So far, the studies carried out with the radiolabelled 14C-curcumin (235) by our 
collaborators is in agreement with related studies in that curcumin may be useful in 
the chemoprevention o f human intestinal malignancies related to APC  mutations. In 
a recent paper submitted by Perkins et al221, it was reported that a daily dose o f 17g 
of curcumin was required for efficacy in humans. This was based on studies carried 
out with mice, which demonstrated that a dietary concentration o f 0.2 and 0.5% of
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curcumin reduced ademona multiplicity by 39 and 40% respectively, in comparison 
to untreated mice. For curcumin to be effective as a chemopreventative agent, 
concentrations o f ~ 100 nmole / g was required. When extrapolated to the humans it 




All melting points were determined using a Reichert-Jung Thermo Galen Kofler 
block. NMR spectra were recorded on either JEOL EX400 Varian Mercury 400 
or JEOL GX270 spectrometers. Thin layer chromatography (TLC) was performed on 
precoated silica plates (Merck TLC aluminium silica sheets 60 F254, Art no. 5554). 
Visualisation was made by dipping in potassium permanganate solution (for 
detection o f esters) / phosphomolybdic acid in methanol (for detection o f alcohols) / 
ninhydrin (for detection of amines) (followed by heating) or by U.V. light (for 
detection o f aromatic compounds), where appropriate. Preparative thin layer 
chromatography was performed on silica plates (Merck TLC silica gel 60 F254, 20 x 
20 cm, layer thickness 2 mm, Art no. 5717). Elemental analysis (CHN) was carried 
out at the University o f Bath microanalysis service. Mass spectra were recorded at 
the University o f Bath mass spectrometry service, on VG 7070 double focussing and 
VG Autospec instruments. Infra-red spectra were performed on a Perkin-Elmer 782 
FT-IR spectrometer. HPLC analysis was performed using a Kromasil 10C18 semi­
preparative column and a JASCO PU-986 preparative pump with methanol as the 
eluent and flow rate at 5 mL min'1. UV detection was at 326 nm by a JASCO UV- 
975 detector and an injection volume o f 20 pL was used. Chemicals were purchased 
from the Aldrich / Sigma, Fluka, Lancaster or Acros chemical companies. 
Tetrahydrofuran, 1,2-dimethoxyethane and diethyl ether were obtained in 
“anhydrous” form and dried by distillation from sodium and benzophenone indicator. 
Solutions in organic solvents were dried over magnesium sulfate or sodium sulfate. 
Experiments were conducted at ambient temperature, except when noted.
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SARCOSINE ETHYL ESTER HYDROCHLORIDE (82)
E tO zC
> e  
M eH 2N ©  Cl
To sarcosine (81) (50.0 g, 0.56 mol) in EtOH (1000 mL) was added thionyl chloride 
(123 mL, 1.69 mol). The mixture was stirred for 24 h. Evaporation and washing 
with Et2 0  (1000 mL) gave (82) (86.0 g, 100%) as white crystals: mp 129-131°C (no 
literature mp reported); *H NMR (CDC13) 5 1.31 (3 H, t , J =  7.0 Hz, CH2Cf/3), 2.85 
(3 H, s, NCH3), 3.89 (2 H, s, NCH2), 4.29 (2 H, q, J =  7.0 Hz, Ctf2CH3), 9.73 (2 H, s, 
N*H2); Vmax (KBr) 3400, 2770 and 1730 cm'1; MS (FAB'") m/z 235 (2 M + H), 118 
(M + H).






Compound (82) (170.0 g, 1.11 mol) was dissolved with heating in 99% formic acid 
(138 mL, 3.7 mol) and was added to a hot solution o f sodium formate (83.0 g, 1.22 
mol) in 99% formic acid (111 mL, 2.9 mol). The solution was stirred for 4 h then 
filtered. The solid was washed with Ac20  (500 mL, 5.32 mol) which was then added 
slowly to the formic acid solution. The mixture was heated for 1 h and the solvent 
was evaporated. Distillation gave (84) (113.3 g, 70%) as a colourless liquid bpo.i 
95°C (lit193 bpo.2 93-95°C): TLC R f = 0.4 (EtOAc); v™  (KBr) 1730 and 1665 cm'1; 
'H NMR (CDC13; Rotamer 1) 8  1.29 (3 H, t, C //3CH2,J  = 7.1 Hz), 3.05 (3 H, s, 
NCH3), 4.10 (2 H, s, NCH2), 4.26 (2 H, q, Ctf2CH3, J =  7.1 Hz), 8.13 (1 H, s, CHO); 
‘H NMR (CDC13; Rotamer 2) 8  1.30 (3 H, t, Gtf3CH2, J  = 7.1 Hz), 2.94 (3 H, s, 
NCH3), 3.99 (2 H, s, CH2N), 4.21 (2 H, q, C //2CH3, 7 = 7 .1  Hz), 8.05 (1 H, s, CHO). 
Rotamers 1 and 2 were evident in the ratio 1:2.
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PROCEDURE (2)
Compound (82) (154.8 g, 1.0 mol) was dissolved with heating in 99% formic acid 
(126 mL, 3.5 mol) and was added to a hot solution o f sodium formate (75.0 g, 1.1 
mol) in 99% formic acid (100 mL, 2.7 mol). The solution was stirred for 4 h then 
filtered. The solid was washed with AC2O (457 mL, 4.8 mol) which was then added 
slowly to the formic acid solution. The mixture was heated for 1 h and the solvent 
was evaporated. The oil, in EtOAc, was washed with aq. NaHCOa and brine. 
Drying, filtration and evaporation gave (84) (69.8g, 48%) as a colourless oil, with 
properties as above.
PROCEDURE (3)
To (82) (98.1 g, 0.64 mol) in water (450 mL), was added sodium carbonate (-10.0 g) 
until the pH reached 11. The solution was extracted (EtOAc) and the extracts were 
washed with brine, dried and filtered. Evaporation gave (83) (21.6 g, 29%) as a 
colourless oil. 'H NMR (CDCI3) 8  1.05 (3 H, t, J  =  7.3 Hz, CH3CH2), 3.12 (2 H, s, 
NCH2), 3.96 (2 H, q, J  =  7.3 Hz, CH3C #2). Ethyl formate (205 mL, 2.55 mol) and 
triethylamine (5 mL, 0.04 mol) were added to (83) (21.6 g, 0.18 mol). The solution 
was stirred for 24 h, then boiled under reflux for 24 h and the solvents were 
evaporated. The oil, in CHCI3 , was washed with aq. HC1 (2 M) and brine. Drying, 
filtration and evaporation yielded (84) (23.2 g, 87%) as a colourless oil, with 
properties as above.
PROCEDURE (4)
To (82) (85.0 g, 0.55 mol) was added EtOH (500 mL), ethyl formate (170 mL, 
2.1mol) and triethylamine (116 mL, 0.83 mol). The mixture was stirred for 48 h, 
then boiled under reflux for 10 h. After evaporation the oil, in EtOAc, was washed 
with aq. HC1 (2M), and brine. Drying, filtration and evaporation yielded (84) (9.23 
g, 1 1 %) as a colourless oil, with properties as above.
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PROCEDURE (5)
To (82) (87.8 g, 0.57 mol) was added ethyl formate (600 mL, 7.5 mol) and 
triethylamine (159 mL, 1.14 mol). The mixture was stirred for 48 h. After 
evaporation the oil, in EtOAc, was washed with aq. HC1 (2M), and brine. Drying, 
filtration and evaporation yielded (84) (15.1 g, 18%) as a colourless oil, with 
properties as above.





To (82) (103.0 g, 0.67 mol) was added H2O (2000 mL) and sodium carbonate (~10.0 
g) until the pH reached 11. The solution was extracted (EtOAc). The extract was 
washed with brine, dried and filtered. Evaporation gave (83) (7.21 g, 9%) as a 
colourless oil. To (83) (7.21 g, 62 mmol) was added dropwise di-/-butyl dicarbonate 
(13.5 g, 62 mmol) in CH2CI2 (20 mL). The solution was stirred for 24 h. 
Evaporation gave (85) (13.0 g, 97%) as a pale yellow oil: TLC R f = 0.7 (EtOAc); 
W  (KBr) 1750, 1700 cm'1; 'H NMR (CDC13; rotamer 1) 8  1.27 (3 H, t, J =  7.1 Hz, 
C //3CH2), 1.48 (9 H, s, Bu'), 2.94 (3 H, s, NCH3), 3.89 (2 H, s, NCH2), 4.20 (2 H, q, 
J =  7.1 Hz, C //2CH3); (CDCb; rotamer 2 ) 8  1.29 (3 H, t, J =  7.1 Hz, Ci73CH2), 1.48 
(9 H, s, Bu*), 2.92 (3 H, s, NCH3), 3.97 (2 H, s, NCH2), 4.19 (2 H, q, / =  7.1 Hz, 
C //2CH3). Rotamers 1 and 2 were evident in the ratio 1:1; MS (FAB+) m/z 218.1395 
(M + H) (C10H20N 1O4 requires 218.1392), 118 (M + H -  Boc).
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ETHYL 3,3-DIETHOXY-2-METHYLAMINOPROPANOATE (87)
E t 0 2C O E t
)—(
M eH N O E t
PROCEDURE (1)
To (84) (113.3 g, 0.78 mol) and ethyl formate (187 mL, 2.28 mol) in dry Et20 (228 
mL) at 0°C was added a suspension o f sodium ethoxide (58.5 g, 0.86 mol) in dry 
Et20 (685 mL) dropwise with stirring. After 1 h at 0°C, the mixture was diluted with 
dry Et20 (500 mL) and was allowed to stand overnight at 4°C. The Et20 was 
decanted. The residual sodium enolate (86) was treated with EtOH (1370 mL), 
saturated with HC1 and was stirred for 6 h. The mixture was further saturated with 
HC1 and was boiled under reflux for 10 h. Aq. potassium carbonate was added until 
the pH reached 13. Extraction with EtOAc, washing with brine, drying, filtering, 
evaporation and Kugelrohr distillation gave (87) (69.5 g, 41%) as a pale yellow oil 
bpo. ,5  120°C (lit193 bpo.os 61-62°C): TLC R f = 0.2 (EtOAc /  hexane 3:1); 3390
and 1680 cm'1; 'H NMR (CDC13) 6 1.17 (3 H, t, J =  7.0 Hz, OCH2Ci73), 1.20 (3 H, t, 
J =  7.1 Hz, OCH2CH3), 1-28 (3 H, t, J  = 7.1 Hz, CO2 CH2OT3), 2.39 (3 H, s, NCH3), 
3.34 (1 H, d, J =  6.0 Hz, NCHCO2), 3.50-3.60 (2 H, m) and 3.65-3.80 (2 H, m) (2 x 
OGtf2CH3), 4.235 (1 H, q, J =  7.0 Hz) and 4.238 (1 H, q, J  =  7.1 Hz, C 02CH2CH3,), 
4.61 (1 H, d, J =  6.0 Hz, OCHO); MS (FAB4)  m/z 220 (M + H), 174 (M -  EtOH).
PROCEDURE (2)
To (84) (99.8 g, 0.69 mol) and ethyl formate (161 mL, 2.0 mol) in dry Et20 (200 mL) 
at 0°C was added a suspension o f sodium ethoxide (51.5 g, 0.76 mol) in dry Et20 
(300 mL) dropwise with stirring. After 1 h at 0°C, the mixture was diluted with dry 
Et20 (300 mL) and was allowed to stand overnight at 4°C. The Et20 was decanted. 
The residual sodium enolate (86), was treated with EtOH (1200 mL) saturated with 
HC1 and was stirred for 6 h. The mixture was further saturated with HC1 for 6 h. Aq. 
potassium carbonate was added until the pH reached 13. Extraction with EtOAc,
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washing with brine, drying, filtering, evaporation and Kugelrohr distillation gave (87) 
and (88). The crude oil in EtOH (200 mL) was saturated with HC1 for 3 h and was 
boiled under reflux for 3 h. Aq. potassium carbonate was added until the pH reached 
13. Extraction with EtOAc, washing with brine, drying, filtering, evaporation and 




Compound (87) (1.6 g, 7.3 mmol) in aq. HC1 (10%, 21 mL) was stirred at 60°C for 
12 h. After cooling to -10°C, the pH was brought to 4.5 with aq. NaOH (10%) and 
cyanamide (0.8 g, 19 mmol) was added. The mixture was stirred at 60°C for 2 h, 
maintaining the pH at 4.5 by addition o f either aq. HC1 (10%) or aq. NaOH (10%) 
and the solvents evaporated. The residue was triturated with Et20 (100 mL) to 
remove unreacted cyanamide and was extracted thrice with EtOH (300 mL) saturated 
with HC1. Evaporation and recrystallisation (propan-2-ol) gave (91) (0.82 g, 55%) as 
pale buff crystals: mp 205-210°C (lit.192 mp 200-205°C); TLC R f = 0.5 (CH2C12 /  
MeOH / H20  / AcOH 25:10:2:1); v„„ (KBr) 3380 and 1660 cm'1; ‘H NMR (D20 )  8 
1.27 (3 H, t, J  =  7.0 Hz, C i/3CH2), 3.64 (3 H, s, NCH3), 4.26 (2 H, q, J =  7.0 Hz, 
CH2), 7.76 (1 H, s, 4-H), 8.26 (3 H, brs, N*H3); MS (FAB*) m/z 377/375 (2 M + 2 H 




© n h 3 ci
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ETHYL 1-METHYL-2-NITROIMIDAZOLE-5-CARBOXYLATE (92) AND 
ETHYL 1-METHYL-2-CHLOROIMIDAZOLE-5-CARBOXYLATE (93)
E t0 2C E t0 2C
V=\ * V=\
PROCEDURE (1)
y N M e-N yN
N O , Cl
Sodium nitrite (1.17 g, 17 mmol) in H2O (4 mL) was added dropwise at -20°C to a 
stirred mixture o f (91) (3.19 g, 15.5 mmol), H20  (9.5 mL) and aq. HBF4 (40%, 10.8 
mL). Stirring was continued at -15°C for 50 min. The solution was added to a well- 
stirred mixture o f sodium nitrite (10.8 g, 0.16 mol), copper powder (3.28 g, 0.05 
mmol) and H20  (300 mL). After 6  h, the copper was filtered off and the filtrate was 
brought to pH 2 with aq. H2S 0 4 (10%). The evaporation residue, in EtOAc, was 
washed with aq. NaHC0 3 , brine, dried and filtered. Evaporation and column 
chromatography (hexane /  EtOAc 3:1) gave (92) (1.95 g, 63%) as pale yellow 
crystals: mp 59-61°C (lit. 192 mp 60°C); TLC R f = 0.3 (EtOAc /  hexane 1:3); 'H 
NMR (CDCI3) 6  1.41 (3 H, t, J =  7.1 Hz, CH3CH2), 4.35 (3 H, s, NCH3), 4.40 (2 H, 
q, J =  7.1 Hz, CH2), 7.75 (1 H, s, 4-H). Further elution gave (93) (113 mg, 4%) as a 
colourless oil: TLC R f = 0.5 (EtOAc); v „  (KBr) 2980, 1715 and 770 cm'1; 'H 
NMR (CDCI3) 8  1.29 (3 H, t, J =  7.1 Hz, C //3CH2O), 3.82 (3 H, s, NCH3), 4.25 (2 H, 
q, 7  = 7.1 Hz, CH2), 7.20 (1 H, s, 4-H); MS (FAB9)  m/z 191.0399 (M + H) 
(C7Hi037C1N2O2 requires 191.0401), 189.0437 (M + H) (C7Hi035C1N2O4  requires 
189.0431).
PROCEDURE (2)
Sodium nitrite (0.86 g, 12.4 mmol) in H20  (3 mL) was added dropwise at -20°C to a 
stirred mixture o f (91) (2.34 g, 11.4 mmol), H20  (6.9 mL) and aq. HBF4 (40%, 8.1 
mL). Stirring was continued at -15°C for 50 min. The solution was added to a well- 
stirred mixture o f sodium nitrite (7.9 g, 0.11 mol), copper powder (2.12g, 38.0 mmol) 
and H20  (217 mL). After 2 h, the copper was filtered off and the filtrate was brought
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to pH 2 with aq. HC1 (10%). The evaporation residue, in EtOAc, was washed with 
aq. NaHC0 3 , brine, dried and filtered. Evaporation and column chromatography 
(hexane / EtOAc 3:1) gave (92) (1.08 g, 48%) as pale yellow crystals, with properties 
as above. Further elution gave (93) (0.4g, 18%) as a colourless oil, with properties as 
above.
5-HYDROXYMETHYL-1-METHYL-2-NITROIMIDAZOLE (94) AND 5- 
HYDROXYMETHYL-l-METHYL-2-CHLOROIMIDAZOLE (95)
PROCEDURE (1)
To (92) (0.86 g, 4.3 mmol) in anhydrous THF (130 mL) was added solid LiBIL (0.19 
g, 9.0 mmol). The solution was stirred for 48 h, then cooled to 0°C. The excess 
LiBfLj was decomposed with AcOH (1.0 mL). Evaporation and column 
chromatography (hexane / EtOAc 3:1) gave (94) (0.41 g, 60%) as pale yellow 
crystals: mp 139-141°C (lit. 192 mp 140°C); TLC R f = 0.2 (EtOAc); (KBr) 3220, 
1530 and 1355 cm'1; •H NMR ((CD3)2SO) 8  3.91 (3 H, s, CH3), 4.55 (2 H, d , J =  5.0 
Hz, CH2), 5.50 (1 H, t, J =  5.0 Hz, OH), 7.11 (1 H, s, 4-H).
PROCEDURE (2)
To (92) (330 mg, 1.7 mmol) in anhydrous THF (50 mL) was added solid LiBH* (40 
mg, 1.8 mmol). The solution was stirred for 20 h, after which more solid LiBFL (33 
mg, 1.52 mmol) was added. The solution was stirred for a further 48 h, cooled to 0°C 
and the excess LiBIL was decomposed with aq. HC1 (10%, 1.0 mL). Evaporation 
and column chromatography (hexane / EtOAc 3:1) gave (94) (110 mg, 42%) as pale 
yellow crystals, with properties as above. Further elution gave crude (95) (42 mg, 
17%): *H NMR (((CD3)2SO) 6  3.55 (3H, s, CH3), 4.40 (2 H, d, J =  5.2 Hz, CH2), 
5.15 (1 H, t, J =  5.2 Hz, OH), 6 . 8  (1 H, s, 4-H).
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PROCEDURE (3)
To (92) (1.31 g, 7.0 mmol) in anhydrous THF (200 mL) was added solid LiBIL (0.29 
g, 13.3 mmol). The solution was stirred for 48 h, then cooled to 0°C. The excess 
LiBFLt was decomposed with aq. HC1 (10%, 1.0 mL). Evaporation and column 
chromatography (hexane / EtOAc 3:1) gave (94) (0.37g, 36%) as pale yellow 




To (92) (1.56 g, 7.8 mmol) in anhydrous THF (235 mL) was added LiBHU (2.0 M 
solution in THF, 4.3 mL, 8 . 6  mmol). The solution was stirred for 24 h, then cooled 
to 0°C. The excess LiBH* was decomposed with AcOH (1.5 mL). Evaporation and 
column chromatography (hexane / EtOAc 3:1) gave (96) (0.80 g, 91%) as off-white 
crystals: mp 114-116°C (lit.228 mp 113-114°C); v™* (KBr) 3400 cm'1; *H NMR 
((CD3)2SO) 6  3.60 (3 H, s, NCH3), 4.41 (2 H, s, CH2), 6.76 (1 H, s, 4-H), 7.53 (1 H, 





To (94) (50 mg, 0.32 mmol) in dry pyridine (1.0 mL) at 0°C was added 
methanesulfonyl chloride (50 mg, 0.48 mmol) and the solution was stirred for 3 h. 
The evaporation residue, in CHC13, was washed with aq. CuS0 4 , aq. NaHC03 and 
brine and was dried and filtered. Evaporation gave (101) (39 mg, 70%) as yellow
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crystals: mp 94-96°C (decomp.); TLC Rf = 0.8 (EtOAc); 'H NMR (CDCI3) 8  4.10 (3 
H, s, NCH3), 4.63 (2 H, s, CH2), 7.20 (1 H, s, 4-H); MS m/z (El) 177.0131 (M) 
(12C5H6N 30 2 37C1 requires 177.0119), 175.0158 (M) (^CsHeNjC^Cl requires 
175.0149), 140 (100%) (M - Cl).
PROCEDURE (2)
To (94) (50 mg, 0.32 mmol) in dry pyridine (1.0 mL) at 0°C, was added 4- 
methylbenzenesulfonyl chloride (115 mg, 0.60 mmol) and the solution was stirred for 
6  h. The evaporation residue, in CHCI3 , was washed with aq. CUSO4, aq. NaHCC>3 
and brine and was dried and filtered. Evaporation gave (101) (17.1 mg, 31%) as pale 






To (94) (50 mg, 0.32 mmol) was added thionyl chloride (1.0 mL, 13.7 mmol) and the 
solution was stirred for 3 h. Evaporation gave crude (98) (44 mg, 96%) as a 
colourless oil: TLC R f = 0.5 (EtOAc / hexane 1:1); Vmax 3340, 1740 and 760 cm"1; 
!H NMR (CDCI3) 8  3.93 (3 H, s, NCH3), 7.69 (1 H, s, 4-H), 9.65 (1 H, s, CHO); MS 





To (94) (50 mg, 0.32 mmol) in dry DMF (1.0 mL) was added bromine (53 mg, 330 
pmol) and triphenylphosphine (90 mg, 343 pmol) and the mixture was stirred for 16 
h. The evaporation residue, in EtOAc, was washed with H20 ,  brine, dried and 
filtered. Evaporation and preparative TLC (EtOAc / hexane 1:1) gave (102) (12 mg,
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17%) as pale yellow crystals: mp 84-87°C (decomp.); TLC R f = 0.8 (EtOAc); 
NMR (CDCI3) 83.98 (3 H, s, NCH3), 4.41 (2 H, CH2), 7.13 (1 H, s, imidazole 4-H); 
MS (El) m/z 220.9562 (M) (C5H681BrN30 2  requires 220.9623), 218.9582 (M) 





To (109) (74.8 g, 0.41 mol) in MeOH (1500 mL) was added thionyl chloride (50 mL, 
0.7 mol). The mixture was boiled under reflux for 20 h. Evaporation gave (110) 
(78.6 g, 98%) as pale yellow crystals: mp 64-66°C (lit. 197 mp 64-65°C); TLC R f = 
0.7 (EtOAc); !H NMR (CDC13) 8  2.61 (3 H, s, ArCH3), 3.93 (3 H, s, H3CO), 7.38 (1 
H, t, J =  8.0 Hz, 5-H), 7.84 (1 H, d, J = 8.0 Hz, 6 -H), 7.98 (1 H, d, J =  8.0 Hz, 4-H).
5-NITROISOCOUMARIN (112) AND 3-METHOXY-5-NITRO-3,4- 
DIHYDROISOCOUMARIN (113)
O O
n o 2 n o 2
PROCEDURE (1)
To (110) (50.0 g, 0.26 mol) in DMF (153 mL) was added dimethylformamide 
dimethylacetal (120 mL). The solution was heated at 120°C for 20 h. Evaporation 
gave the crude enamine (111) as a black tar: !H NMR (CDC13) 8  2.83 ( 6  H, s, 
N(CH3)2), 5.66 (1 H, d, J  = 13.6 Hz, NC=CH), 6.34 (1 H, d, J =  13.6 Hz, NCH=C),
7.09 (1 H, t , J =  7.9 Hz, 7-H), 7.70 (1 H, d, J =  7.9 Hz, 6 -H), 7.72 (1 H, d, J =  7.9 Hz, 
8 -H). Chromatography (hexane / EtOAc 10:1) gave (112) (5.0 g, 10%) as pale 
yellow crystals. Further elution gave crude (112) and (113). Recrystallisation 
(hexane / EtOAc 10:1) gave (112) (24.8 g, 50%) as pale yellow crystals: mp 172- 
173°C (lit. 197 mp 173-174°C); TLC R f = 0.2 (EtOAc /  hexane 1:10); (KBr) 1720,
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1540 and 1340 cm'1; ’H NMR (CDC13) 8  7.39 (1 H, dd, J =  6 .1,0.5 Hz, 4-H), 7.44 (1 
H, d, J =  6.1 Hz, 3-H), 7.68 (1 H, t, J =  8.1 Hz, 7-H), 8.50 (1 H, dd, J =  8.1,1.3 Hz,
6 -H), 8.65 (1 H, ddd, 8 .1 ,1 .3 ,0 .5  Hz, 8 -H); MS (FAB*) m/z 192 (M + H).
PROCEDURE (2)
To (110) (78.6 g, 0.4 mol) in DMF (240 mL) was added dimethylformamide 
dimethylacetal (185 mL). The solution was heated at 120°C for 20 h. Evaporation 
gave the crude enamine (111) as a black tar. Column chromatography (hexane / 
EtOAc 10:1) gave (1 1 2 ) (29.9 g, 39%) as pale yellow crystals, with properties as 
above. Further elution gave (113) (9.3 g, 10%) as pale yellow crystals: mp 112- 
113°C (lit. 197 mp 111.5-112.5°C); TLC R f = 0.15 (EtOAc / hexane 1:10); NMR 
(CDC13) 6  3.54 (3 H, s, CH3), 3.59 (2 H, d, J =  3.1 Hz, 4-H2), 5.52 (1 H, t, J =  3.1 
Hz, 3-H), 7.59 (1 H, t, J = 8.2 Hz, 7-H), 8.30 (1 H, dd, J = 8.2, 1.2 Hz, 6 -H), 8.44 (1 
H, d, J  = 8.2, 1.2 Hz, 8 -H); MS (FAB+) m/z 447 (2 M  + H), 224 (100%) (M + H), 
192 (M + H - MeOH), 173 (M -  H20 ).
5-AMINOISOCOUMARIN (114)
PROCEDURE (1)
To (112) (2.98 g, 15.6 mmol) in THF (44 mL) was added aq. HC1 (2M, 8  mL). Pd/C 
(10%, 370 mg,) was added and the flask was filled with hydrogen for 6  h, after which 
the mixture was filtered through Celite and the solvent was evaporated. The residue, 
in CH2C12, was washed with aq. NaHC03, brine, dried and filtered. Evaporation 
gave (114) (2.49 g, 99%), as pale yellow crystals: mp 185-187°C (lit. 197 mp 194- 
195°C); TLC R f = 0.4 (EtOAc / hexane 1:1); NMR (CDC13) 8  3.90 (2 H, brs, 
NH2), 6.37 (1 H, dd, J = 5.9, 0.5 Hz, 4-H), 6.96 (1 H, dd, J =  7.9, 1.1 Hz, 6 -H), 7.19 
(1 H, d, J = 5.9 Hz, 3-H), 7.25 (1 H, t, J =  7.9 Hz, 7-H), 7.68 (1 H, ddd, J =  7.9, 1.1, 




To (112) (3.88 g, 20.3 mmol) in EtOH (50 mL) was added SnCb (11.6 g, 60.9 
mmol). The solution was heated at 70°C for 1 h, after which it was added to ice. The 
pH was brought to 7-8 by addition o f aq. NaHC0 3 , (5%). Extraction with EtOAc, 
washing with brine, drying, filtering and evaporation gave (114) (2.5 g, 77%) as pale 
yellow crystals, with properties as above.
5-AMINO-3,4-DIHYDROISOCOUMARIN (115)
To (112) (1.0 g, 5.2 mmol) in THF (15 mL) was added aq. HC1 (2 M, 3.0 mL). Pd/C 
(10%, 124 mg,) was added and the flask was exposed to hydrogen for 12 h, after 
which the mixture was filtered through Celite and the solvent was evaporated. The 
residual solid, in CH2CI2 , was washed with aq. NaHCOa and brine, was dried and 
was filtered. Evaporation gave (115) (0.78 g, 91%) as pale yellow crystals: mp 138- 
140°C; TLC Rf = 0.2 (EtOAc / hexane 1:1); Vmax (KBr) 3350, 3305 and 1710 cm'1; 
!H NMR (CDCI3) 8  2.74 (2 H, t, J = 6.1 Hz, 4-H2), 4.46 (2 H, t, / =  6.1 Hz, 3-H2), 
6 . 8 6  (1 H, dd, J =  7.9, 1.1 Hz, 6 -H), 7.13 (1 H, t, J =  8.1 Hz, 7-H), 7.50 (1 H, dd, / =
8.1, 1.1 Hz, 8 -H); MS (FAB+) m/z 164.0719 (M + H) (12C9H9N i0 2 requires 







To (114) (2.49 g, 15.5 mmol) was added aq. H2SO4 (2M, 70 mL) and the solution 
cooled to 0°C. A solution o f sodium nitrite (1.07 g, 15.5 mmol) in H2O (5 mL) was 
added, maintaining the temperature < 5°C throughout. KBr (3.65 g, 30.9 mmol) and 
CuBr (4.45 g, 30.9 mmol) were added slowly to the solution. The solution was 
stirred for a further 2 h. The evaporation residue, in EtOAc, was washed with H2 O, 
brine, dried and filtered. Evaporation, column chromatography (hexane /  EtOAc 5:1) 
and recrystallisation (hexane / EtOAc) gave (116) (1.22 g, 35%) as white crystals: 
mp 113-115°C; TLC R f = 0.9 (EtOAc); (KBr) 1735 and 700 cm"1; !H NMR 
(CDC13) 6  6.87 (1 H, dd, J =  6 .0 ,0 .7  Hz, 4-H), 7.23 (1 H, d, J =  6.0 Hz, 3-H), 7.39 (1
H, t, J -  7.9 Hz, 7-H), 7.95 (1 H, dd, J =  7.9, 1.1 Hz, 6 -H), 8.29 (1 H, ddd, J =  7.9,
I.1, 0.7 Hz, 8 -H); MS (FAB4)  m/z 226.9534 (M + H) (C9H50 281Br requires 
226.9531), 224.9551 (M + H) (C9H50 279Br requires 224.9551); Found: C, 48.0; H, 




Compound (116) (0.60 g, 2.7 mol) in 2-methoxyethanol (50 mL) was saturated with 
NH3 for 1 h. The solution was boiled under reflux for 8  h. Evaporation and 
recrystallisation (MeCN) gave (108) (428 mg, 71%) as white crystals: mp 220- 
222°C (lit.70 mp 242-244°C); TLC R f = 0.6 (EtOAc); (KBr) 3400,1720 and 690 
cm"1; lH NMR ((CD3)2SO) 8  6 . 6 6  (1 H, d, J =  7.9 Hz, 4-H), 7.35 (1 H, dd, J =  8.1,
7.7 Hz, 7-H), 7.42 (1 H, d, .7= 7 .9  Hz, 3-H), 8.03 (1 H, d, J =  7.7 Hz, 6 -H), 8.21 (1 
H, d, J =  8.1 Hz, 8 -H), 11.55 (1 H, brs, NH); MS (FAB4) m/z 377 (M + H + mNBA), 
224 (M + H).
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5-BROMO-2-(4-METHOXYPHENYLMETHYL)IS OQUINOLIN-1 -ONE (117)
o
Br
Compound (116) (100 mg, 0.44 mmol) in 2-methoxyethanol (1.0 mL) was boiled 
under reflux with 4-methoxybenzylamine (63 mg, 0.44 mmol) for 24 h. Evaporation, 
column chromatography (hexane / EtOAc 5:1), and recrystallisation (Et2 0 ) gave 
(117) (40 mg, 27%) as white crystals: mp 97-100°C (lit. 70 mp 98-100°C); TLC R f=  
0.8 (EtOAc / hexane 1:1); w  (KBr) 1640, 1610 and 690 cm'1; !H NMR (CDC13) 5 
3.79 (3 H, s, CH3), 5.15 (2 H, s, CH2), 6.82 (1 H, d, J =  7.6 Hz, 4-H), 6.87 (2 H, d, J  
= 8.5 Hz, Ph 3,5-H2), 7.18 (1 H, d, J = 7.6 Hz, 3-H), 7.27 (2 H, J = 8.5 Hz, Ph 2,6- 
H2), 7.33 (1 H, t, J = 8.0 Hz, 7-H), 7.87 (1 H, dd, J =  8.0, 1.5 Hz, 6 -H), 8.43 (1 H, 





Lithium bis(trimethylsilyl)amide (1.0 M in THF, 340 pL, 340 pmol) was stirred with 
(108) (58 mg, 260 pmol) in dry DMF (1.0 mL) for 2 h. Compound (101) (37 mg, 
210 pmol) in dry DMF (1.0 mL) and Nal (2 mg) were added and the mixture was 
stirred for 2 d. The evaporation residue, in EtOAc, was washed with H20  and brine 
and was dried and filtered. Evaporation and column chromatography (EtOAc /  
hexane 1:2) gave (118) ( 6 6  mg, 85%) as pale yellow crystals: mp 208-210°C; TLC 
R f = 0.8 (EtOAc / hexane 1:1); Vmax (KBr) 1635, 1610, 1525, 1350 and 700 cm'1; !H 
NMR (CDC13) 8  3.99 (3 H, s, NCH3), 5.23 (2 H, s, CH2), 6.93 (1 H, dd, J = 8.4, 0.5 
Hz, isoquinoline 4-H), 7.14 (1 H, d, / =  8.4 Hz, isoquinoline 3-H), 7.23 (1 H, s, 
imidazole 4-H), 7.38 (1 H, t, J =  8.1 Hz, isoquinoline 7-H), 7.93 (1H, dd, J =  8.1, 1.1
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Hz, isoquinoline 6 -H), 8.39 (1 H, ddd, J  =  8.2, 1.1, 0.5 Hz, isoquinoline 8 -H); MS 
(El) m/z 363.9983 (M) (C i^ n ^ B r H A  requires 362.0015), 362, 345, 318, 316, 140; 
Found: C, 46.4; H, 3.09; N, 15.0; Ci4HnBrN40 3  requires C, 46.30; H, 3.05; N, 
15.43%.
PROCEDURE (2)
Lithium bis(trimethylsilyl)amide (1.0 M in THF, 35 pL, 35 pmol) was stirred with 
(108) (5 mg, 23.5 pmol) in dry DMF (0.5 mL) for 2 h. Compound (102) (4 mg, 18.1 
pmol) in dry DMF (0.5 mL) and Nal (2 mg) were added and the mixture was stirred 
for 5 d. The evaporation residue, in EtOAc, was washed with H2O, brine, dried and 
filtered. Evaporation and preparative TLC (EtOAc / hexane 1:2) gave (118) (4.3 mg, 
65%) as pale yellow crystals, with the above properties.
REDUCTIVELY ACTIVATED RELEASE OF 5-BROMOISOQUINOLIN-l- 
ONE (108)
PROCEDURE (1)
To (94) / (108) /  (118) (0.5 mg) and NILCl (0.5 mg) in MeOH (0.95 mL) and H20  
(0.05 mL) was added Zn dust (10 mg). The mixture was stirred. At various time 
points, aliquots (100 pL) were removed, filtered through glass wool and analysed by 
HPLC.
PROCEDURE (2)
To (94) / (108) / (118) (0.5 mg) in MeOH (1.0 mL) was added SnCl2 (1.3 mg). The 
mixture was stirred. At various time points aliquots (100 pL) were removed, filtered 
through glass wool and analysed by HPLC.
PROCEDURE (3)
128
To (94) / (108) / (118) (5.0 mg) and Pd/C (10%, 5.0 mg) in Pr'OH (2.0 mL) and H20  
(0.04 mL) was added NaBtL (2.0 mg). The mixture was stirred. At various time 
points aliquots (100 pL) were removed, filtered through glass wool and analysed by 
HPLC.
PROCEDURE (4)
To (94) / (108) / (118) (2.2 mg) in Pr'OH (1.0 mL) was added Pd/C (10%, 12 mg). 
The mixture was stirred. At various time points, aliquots (100 pL) were removed, 
filtered through glass wool and analysed by HPLC. Evaporation and column 
chromatography (EtOAc / hexane 1:1 ) gave (120) as colourless crystals: mp 209- 
211°C (lit. 229 mp 211-214°C); TLC R f = 0.2 (EtOAc /  hexane 1:1); ‘H NMR 
((CD3)2SO); 8  6.55 (1 H, d, J =  7.3 Hz, 4-H), 7.16 (1 H, dd, J  = 7.0, 5.5 Hz, 3-H), 
7.48 (1 H, m, 5-H), 7.68 (2 H, m, 6,7-H2), 8.17 (1 H, d, J =  8.1 Hz, 8 -H), 11.24 (1 H, 





To (114) (100 mg, 0.62 mmol) in CH2CI2 (1.0 mL) was added DMF (0.5 mL) and 
triethylamine (10 pL). The solution was cooled to 0°C and di-f-butyl dicarbonate 
(403 mg, 1.84 mmol) in CH2CI2 (1.0 mL) was added slowly. The solution was 
stirred for 4 d. The evaporation residue in EtOAc, was washed with H20 , brine, 
dried and filtered. Evaporation and column chromatography (EtOAc / hexane 1:4) 
gave (121) (130 mg, 58%) as white crystals: mp 165-167°C; TLC R f = 0.8 (EtOAc / 
hexane 1:1); w  (KBr) 3415,1720 and 635 cm'1; ‘H NMR (CDC13) 8  1.38 (18 H, s, 
2 x Bu'), 6.47 (1 H, dd ,/ =  5.9, 0.6 Hz, 4-H), 7.32 (1 H, d, J =  5.9 Hz, 3-H), 7.53 (1
H, d, J =  7.9 Hz, 7-H), 7.54 (1 H, dd, J =  7.9, 1.3 Hz, 6 -H), 8.29 (1 H, ddd, J = 7.9,
I.3, 0.6 Hz, 8 -H); MS (FAB*) m/z 362.1617 (M + H) (Ci9H24N i0 6 requires
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362.1604), 361.1544 (M) (Ci9H2 3N i0 6 requires 361.1525), 262 (M + H -  Boc), 206 
(M + H -B o c -B u ') .
5 -(l, l-DIMETHYLETHOXYCARBONYLAMINO)ISOCOUMARIN (122)
o
N H B oc
To (114) (0.70 g, 4.4 mmol) in CH2CI2 (3.0 mL) was added DMF (3.5 mL) and 
triethylamine (70 pL). The solution was cooled to 0°C and di-/-butyl dicarbonate 
( 1 .4 g, 6.4 mmol), in CH2CI2 (3.0 mL) was added and the solution was stirred for 4 d. 
The evaporation residue, in EtOAc, was washed with H20 , brine, dried and filtered. 
Evaporation and column chromatography (EtOAc / hexane 1:4) gave (122) (635 mg, 
56%) as pale yellow crystals: mp 188-190°C; TLC R f = 0.7 (EtOAc / hexane 1:1); 
Vmax (KBr) 3320, 1720 and 1682 cm'1; *H NMR (CDCI3) 8  1.45 (9 H, s, Bu'), 6.49 (1 
H, d, J = 5.9 Hz, 4-H), 6.50 (1 H, brs, N-H), 7.22 (1 H, d , J =  5.9 Hz, 3-H), 7.42 (1 
H, t, J =  7.9 Hz, 7-H), 7.97 (1 H, d, J =  7.9 Hz, 6 -H), 8.02 (1 H, d, J =  7.9 Hz, 8 -H); 
MS (FAB+) m/z 262.1085 (M + H) (Ci4Hi6N i0 4 requires 262.1079); 261.1008 (M) 
(C14H15N 1O4 requires 261.1001), 206 (M -  Bu'); Found C, 64.20; H, 5.83; N, 5.35 
C14H 15N 1O4 requires C, 64.36; H, 5.75; N, 5.36.
130
5-(l, 1 -DIMETH YLETHOXY CARBONYL AMIN 0)IS OQUIN OLIN-1 -ONE
(123)
o
N H B oc
PROCEDURE (1)
To (121) ( 6 8  mg, 0.19 mmol) was added 2-methoxyethanol (10 mL). The solution 
was saturated with NH3 for 1 h after which it was boiled under reflux for 24 h. 
Evaporation and column chromatography (EtOAc / hexane 1:1) gave (123) (35 mg, 
71%) as pale yellow crystals: mp >230°C; TLC R f = 0.5 (EtOAc); Vmax (KBr) 3320, 
1690 and 1670 cm*1; *H NMR (CDCI3) 8  1.54 (9 H, s, (Bu'), 6.58 (1 H, d, J =  7.3 Hz,
4-H), 6.61 (1 H, brs, NHBoc), 7.22 (1 H, d, J =  7.3 Hz, 3-H), 7.49 (1 H, t, J =  8.1 Hz,
7-H), 8.04 (1 H, d, J = 8.1 Hz, 6 -H), 8.22 (1 H, d, J =  8.1 Hz, 8 -H), 10.60 (1 H, brs, 
N-H); MS (FAB+) m/z 261.1235 (M + H) (Ci4H17N 2 0 3  requires 261.1239); 260.1169 
(M) (Ci4H16N20 3  requires 260.1161); Found C, 63.5; H, 6.28; N, 10.58; Ci4Hi6N20 3. 
0.25 H20  C, 63.60; H, 6.22, N, 10.20.
PROCEDURE (2)
To (122) (376 mg, 1.4 mmol) was added 2-methoxyethanol (10 mL). The solution 
was saturated with NH3 for 1 h after which it was boiled under reflux for 24 h. 
Evaporation and column chromatography (EtOAc / hexane 1:1) gave (123) (283 mg, 




6 NH 3  Cl©
HC1 was passed through (124) (50 mg, 0.19 mmol) in CHCI3 (20 mL) for 1 h. 
Filtration gave (125) (30 mg, 79%) as white crystals: mp >230°C (no literature mp 
reported); (KBr) 3140 and 1670 cm'1; lH NMR (CDCI3) 5 4.02 (3 H, s, N +H3),
6.63 (1 H, d, J =  7.4 Hz, 4-H), 7.31 (1 H, d, J =  7.4 Hz, 3-H), 7.47 (1 H, t, J =  7.8 Hz,
7-H), 7.70 (1 H, d, J = 7.8 Hz, 6 -H), 8.09 (1 H, d, J =  7.8 Hz, 8 -H), 11.50 (1 H, brs, 




N H B oc
Lithium bis(trimethylsilyl)amide (1.0 M in THF, 280 pL, 0.28 mmol) was stirred 
with (123) (45 mg, 0.17 mmol) in dry DMF (1.0 mL) for 2 h. Compound (101) (39.5 
mg, 0.22 mmol) in dry DMF (1.0 mL) and Nal (2 mg) were added and the mixture 
was stirred for 2 d. The evaporation residue, in EtOAc, was washed with H20  and 
brine and was dried and filtered. Evaporation and column chromatography (EtOAc / 
hexane 1:1) gave (126) (37 mg, 54%) as a yellow oil: TLC R f = 0.7 (EtOAc); !H 
NMR (CDCI3) 8  1.53 (9 H, s, Bu'), 4.05 (3 H, s, NCH3), 5.29 (2 H, s, CH2), 6.58 (1 
H, brs, N-H), 6.60 (1 H, d, J =  7.7 Hz isoquinoline 4-H), 7.07 (1 H, d, J =  7.7 Hz, 
isoquinoline 3-H), 7.21 (1 H, s, imidazole 4-H), 7.52 (1 H, t, J — 7.9 Hz, isoquinoline
7-H), 7.98 (1 H, d, J  = 7.9 Hz isoquinoline 6 -H), 8.24 (1 H, d, J  = 7.9 Hz, 
isoquinoline 8 -H); MS (FAB+) m/z 400.1624 (M + H) (C^H^NsOs requires 
400.1621), 399.1551 (M) (Ci9H2 iN50 5 requires 399.1543).
132
5-AMIN 0 -2 -((l -METH YL-2-NITROIMID AZOL-5-YL)METHYL)- 
ISOQUINOLIN-1-ONE (127)
o
To (126) (10 mg, 0.03 mmol) was added trifluoroacetic acid (1.0 mL). The solution 
was stirred for 20 min. After evaporation, the oil, in EtOAc, was washed with aq. 
K2CO3 (2 M) and brine and was dried and filtered. Evaporation gave (127) (6.0 mg, 
80%) as yellow crystals: mp >230°C; TLC R f = 0.3 (EtOAc); Vmax 3360 cm'1; 
NMR (CDCI3) 6  1.58 (2 H, brs, NH2), 4.05 (3 H, s, NCH3), 5.30 (2 H, s, CH2), 6.51 
(1 H, d, J  -  7.9 Hz, isoquinoline 4-H), 7.00 (1 H, dd, J =  7.7, 1.1 Hz, isoquinoline 6 - 
H), 7.01 (1 H, dt J =  7.9 Hz, 3-H), 7.22 (1 H, s, imidazole 4-H), 7.34 (1 H, t, J =  8.1 
Hz, isoquinoline 7-H), 7.88 (1 H, d, J  = 8.1 Hz, isoquinoline 8 -H); MS (FAB*) m/z 
300.1087 (M + H) (C14H 14N 5O3 requires 300.1097), 299.1010 (M) (C14H13N5O3 
requires 299.1018); NMR (CF3C 02D) 5 4.52 (3 H, s, NCH3), 5.68 (2 H, s, CH2),
7.19 (1 H, t, J =  7.3 Hz, isoquinoline 4-H), 7.78 (1 H, dd, J -  7.3 Hz, isoquinoline 3- 
H), 7.83 (1 H, d, J =  7.3 Hz, 7-H), 7.86 (1 H, s, imidazole 4-H), 8.11 (1 H, d ,J =  7.3 
Hz, isoquinoline 6-H), 8.62 (1 H, d, J  = 7.3 Hz, isoquinoline 8-H); MS (FAB*) m/z 





To (94) (78 mg, 0.5 mmol), (128) (92 mg, 0.38 mmol) and Nal (2 mg) in dry DMF (1 
mL) was added lithium bis(trimethylsilyl)amide (1.0 M in THF, 625 pL, 0.61 mmol) 
under Ar. The solution was stirred for 12 h at 20°C and at 50°C for 24 h. The 
evaporation residue, in EtOAc, was washed with H2O, aq. NaHC0 3 , brine, dried and 
filtered. Evaporation and column chromatography (EtOAc / hexane 1:1) gave (130) 
(65 mg, 77%) as pale yellow crystals: mp 238-240°C (lit.230 mp 237-239°C); TLC R f 
= 0.6 (EtOAc / hexane 1:1); lU  NMR (CDC13) 6  7.56 (4 H, m, Ph 3,4,5-H3 + 6 -H), 
7.84 (2 H, m, 7,8-H2), 8.23 (3 H, m, Ph 2,6-H2 + 5-H), 10.20 (1 H, s, NH).
PROCEDURE (2)
To (94) (85 mg, 0.5 mmol) and (128) (100 mg, 0.4 mmol) was added lithium 
bis(trimethylsilyl)amide (1.0 M in THF, 420 pL, 0.42 mmol) and the mixture was 
boiled under reflux for 10 h, under Ar. The evaporation residue, in EtOAc, was 
washed with H20 ,  aq. NaHC0 3 , brine, dried and filtered. Evaporation and column 
chromatography (EtOAc / hexane 1:1) gave (130) (70 mg, 76%) as pale yellow 
crystals, with properties as above.
DIETHYL IMINODIACETATE HYDROCHLORIDE (132)
EtOoC
)
E t0 2C H 2CH2N© Cl0
To (131) (10.5 g, 0.08 mol) in EtOH (200 mL) was added thionyl chloride (35 mL, 
0.5 mol). The mixture was stirred for 24 h. Evaporation and washing with Et20  
(500 mL) gave (132) (17.8 g, 100%) as a buff gum: 'H NMR (CDCI3) 8  1.31 ( 6  H, t,
134
J  = 7.0 Hz, 2 x CH2C//j), 3.49 (4 H, s, 2 x NCH2), 4.22 (4 H, q, J  = 7.0 Hz, 2 x 






Compound (132) (34.5 g, 0.15 mol) was dissolved with heating in 99% formic acid 
(19 mL, 0.5 mol) and was added to a hot solution o f sodium formate (11.5 g, 0.17 
mol) in 99% formic acid (15 mL, 0.41 mol). The solution was stirred for 4 h then 
filtered. The solid was washed with Ac20  (70 mL, 0.73 mol) which was then added 
slowly to the formic acid solution. The mixture was boiled under reflux for 1 h and 
the solvent was evaporated. Distillation gave (134) (28.5 g, 8 6 %) as a colourless 
liquid bpo.i 100°C: TLC R f = 0.3 (EtOAc); 1740 cm'1; lH NMR (CDC13) 5  1.27 
(3 H, t, J  = 7.1 Hz, CH2CH3), 1.28 (3 H, t, J  = 7.1 Hz, CH2CH3), 4.13 (4 H, s, 2 x 
NCH2), 4.24 (2 H, q, J =  7.1 Hz, Ci/2 CH3), 4.25 (2 H, q, J - 7.1 Hz, C //2CH3), 8.12 
(1 H, s, NCHO); MS (EI+) m/z 218.0979 (M + H) (C9Hi6N i0 5 requires 218.1028), 
217.0942 (M) (C9H15N 1O5 requires 217.0950), 189 (M -  C2H4).
PROCEDURE (2)
Compound (132) (20.0 g, 0.09 mol) was dissolved with heating in 99% formic acid 
(12 mL, 0.3 mol) and was added to a hot solution o f sodium formate (6.9 g, 0.1 mol) 
in 99% formic acid (10 mL, 0.2 mol). The solution was stirred for 4 h then filtered. 
The solid was washed with Ac20  (41 mL, 0.4 mol) which was then added slowly to 
the formic acid solution. The mixture was heated for 1 h and the solvent was 
evaporated. The oil, in EtOAc, was washed with aq. NaHC0 3  and brine. Drying, 





E t0 2C OEt 
)—(
E t0 2CH2CHN OEt
To (134) (26.2 g, 0.12 mol) and ethyl formate (26 mL, 0.33 mol) in dry Et2 0  (55 mL) 
at 0°C was added a suspension o f sodium ethoxide (9.0 g, 0.13 mol) in dry Et2 0  (160 
mL) dropwise with stirring. After 1 h at 0°C, the mixture was diluted with dry Et2 0  
(500 mL) and allowed to stand overnight at 4°C. The Et2 0  was decanted. The 
residual sodium enolate (135), was treated with EtOH (320 mL) saturated with HC1 
and was stirred for 6  h. The mixture was further saturated with HC1 and boiled under 
reflux for 10 h. Aq. potassium carbonate was added until pH reached 13. Extraction 
with EtOAc, washing with brine, drying, filtering, evaporation and Kugelrohr 
distillation gave (136) (21.9 g, 62%) as a pale yellow oil bpo.15 210°C: TLC R f = 0.5 
(EtOAc); Vmax 3320, 1730 and 1635 cm*1; lH NMR (CDC13) 6  1.17 (3 H, t, /  = 7.0 
Hz, OCH2C//3), 1.20 (3 H, t, J  = 7.0 Hz, OCH2Cf/3), 1-24 (3 H, t, J  = 7.0 Hz, 
CO2CH2C//3) 1.27 (3 H, t, J =  7.0 Hz, C 02CH2C //3), 2.25 (1 H, brs, NH), 3.39 (1 H, 
d, J =  18.0 Hz), and 3.47 (1 H, d, J  = 18.0 Hz) (NCH2), 3.52 (1 H, d, J =  5.7 Hz, 
NCHCO2), 3.54 (1 H, dq, J =  14.0, 7.0 Hz), 3.55 (1 H, dq, J =  14.0, 7.0 Hz), 3.71 (1 
H, dq, J = 14.0, 7.0 Hz), 3.72 (1 H, dq, J =  14.0, 7.0 Hz) (2 x OCH2), 4.12 (1 H, dq, J  
= 14.0, 7.0 Hz) and 4.19 (1 H, dq, J =  14.0, 7.0 Hz) (CHC02C/72), 4.15 (2 H, q, J  = 
7.0 Hz, CH2C 02Ctf2), 4.66 (1 H, d, J =  5.7 Hz, OCHO); MS (FAB'") m/z 292.1763 





Compound (142) (5.67 g, 36.4 mmol) in AC2O (213 mL) was boiled under reflux for 
2 d. The solid formed was removed by filtration and the filtrate was evaporated. 
Recrystallisation (EtOH / Et20 3:2) gave (144) (2.0 g, 49%) as pale buff crystals: mp
136
260-265°C (lit.207 mp 279-281°C); TLC R f = 0.4 (CH2C12 /  MeOH / H20  / AcOH 




N ^ N H
PROCEDURE (1)
Compound (144) (5.54 g, 49 mmol) in EtOH (500 mL) was boiled under reflux with 
thionyl chloride (30 mL, 410 mmol) for 5 h. Evaporation gave (145) (6.2 g, 90%) as 
pale buff crystals: mp 155-157°C (lit.207 mp 156-158°C); TLC R f = 0.2 (EtOAc / 
hexane 1:2); *H NMR (D20 )  8  1.19 (3 H, t, J =  7.0 Hz, CH3), 3.66 (2 H, q, J  = 7.0 
Hz, CH2), 7.52 (1 H, s, 5-H), 7.66 (1 H, s, 2-H).
PROCEDURE (2)
To (144) (4.82 g, 43 mmol) in EtOH (90 mL) was added conc. H2S0 4  (5 mL). The 
mixture was stirred and refluxed for 40 h, under N2. The solution was cooled in an 
ice bath and neutralised to pH 8  with aq. NaOH (10%, 20 mL). Evaporation and 





Compound (145) (6.81 g, 48.6 mmol) in dry DMF (162 mL) was stirred with 
triethylamine (21 mL) and chlorotriphenylmethane (13.9 g, 49.6 mmol) for 16 h. The 
evaporation residue, in CHCI3, was washed with aq. NaHC03 and brine and was 
dried and filtered. Recrystallisation (EtOH / H20  3:1) gave (146) (0.52 g, 3%) as
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pale yellow crystals. Evaporation o f the filtrate and column chromatography (EtOAc 
/ hexane 1:2) gave (146) (11.3 g, 61%) as pale yellow crystals: mp 167-169°C (lit.207 
mp 168-169°C); TLC R f= 0.6 (EtOAc / hexane 1:2); NMR (CDC13) 6  1.37 (3 H, 
t, J = 7.0 Hz, CH3), 4.35 (2 H, q, J =  7.0 Hz, CH2), 7.10 ( 6  H, m, 3 x Ph 2,6-H2), 7.35 
(9 H, m, 3 x Ph 3,4,5-H3), 7.46 (1 H, d, J =  1.4 Hz, 5-H), 7.58 (1 H, d, J =  1.4 Hz, 2- 
H).




To a suspension o f LiAlHj (1.25 g, 30 mmol) in dry THF (108 mL) at 0°C was added 
a solution o f (146) (10.8 g, 28 mmol) in dry THF (108 mL) over 15 min with stirring. 
The mixture was stirred at 20°C for 1 h, then cooled to 0°C. H20  (1.25 mL) was 
added slowly, followed by aq. NaOH (10%, 1.85 mL) and H20  (3.0 mL). The 
mixture was stirred for 30 min then filtered. The filter cake was washed with hot 
THF and extracted with hot EtOH. The combined ethanolic extracts and THF filtrate 
were cooled to give, after filtration and drying, (147) (8.9 g, 93%) as white crystals: 
mp 238-241°C (lit. 207 mp 239-240°C); TLC R f = 0.3 (EtOAc / MeOH 5:1); 'H NMR 
(CDCI3) 8  4.51 (2 H, s, CH2), 6.71 (1 H, d, J =  1.5 Hz, 5-H), 7.10 ( 6  H, m, 3  x Ph 
2,6-H2), 7.35 (9 H, m, 3 x Ph 3,4,5-H3), 7.35 (1 H, d, J =  1.5 Hz, 2-H); MS (FAB4)  







To (147) (2.15 g, 6.3 mmol) and imidazole (1.03 g, 15.1 mmol) in dry DMF (8.2 mL) 
was added /-butyldimethylchlorosilane (1.14 g, 7.6 mmol). The solution was heated 
at 45°C for 14 h, under N2 . Saturated aq. Na2C0 3  was added and the mixture was 
extracted with Et20. The extract was washed with brine, dried and filtered. 
Evaporation gave (153) (2.84 g, 99%), as colourless crystals: mp 81-83°C (lit.208 mp 
79-80°C); TLC R f = 0.7 (EtOAc / MeOH 5:1); *H NMR (CDC13) 6 0.01 (6 H, s, 
Si(CH3)2), 0.83 (9 H, s, Bu'), 4.67 (2 H, s, CH2), 6.71 (1 H, s, 5-H), 7.10 (6 H, m, 3 x 
Ph 2,6-H2), 7.35 (9 H, m, 3 x Ph 3,4,5-H3), 7.36 (1 H, s, 2-H); MS (FAB+) m/z 909 
(2 M + H), 477 (M + Na), 456.2554 (M + H) (C28H35N2OSi requires 456.2552), 
455.2531 (M) (C29H34N2OSi requires 455.2519).
PROCEDURE (2)
To (147) (0.99 g, 2.9 mmol) and imidazole (0.43 g, 6.0 mmol) in dry DMF (10.0 mL) 
was added /-butyldimethylchlorosilane (0.45 g, 3.0 mmol). The mixture was stirred 
for 5 d. The evaporation residue, in CHCI3, was washed with saturated aq. Na2C03, 
H2O, brine, dried and filtered. Evaporation and column chromatography (hexane / 






To (147) (250 mg, 0.74 mmol) in DME (2.0 mL) was added BuLi (1.6 M in hexanes; 
460 |iL, 0.7 mmol). The solution was heated at 45°C for 4 h and at 20°C for 12 h, 
under Ar. D2O (0.1 mL) in DME (0.5 mL) was added and the solution was stirred for 
1 h. The evaporation residue, in EtOAc, was washed with H2O, brine, dried and 
filtered. Evaporation gave crude (152): NMR ((CD3)2SO) 6 4.33 (2 H, d, J =  5.0
Hz, CH2), 4.90 (1 H, t, J = 5.0 Hz, OH), 6.72 (1 H, s, 5-H), 7.10 (6 H, m, 3 x Ph 2, 6- 
H2), 7.30 (0.5 H, d, J =  1.4 Hz, 2-H), 7.41 (9 H, m, 3 x Ph 3,4,5-H3); MS (FAB+) m/z 
342.1718 (M + H) (C23H2o2HN20  requires 342.1717), 341.1662 (M) (C23Hi92HN20  
requires 341.1638), 243 (CPI13).
PROPYL NITRATE (157)
0 - N 0 2
Concentrated nitric acid (10 mL) at 0°C was added slowly to concentrated sulfuric 
acid (10 mL) at 0°C. Propanol (7 mL) was very slowly added dropwise to the ice- 
cooled solution. The solution was vigorously stirred and the temperature kept <3 °C. 
The ester was decanted and immediately washed with aq. Na2C0 3  (10 mL), H2O (10 
mL), dried (CaCL) and filtered to yield (157) (5 mL) as a colourless liquid: ]H NMR 
(CDCI3) 6 1.01 (3 H, t, J = 7.5 Hz, CH3), 1.76 (2 H, m, CU3CH2CH2X 4.42 (2 H, t, J  




To (158) (500 mg, 3.2 mmol) in dry MeOH (100 mL) was added NaBtL (360 mg,
9.5 mmol). The solution was stirred for 1 h. The excess NaBfLt was decomposed 
with glacial AcOH (1.0 mL). The evaporation residue, in EtOAc, was washed with 
H2O, NaHCOs, brine, dried and filtered. Evaporation gave (159) (500 mg, 99%) as a 
buff oil: TLC R f = 0.4 (EtOAc / hexane 1:1); lH NMR (CDC13) 8  4.59 (2 H, s, CH2), 
6.94 (1 H, dt, J =  4.0, 0.7 Hz, 4-H), 7.83 (1 H, d, J =  4.0 Hz, 3-H).
5-CHLOROMETHYL-2-NITROTHIOPHENE (160)
n o 2
To (159) (500 mg, 3.1 mmol) was added thionyl chloride (1.0 mL, 13.7 mmol). The 
solution was stirred for 2 h. Evaporation and column chromatography (EtOAc / 
hexane 1:1) gave (160) (550 mg, 99%) as a buff oil: TLC R f = 0.9 (EtOAc / hexane 
1:1); !H NMR (CDC13) 5 4.73 (2 H, d, J = 0.8 Hz, CH2), 7.05 (1 H, dd, J = 4.0, 0.8 
Hz, 4-H), 7.80 (1 H, d, J =  4.0 Hz, 3-H).
NAPHTHALENE-1-CARBOXAMIDE (176)
c o n h 2
To (174) (2.25g, 13.1 mmol) was added thionyl chloride (60 mL, 0.82 mol) and the 
solution was stirred for 24 h. Evaporation gave (175) (2.5 g, 100%) as pale buff oil; 
TLC R f= 0.2 (EtOAc /  hexane 1:1); 'H NMR (CDCI3) 8  7.53 (1 H, t , J =  7.8 Hz, 3- 
H), 7.55 (1 H, dt, J =  7.8, 1.3 Hz, 7-H), 7.65 (1 H, ddd, J =  8 .6 , 6.9, 1.7 Hz, 6 -H), 
7.88 (1 H, dd, J =  8.2,1.7 Hz, 8 -H), 8.08 (1 H, d, J =  8.2 Hz, 4-H), 8.53 (1 H, dd, J =
141
7.3, 1.3 Hz, 5-H), 8.73 (1 H, d, J=  9 Hz, 2-H). Compound (175) (2.5 g, 13.1 mmol) 
in CHCI3 (50 mL) was saturated with NH3 for 1 h. Filtration gave (176) (1.95 g, 
87%) as pale buff crystals: mp 198-200°C (lit. 23 1 mp 203-204°C); TLC Rf = 0.2 
(EtOAC / hexane 1:1); v,™ 3310, 3140 and 1650 cm'1; lH NMR (CDC13) 8  7.74 (4 
H, m, 3,5,6,7-EU, N-H), 7.96 (1 H, d, J=  5.5 Hz, 4-H), 7.99 (1 H, brs, NH), 8.00 (1 
H, d, J  = 8.1 Hz, 8 -H), 8.30 (1 H, d, J=  9.9 Hz, 2-H); MS (FAB+) m/z 343 (2 M + 




To (178) (385 mg, 2.2 mmol) was added thionyl chloride (10.0 mL, 0.14 mol). The 
solution was boiled under reflux for 12 h. Following evaporation the oil, in CHCI3 
(50 mL), was saturated with NH3 for 1 h. Filtration gave (180) (0.34 g, 90%) as pale 
buff crystals: mp 170-172°C (lit. 2 3 2  mp 171-173°C); TLC Rf = 0.2 (EtOAc / CH2 C12  
1:2); lR  NMR (CDC13) 8  6.04 (1 H, brs, NH), 7.44 (1 H, dd, / =  8.4, 4.4 Hz, 3-H),
7.63 (1 H, t, J=  8.1 Hz, 6 -H), 7.94 (1 H, dd, J=  8.4, 1.8 Hz, 4-H), 8.23 (1 H, dd, / =
8.4, 1.8 Hz, 5-H), 8.81 (1 H, dd, J=  7.3, 1.8 Hz, 7-H), 8 . 8 8  (1 H, dd, J=  4.4,1.8 Hz, 
2-H), 10.94 (1 H, brs, NH).
PROCEDURE (2)
To (178) (0.5 g, 2.9 mmol) in MeOH (200 mL) was added thionyl chloride (20 mL, 
0.28 mol). The solution was stirred for 24 h. To the evaporation oil, in MeOH (25 
mL), was added conc. NH3 (25 mL) at 0°C. Filtration and column chromatography 




To (191) (0.25 g, 1.2 mmol) in dry THF (1 mL) at -79°C was added BuLi (1.6 M in 
hexanes, 0.83 mL, 1.3 mmol). After 30 min trimethylsilylisocyanate (0.5 mL, 3.7 
mmol) was added. The solution was stirred for a further 15 min at -79°C and for 12 
h at 2 0 °C. The evaporation residue, U1CH2 CI2 , was washed with H2 O, brine, dried 
and filtered. Evaporation and column chromatography (CH2 CI2  / EtOAc 2 :1 ) gave 
(180) (164 mg, 79%) as pale buff crystals, with properties as above.
PROCEDURE (4)
To (187) (0.5 g, 2.2 mmol) in dry THF (2 mL) at -79°C was added BuLi (1.6 M in 
hexanes, 1.65 mL, 2.5 mmol). After 30 min trimethylsilylisocyanate (1.0 mL, 7.4 
mmol) was added. The solution was stirred for a further 15 min at -79°C and for 12 
h at 20°C. The evaporation residue, in CH2 CI2 , was washed with H2 O, brine, dried 
and filtered. Evaporation and column chromatography (CH2 CI2  / EtOAc 2 :1 ) gave 
(180) (295 mg, 77%) as pale buff crystals, with properties as above: In some runs 
was obtained crude 2-butylquinoline (190) (21.7 mg, 19%): TLC Rf = 0.6 (EtOAc); 
!H NMR (CDCI3) 8  0.89 (3 H, t, J  = 7.3 Hz, CH3), 1.37 (2 H, sextet, J =  7.3 Hz, 
C/7 2 CH3), 1.72 (2 H, qn, J  = 7.3 Hz, CH2CH2 CH3), 2.90 (2 H, t, J  = 7.3 Hz, 
C//2 CH2 CH2CH3), 7.21 (1 H, dd, J =  8.4, 5.0 Hz, 3-H), 7.40 (1 H, m, 6 -H), 7.60 (1 
H, m, 7-H), 7.70 (1 H, d, J=  8.1 Hz, 5-H), 7.97 (1 H, d, J=  8.4 Hz, 4-H), 7.98 (1 H, 
d,J=  8.1 Hz, 8 -H).
PROCEDURE (5)
To (183) (60 mg, 0.4 mmol) in EtOH (1 mL) was added aq. NaOH (20.0 pL, 0.5 M) 
and 27% H2O2 (20.0 pL). The solution was heated at 50°C for 1 h, then neutralised 
with aq. HC1 (1.0 mL, 2M). The evaporation residue, in EtOAc, was washed with 
brine, dried and filtered. Evaporation and column chromatography (EtOAc / CH2 CI2  





To (180) (146 mg, 0.85 mmol) was added thionyl chloride (2.0 mL, 27.0 mmol). The 
solution was boiled under reflux for 1 h. Evaporation and column chromatography 
(EtOAc / hexane 1:1) gave (183) (105 mg, 80%), as pale yellow crystals: mp 85- 
86°C (lit.233 mp 87.5-88.3°C); TLC R f = 0.7 (EtOAc); 2240 cm'1; !H NMR 
(CDC13) 6 7.57 (1 H, dd, J = 8.4, 4.2 Hz, 3-H), 7.63 (1 H, dd, J =  8.2, 7.1 Hz, 6-H),
8.09 (1 H, dd, / =  8.2, 1.6 Hz, 4-H), 8.14 (1 H, dd, J =  7.1, 1.3 Hz, 5-H), 8.27 (1 H, 
dd, J = 8.4, 1.3 Hz, 7-H), 9.11 (1 H, dd, J = 4.2,1.6 Hz, 2-H).
PROCEDURE (2)
To (180) (100 mg, 0.6 mmol) in pyridine (110 pL) was added 4-methyl- 
benzenesulfonyl chloride (110 mg, 0.6 mmol). The solution was stirred for 3 h. The 
evaporation residue, in EtOAc, was washed with aq. HC1 (2 M), aq. NaHC0 3 , brine, 
dried and filtered. Evaporation gave (183) (87 mg, 97%) as pale yellow crystals, 
with properties as above.
QUINOLINE-N-OXIDE (185)
To (184) (50.2 g, 0.4 mol) in glacial AcOH (430 mL) was added aq. H2O2 (140 mL, 
30%). The solution was boiled under reflux for 24 h. The evaporation residue, in 
EtOAc, was washed with aq. Na2C0 3 , brine, dried and filtered. Evaporation gave 
(185) (53.5 g, 95%), as buff hygroscopic crystals: TLC R f = 0.5 (MeOH); VmaX 1220 
cm 1; !H NMR (CDCI3) 8 7.30 (1 H, dd, J =  8.4, 6.1 Hz, 3-H), 7.65 (1 H, ddd, J  =
O
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8.2, 7.0, 1.3 Hz, 6 -H), 7.75 (1 H, d, J =  8 . 6  Hz, 4-H), 7.77 (1 H, ddd, J =  8 .6 , 7.0,1.5  
Hz, 7-H), 7.87 (1 H, d, J =  8.2 Hz, 5-H), 8.55 (1 H, dd, J =  6.1, 0.9 Hz, 2-H), 8.76 (1 
H, d, J =  8 . 6  Hz, 8 -H); MS (FAB+) m/z 291 ( 2  M + H), 146 (M + H).
8 -(CHLOROMERCURI)QUINOLINE-N-OXIDE (186)
CIHg O
To (185) (20.0 g, 0.14 mol) in glacial AcOH (20 mL) was added Hg(OAc)2  (44.1 g, 
0.14 mol). The mixture was boiled under reflux for 5 h. The residue was poured into 
brine (200 mL) and the solid formed was filtered and washed with H2O (200 mL) to 
give (186) (43.5 g, 83%), as pale buff crystals: mp >230°C (lit.210 mp 235°C 
(decomp); !H NMR ((CD3)2SO) 6  7.58 (1 H, dd, J =  8.4, 5.9 Hz, 3-H), 7.78 (1 H, dd, 
J =  8.4, 7.1 Hz, 6 -H), 8.02 (1 H, d, J =  7.1 Hz, 7-H), 8.05 (1 H, d, J = 8.4 Hz, 4-H), 
8.11 (1 H, d, J =  8.2 Hz, 5-H), 8.76 (1 H, dd, J =  5.9, 1.0 Hz, 2-H); MS (FAB+) m/z 
381 (M + H) isotope cluster at 381, 346 (M - Cl), 145 (M -  HgCl), 129 (M -  
HgCIO).
8 -BROMOQUINOLINE-N-OXIDE (187)
Bromine (0.51 g, 3.13 mol) and KBr (0.41 g, 3.4 mmol) in H2O (2 mL) was slowly 
added to (186) (1.08 g, 2.9 mmol) with vigorous stirring. Aq. NaOH (500 mL, 10%) 
was added to the mixture. The evaporation residue, in CHCI3 , was washed with 
brine, dried and filtered. Evaporation and column chromatography (EtOAc) gave 
(187) (183 mg, 29%), as pale buff crystals: mp 210-212°C (lit. 210 mp 102-104°C); 
TLC R f = 0.3 (EtOAc); !H NMR ((CD3)2SO) 5 7.58 (1 H, dd, J =  8.4, 6.0 Hz, 3-H), 
7.78 (1 H, dd, J =  8.0, 7.0 Hz, 6 -H), 8.02 (1 H, d, J =  7.0 Hz, 7-H), 8.04 (1 H, d, J  =
8.4 Hz, 4-H), 8.10 (1 H, d, J =  8.0 Hz, 5-H), 8.75 (1 H, d, J =  6.0 Hz, 2-H); MS (E f)  
m/z 225.9641 (M + H) (C9H781BrNO requires 225.9691), 224.9613 (M) (C9H681Br
Br O
145
NO requires 224.9612), 223.9669 (M + H) (C9H779BrNO requires 223.9711), 
222.9634 (M) (C9H679BrNO requires 222.9633), 144 (M -  Br), 128 (M -  BrO).
8-BROMO-3-HYDROXYQUINOLINE (192)
To (191) (202 mg, 0.97 mmol) in glacial AcOH (1 mL) was added aq. H2O2 (1.0 mL, 
30%). The solution was boiled under reflux for 24 h. The evaporation residue, in 
C H C I3 , was washed with aq. NaHCC>3 and brine and was dried and filtered. 
Evaporation and column chromatography (EtOAc) gave (192) (188 mg, 8 6 %), as off- 
white crystals: mp 224-226°C; TLC R f = 0.5 (EtOAc); 'H NMR (CDC13) 8  7.36 (1 
H, t, J =  8.0 Hz, 6 -H), 7.51 (1 H, d, J  = 2.7 Hz, 4-H), 7.67 (1 H, dd, /  = 8.1,1.1 Hz,
5-H), 7.90 (1 H, dd, J = 8 .8 ,1 .1 Hz, 7-H), 8.79 (1 H, d, J =  2.7 Hz, 2-H); MS (FAB*) 
m/z 225.9672 (M + H) (C9H781Br NO requires 225.9691), 223.9699 (M + H) 
(C9H779BrNO requires 223.9711); Found: C, 46.9; H, 2.95; N, 5.64; C9H6BrNO3.0.25 
H 2O  requires C, 46.38; H , 3.03; N, 6.01%.
8 -METHYLQUINOLINE-N-OXIDE (199)
To (198) (1.4 g, 9.8 mmol) in CHCI3 (30 mL) was added 3-chloroperoxybenzoic acid 
(3.35 g, 19.4 mmol). The solution was stirred for 48 h. The evaporation residue, in 
CHCI3, was washed with aq. NaHC0 3 , brine, dried and filtered. Evaporation and 
column chromatography (EtOAc / MeOH 5:1) gave (199) (1.48g, 95%) as white 
crystals: mp 34-35°C (lit.214 mp 36-38°C); TLC R f = 0.3 (EtOAc / MeOH 5:1); v™* 
1220 cm'1; NMR (CDC13) 5 3.19 (3 H, s, CH3), 7.18 (1 H, dd, J =  8.3, 6.1 Hz, 3- 
H), 7.44 (4 H, m) (4 ,5 ,6 ,7 -H4), 8.39 (1 H, dd, J =  6.0, 1.1 Hz, 2-H); MS (FAB+) m/z 






To (198) (240 mg, 1.7 mmol) in glacial AcOH (2 mL) was added aq. H2 O2 (1.0 mL, 
30%). The solution was boiled under reflux for 24 h. The evaporation residue, in 
CHCI3 , was washed with aq. NaHCOs and brine and was dried and filtered. 
Evaporation and column chromatography (EtOAc / hexane 1:1) gave (200) (247 mg, 
93%) as pale yellow crystals: mp 209-211°C (lit. 2 1 3  mp 211°C); TLC Rf = 0.9 
(EtOAc); 2900 cm'1; lR  NMR (CDC13) 5 2.66 (3 H, s, CH3), 7.36 (2 H, m, 5,6- 
H2), 7.47 (1 H, d, J =  2.6 Hz, 4-H), 7.62 (1 H, m, 7-H), 8.60 (1 H, d, J - 2.6 Hz, 2- 
H), 10.25 (1 H, brs, OH); MS (FAB+) m/z 160.0717 (M + H) (C10H10NO requires 
160.0762), 159.0682 (M) (C10H9NO requires 159.0684).
8-METHYLQUINOLIN-4-ONE (201)
To (198) (164 mg, 1.1 mmol) was added Se0 2  (260 mg, 2.3 mmol). The mixture 
was heated at 200°C for 5 min. The residue, in CHCI3 was washed with H2 O, brine, 
dried and filtered. Evaporation and column chromatography (EtOAc / MeOH 5:1) 
gave (201) (150 mg, 82%), as pale yellow crystals, mp 223-225°C; TLC Rf = 0.9 
(EtOAc); 'H NMR (CDClj) 8  2.45 (3 H, s, CH3), 6.61 (1 H, d, J=  9.5 Hz, 3-H), 7.08 
(1 H, dd, J  = 8.4, 7.5 Hz, 6 -H), 7.30 (1 H, d, J — 7.5 Hz, 5-H), 7.37 (1 H, d, J =  8.4 
Hz, 7-H), 7.75 (1 H, d, J=  9.5 Hz, 2-H); MS (FAB+) m/z 160 (M + H).
O
c h 3 h
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8-METHYL-2-PHENYLQUINOLINE (203) AND 8-METHYL-2-
PHENYLQUINOLINE N-OXIDE (204)
To (199) (1.07 g, 7.5 mmol) in dry THF (20 mL) was added PhMgBr (1 M in THF,
7.5 mL, 7.5 mmol) in dry THF (5 mL). The solution was stirred for 5 h. The 
reaction mixture was poured into aq. NH4CI (100 mL, 10%), extracted with CHCI3, 
washed with brine, dried and filtered. The evaporation residue, in dry benzene (15 
mL), was treated with lead dioxide (PbC>2 , 2.1 g, 8 . 8  mmol) and the mixture was 
stirred for 2  h. Filtration, evaporation and column chromatography (CH2CI2) gave 
(203) (0.785 g, 48%), as a pale yellow oil: TLC Rf = 0.9 (CH2C12); !H NMR 
(CDCI3) 8  2.89 (3 H, s, CH3), 7.31 (1 H, tt, J=  7.4, 1.9 Hz, Ph 4-H), 7.41 (3 H, m, Ph
3,5-H2), 7.48 (1 H, dd, J =  7.9, 1.6 Hz, 7-H), 7.55 (2 H, m, 5,6-H2), 7.82 (1 H, d, J  =
8 . 6  Hz, 3-H), 8.09 (1 H, d, J =  8 . 6  Hz, 4-H), 8.23 (1 H, dd, J=  7.0, 1.9 Hz, Ph 2,6- 
H2); 13C NMR (CDCI3 ) 8  18.36 (CH3), 118.41, 125.60, 126.23, 127.37, 127.46, 
127.67, 128.97, 129.43, 129.89, 137.11, 137.87, 140.03, 147.32, 155.68. Further 
elution gave (204) (0.452 g, 29%), as pale yellow crystals: mp >230°C; TLC Rf = 
0.1 (CH2 CI2); Vmax 1210 cm'1; lH NMR (CDC13) 8  3.21 (3 H, s, CH3), 7.39 (1 H, d, J  
= 8 . 6  Hz, Ph 3-H), 7.48 (7 H, m, Ph 3,4,5-H3. and 4,5,6,7-ILO, 7.84 (2 H, dd, J=  8.2,
1.6 Hz, Ph 2,6-H2); 13C NMR (CDCI3) 8  25.51 (CH3), 123.09, 125.39, 126.72, 
127.83, 128.26, 129.09, 129.37, 131.62,133.70, 134.12; MS (FAB +) m/z 471 (2 M + 
H), 236 (M + H), 218 (M -  H2 0); Found: C, 81.50; H, 5.57; N, 5.98; Ci6Hi3NO 
requires C, 81.70; H, 5.53; N, 5.98%.
148
2-PHENYLQUINOLINE-8-CARBOXALDEHYDE (206) AND 2-PHENYL-
QUINOLINE-8-CARBOXYLIC ACID (207)
To (204) (200 mg, 0.9 mmol) was added SeC>2 (0.59 g, 5.3 mmol). The paste was 
heated at 200°C for 45 mins. The melt was extracted with hot CHCI3 , washed with 
H2 O and brine and was dried and filtered. Evaporation and column chromatography 
(CH2 CI2 / hexane 2 0 :1 ) gave (203) (33 mg, 16%) as a pale yellow oil, with properties 
as above. Further elution gave (206) (85 mg, 40%) as white crystals: mp 95-96°C; 
TLC Rf = 0.4 (CH2 CI2); 1680 cm'1; lH NMR (CDC13) 8  7.56 (3 H, m, Ph 3,4,5-
H3), 7.66 (1 H, dd, J =  8.1, 7.3 Hz, 6 -H), 8.04 (1 H, d, J=  8 . 8  Hz, 3-H), 8.11 (1 H, 
dd, J =  8.1, 1.5 Hz, 5-H), 8.29 (2 H, m, Ph 2,6-H2), 8.32 (1 H, d, J=  8 . 8  Hz, 4-H), 
8.34 (1 H, dd, J = 7.3, 1.5 Hz, 7-H), 11.67 (CHO); MS (FAB +) m/z 387 (M + H + 
mNBA), 234.0923 (M + H) (CieHnNO requires 234.0919), 233.0829 (M) 
(C16H11NO requires 233.0841). Further elution gave (207) ( 6 6  mg, 29%) as white 
crystals: mp 155-157°C (lit. 2 3 4  mp 158-159°C); TLC Rf = 0 . 2  (CH2 C12); 1690
cm'1; lH NMR (CDC13) 8  7.58 (3 H, m, Ph 3,4,5-H3), 7.70 (1 H, t, J =  8.1 Hz, 6 -H),
8.20 (4 H, m, Ph 2, 6 -H2, 3, 5-H2), 8.45 (1 H, d, J=  8.5 Hz, 4-H), 8.80 (1 H, dd, J  =
8.1, 1.4 Hz, 7-H), 17.00 (1 H, brs, C02H); MS (FAB+) 250 (M + H), 232 (M -  H2 0), 
205 (M -  C02H).
(+/-)-8-(l-HYDROXY-3-OXOBUTYL)-2-PHENYLQUINOLINE (211)
To (206) (48 mg, 0.21 mmol) was added acetone (1 mL), H2 O2 (30%, 0.2 mL) and 
NaOH (80 mg, 2.0 mmol). The solution was stirred for 72 h. The evaporation 
residue, in EtOAc, was washed with aq. HC1 (2 M), aq. NaHC0 3  and brine and was 
dried and filtered. Evaporation and column chromatography (CH2 CI2 ) gave (2 1 1 ) (50 
mg, 83%) as white crystals, mp 115-116°C; TLC Rf = 0.9 (EtOAc); lU NMR
CHOHCH2COCH3
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(CDC13) 8  2.22 (3 H, s, CH3), 3.25 (2 H, m, CH2), 5.87 (1 H, q, J =  8.2 Hz, CH), 6.07 
(1 H, brs, OH), 7.52 (3 H, m, Ph 3,4,5-H3), 7.69 (1 H, dd, J =  7 .4 ,0 .8  Hz, 3-H), 7.75 
(1 H, dd, J =  8.2, 1.2 Hz, 4-H), 7.93 (1 H, d , J =  8 . 6  Hz, 5-H), 8.12 (2 H, m, Ph 2,6- 
H2), 8.28 (1 H, d, J =  8 . 6  Hz, 7-H); 13C NMR (CDC13) 6  31.38 (CH3), 52.89 (CH2), 
70.98, 118.89, 126.48, 127.25, 127.54, 127.74, 129.24, 129.97, 138.10, 139.02, 
139.64, 145.83, 155.62, 168.58, 208.31 (CO); MS (FAB+) m/z 292.1346 (M + H) 
(Ci9H,8N 0 2 requires 292.1338), 291.1244 (M) (Ci9Hi7N 0 2 requires 291.1259), 274 
(M -  H2 0 ), 234 (M -  CH3COCH3); Found: C, 78.0; H, 5.91; N, 4.69; Ci9Hi7N 0 2 
requires C, 78.32; H, 5.88; N, 4.81%.
2-PHENYLQUINOLINE-8-CARBOXAMIDE (209) AND 4-CHLORO-2- 
PHENYLQUINOLINE-8 -CARBOXAMIDE (210)
„ •  gal
c o n h 2 c o n h 2
PROCEDURE (1)
To (207) (200 mg, 0.8 mmol) was added thionyl chloride (2.0 mL, 27 mmol). The 
solution was boiled under reflux for 24 h. The evaporation residue, in CHCI3 (20 
mL) was saturated with NH3 for 1 h. Filtration gave (209) (130 mg, 65%) as pale 
yellow crystals: mp 212-214°C (lit.234 mp 210-212°C); TLC R f = 0.4 (EtOAc / 
hexane 1:1); vmax 3310, 3120 and 1660 cm'1; ‘H NMR (CDC13) 6  6.36 (1 H, brs, 
NH), 7.55 (3 H, m, Ph 3,4,5-H3), 7.66 (1 H, dd, J =  7.8, 7.4 Hz, 6 -H), 7.92 (1 H, d, J  
= 8 . 6  Hz, 3-H), 8.00 (1 H, dd, J =  7.8,1.8 Hz, 5 -H), 8.02 (2 H, dd, J =  8.2,1.6 Hz, Ph
2,6-H2), 8.34 (1 H, d, J =  8 . 6  Hz, 4-H), 8 . 8 8  (1 H, dd, J =  7.4,1.8 Hz, 7-H), 11.18 (1 
H, brs, NH); l3C NMR 8 C 119.09, 126.04, 127.56, 129.04, 129.81, 132.05, 134.40, 
138.30, 139.01, 145.36, 157.13, 167.61 (CO); MS (FAB4) m/z 249.1036 (M + H) 
(CisHi3N20  requires 249.1028), 248.0952 (M) (Ci6Hi2N20  requires 248.0950), 232 
(M + H -  NH2), 205 (M -  CONH2). Concentration o f the filtrate and recrystallisation 
(EtOAc / hexane 1:1) gave (210) (45 mg, 20%), as pale yellow crystals: mp 226- 
228°C; TLC R f = 0.3 (EtOAc /  hexane 1:1); v,™ 3380 and 1690 cm'1; 'H NMR
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(CDC13) 5 6.06 (1 H, brs, NH), 7.64 (3 H, m, Ph 3,4,5-H3), 7.73 (1 H, dd, J =  8.2, 7.4 
Hz, 6 -H), 7.82 (2 H, m, Ph 2,6-H2), 7.98 (1 H, dd, J =  8 .2,1.7 Hz, 5-H), 8.42 (1 H, s, 
4-H), 8 . 8 8  (1 H, dd, J  = 7.4, 1.7 Hz, 7-H), 10.67 (1 H, brs, NH); MS (FAB+) m/z
285.0616 (M + H) (Ci6Hi237ClN20  requires 285.0609), 283.0652 (M + H) 
(Ci6Hi235C1N20  requires 283.0638), 282.0560 (M) (Ci6Hi235ClN20  requires 
282.0560), 268,266 (M -  NH2), 241,239 (M -  CONH2).
PROCEDURE (2)
To (207) (150 mg, 0.6 mmol) in CH2CI2 (10 mL) was added oxalyl chloride (230 mg,
1.8 mmol). After evaporation the oil, in CHCI3 (20 mL) was saturated with NH3 for 
1 h. Filtration, evaporation and column chromatography (EtOAc / hexane 1:1) gave 
(209) (140 mg, 94%) as pale yellow crystals, with properties as above.
4-BROMO-2-METHOXYPHEN OL (219)
To (218) (19.9 g, 0.16 mmol) in dry CHCI3 (50 mL) at 0°C was added Br2 (25.6 g, 
0.16 mmol) in dry CHCI3 (50 mL) slowly. The solution was stirred at 0°C for 2 h. 
Evaporation and Kugelrohr distillation gave (219) (32.0 g, 98%) as a colourless oil 
bpo.15 137°C (lit235 bpo.os 120°C): TLC R f = 0.7 (hexane); v™* 3500 and 630 cm*1;
H NMR (CDCI3) 5 3.85 (3 H, s, CH3), 5.67 (1 H, s, OH), 6.79 (1 H, d, J =  7 A  Hz, 6 - 






To (219) (10.8 g, 0.05 mol) in dry DMF (10 mL) was added imidazole (7.6 g, 0.11 
mol) and /-butylchlorodimethylsilane (16.2 g, 0.11 mol). The mixture was stirred for 
3 d. The evaporation residue in CHCI3, was washed with H2O and brine and was 
dried and filtered. Evaporation and column chromatography (EtOAc / hexane 1:1) 
gave (220) (14.1 g, 84%) as a pale yellow oil: TLC R f = 0.8 (EtOAc); 'H NMR
To (219) (13.63 g, 67 mmol) and ethoxyethene (25 mL) in CH2CI2 (13 mL) was 
added pyridinium 4-methylbenzenesulfonate (60 mg) and the solution was stirred for 
16 h. The evaporation residue, in EtOAc, was washed with aq. CUSO4 , aq. NaHC0 3  
and brine and was dried and filtered. Evaporation and column chromatography 
(EtOAc / hexane 1:5) gave (227) (18.23g, 99%) as a colourless oil: TLC R f = 0.7 
(EtOAc / hexane 1:1); v™* 690 cm'1; 'H NMR ((CD3)2 SO) 8  1.08 (3 H, t,7 =  7.1 Hz, 
CH2CH}), 1.35 (3 H, d ,7  = 5.3 Hz, CH3), 3.48 (1 H, dq, 7 =  9.5, 7.1 Hz) and 3.68 (1 
H, dq, 7 =  9.5,7.1 Hz) (CH2CH3), 3.78 (3 H, s, OCH3), 5.33 (1 H, q, 7 =  5.3 Hz, CH), 
6.98 (1 H, d, 7 =  8 . 6  Hz, 5-H) 7.04 (1 H, dd, 7 =  8 .6 , 2.0 Hz, 6 -H), 7.16 (1 H, d, 7  = 
2.0 Hz, 2-H); MS (FAB*) m/z 298 (M + Na), 276.0191 (M + H) (C,iH,5 81Br03 
requires 276.0184), 275.0159 (M) (Cu Hi48 lBr03 requires 275.0106), 274.0195 (M + 
H) (CiiH|579Br03 requires 274.0205), 273.0121 (M) (Cu Hl479Br03 requires 
273.0126), 259 (M + H - Me), 202 (M -  EtOCHMe).
(CDC13) 5 0.14 ( 6  H, s, Si(CH3)2), 0.98 (9 H, s, Bu'), 3.79 (3 H, s, OCH3), 6.71 (1 H, 
dd, 7 =  8.1, 0.6 Hz, 5-H), 6.94 (1 H, dd, 7 =  8.1, 2.2 Hz, 6 -H) 6.95 (1 H, dd, 7 =  2.2, 
0.6 Hz, 2-H).
4-BROMO-l-(l-ETHOXYETHYL)-2-METHOXYBENZENE (227)
OCH M eO Et
152
4-HYDROXY-3-METHOXYBENZALDEHYDE (223)
O H C . ^  .O C H 2 
OH
GENERAL PROCEDURE
To (220) in dry THF (1.0 mL) at -78°C was added the lithiating reagent (f-BuLi (1.5 
M in pentanes) /  s-BuLi (1.3 M in cyclohexanes) / n-BuLi (1.6 M in hexanes)) under 
argon and the mixture was stirred at -78°C for 1 / 2 /  4 h. Dry DMF was added and 
the mixture was stirred at -78°C for 2 h and at 20°C for a further 16 h. The 
evaporation residue, in EtOAc was washed with aq. NaHC0 3 , brine, dried and 
filtered. Evaporation gave (222) and (224). NMR (CDCI3) 5 0.17 ( 6  H, s, 
Si(CH3)2), 1.01 (9 H, s, Bu'), 3.87 (3 H, s, OCH3), 6.96 (1 H, d, J =  8.1 Hz, 5-H), 
7.38 (2 H, m, 2,6-H2), 9.83 (1 H, s, CHO). To the residue, in CHCI3 (1.0 mL) was 
added TBAF (1.0 M in THF, 0.5 mL) and the solution stirred for 12 h. Evaporation 
and column chromatography (EtOAc) gave (223): mp 78-80°C (lit.236 mp 76.5- 
78°C); TLC R f = 0.4 (EtOAc / hexane 1:1); v™* 3160 and 1660 cm'1; ]H NMR 
(CDCI3) 5 3.97 (3 H, s, OCH3), 6.22 ( 1  H, s, OH), 7.05 (1 H, d, J  = 8 . 6  Hz, 5-H), 
7.43 (2 H, m, 2,6-H2), 9.83 (1 H, s, CHO); MS (FAB*) m/z 305 (2 M + H), 153 (M + 
H), 135 (M -  H20 ), (FAB ) 151 (M -  H).



































































































To (227) in dry THF (1.0 mL) at -78°C was added the lithiating reagent (f-BuLi (1.5 
M in pentanes) / s-BuLi (1.3 M in cyclohexanes) / n-BuLi (1.6 M in hexanes)) under 
argon and the mixture was stirred at -78°C for 1 /  2 /  4 h. Dry DMF was added and 
the mixture was stirred at -78°C for 2 h and at 20°C for a further 16 h. The 
evaporation residue, in EtOAc was washed with aq. NaHC0 3 , brine, dried and
154
filtered. Evaporation and column chromatography (EtOAc / hexane 1:4) gave (223) 
with the above properties.
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4-HYDROXY-3-METHOXYBENZ- [2H] - ALDEHYDE (231)
02HC O CH3
OH
To (227) (525 mg, 1.9 mmol) in diy THF (3.0 mL) was added BuLi (1.6 M in 
hexanes; 3.6 mL, 5.6 mmol) at -78°C, under Ar. The solution was stirred at -78°C 
for 2 h. Di-[2H3]-methyl-[2H]-formamide (281 mg, 3.5 mmol) was added and the 
solution was stirred at -78°C for 2 h and at 20°C for a further 16 h, under Ar. Aq. 
HC1 (3 M, 7.0 mL) was added under Ar and the solution was stirred for 30 min. The 
evaporation residue in EtOAc was washed with aq. NaHC0 3 , brine, dried and 
filtered. Evaporation and column chromatography (EtOAc / hexane 1:4) gave (223) 
(161 mg, 55%) as off-white crystals: mp 72-75°C (lit.236 mp 76.5-78°C) (unlabelled 
material); TLC R f = 0.4 (EtOAc / hexane 1:1); *H NMR (CDC13) 6  3.91 (3 H, s, 
OCH3), 7.01 (1 H, d, J =  8 . 6  Hz, 5-H), 7.40 (2 H, m, 2, 6 -H2); 13C NMR (CDC13) 6  
55.97 (CH3), 108.95 (2-C), 114.46 (5-C), 127.37 (6 -C), 129.59 (1-C), 147.24 (4-C), 
151.86 (3-C), 190.64 (t, J =  26.4 Hz, C2HO).
4-HYDROXY-3-METHOXYBENZ-[14C]-ALDEHYDE (233)
To (227) (141.2 mg, 0.51 mmol) in dry THF (1.5 mL) was added BuLi (1.6 M in 
hexanes; 1.0 mL, 1.6 mmol) at -78°C, under Ar and the solution was stirred at -78°C 
for 2.5 h. Dimethyl-[14C]-formamide (3.0 mg, 41 pmol, 18.5 MBq) and dry DMF 
(57 mg, 776 pmol) in dry THF (750 pL) were added and the solution was stirred at - 
78°C for 2 h and at 20°C for a further 12 h, under Ar. Aq. HC1 (2 M, 2.0 mL) was 
added under Ar and the solution was stirred for 30 min. The evaporation residue, in 
EtOAc, was washed with aq. NaHC0 3 , brine, dried and filtered. Evaporation and 
column chromatography (EtOAc / hexane 1:1) gave (233) (35.6 mg, 45% chemical 
yield; 1.49 MBq, 8.1% radiochemical yield, specific activity 6.36 MBq mmol'1) as a 





To (223) (1.53 g, 10 mmol) and pentane-2,4-dione (0.5 mL, 5.0 mmol) in dry DMF 
(1 mL) was added H3BO3 (1.0 g, 16.3 mmol) and the mixture was heated for 5 mins 
at 120°C. A mixture o f 1,2,3,4-tetrahydroquinoline (0.1 mL, 0.8 mmol) and glacial 
AcOH (0.3 mL) in DMF (1 mL) was added and the mixture was heated for 8  h at 
120°C. After cooling, aq. AcOH (50 mL, 20%) was added and the mixture was 
stirred for 1 h at 20°C. Evaporation and column chromatography (EtOAc / hexane 
1 :2 ) gave (6 8 ) (1.05 g, 57%) as orange crystals: mp 184-186°C (lit.237 mp 185- 
186°C); TLC R f = 0.9 (EtOAc); v,™ 3500 and 1630 cm"1; *H NMR ((CD3)2 SO) 
63.84 ( 6  H, s, 2 x CH3), 6.06 (1 H, s, 4-H), 6.76 (2 H, d , J =  15.6 Hz, 2, 6 -H2), 6.84 
(2 H, d, J =  7.8 Hz, 2 x Ar 5-H), 7.15 (2 H, d, J =  7.8 Hz, 2 x Ar 6 -H), 7.33 (2 H, s, 2 
x Ar 2-H), 7.56 (2 H, d ,J =  15.6 Hz, 1, 7-H2), 9.70 (2 H, brs, 2 x ArOH); 6 c 55.80 (2 
x CH3), 100.97 (4-C), 111.53, 115.87, 121.22, 123.17, 126.49 (br 2,6 -C2), 140.81 (br
1,7-C2), 148.13,149.49, 183.30 (3,5-C2); MS (FAB+) m/z 369 (M + H).
PROCEDURE (2)
To H3BO3 (1.0 g, 16.2 mmol) in dry DMF (1 mL) was added pentane-2,4-dione (0.5 
mL, 5.0 mmol). The mixture was heated for 10 mins at 120°C. The mixture was 
added to (223) (1.53 g, 10 mmol). A mixture o f 1,2,3,4-tetrahydroquinoline (0.1 mL, 
0.8 mmol) and glacial AcOH (0.3 mL) in DMF (1 mL) was added and the mixture 
was heated for 20 h at 100°C. After cooling, aq. AcOH (50 mL, 20%) was added and 
the mixture stirred for 1 h at 20°C. Evaporation and column chromatography
o o
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(EtOAc / hexane 1:2) gave (6 8 ) (0.75 g, 40%) as orange crystals, with properties as 
above.
PROCEDURE (3)
To B2O3 (1.34 g, 19.3 mmol) in dry DMF (1 mL) was added pentane-2,4-dione (0.5 
mL, 5.0 mmol). The mixture was heated for 15 min at 120°C. The mixture was 
added to (223) (1.53 g, 10 mmol). A mixture o f 1,2,3,4-tetrahydroquinoline (0.1 mL,
0.8 mmol) and glacial AcOH (0.3 mL) in DMF (1 mL) was added and the mixture 
was heated for 10 h at 110°C. After cooling, aq. AcOH (50 mL, 20%) was added and 
the mixture stirred for 1 h at 20°C. Evaporation and column chromatography 
(EtOAc / hexane 1:2) gave (6 8 ) (1.2 g, 65%) as orange crystals, with properties as 
above.
PROCEDURE (4)
To B2O3 (1.2 g, 17.2 mmol) in dry DMF (1 mL) was added pentane-2,4-dione (0.5 
mL, 5.0 mmol). The mixture was heated for 15 min at 120°C. Compound (223) 
(1.53 g, 10 mmol) in dry DMF (1.0 mL) was added and the mixture stirred for 15 
mins at 120°C. A mixture o f 1,2,3,4-tetrahydroquinoline (0.1 mL, 0.8 mmol) and 
glacial AcOH (0.3 mL) in DMF (1 mL) was added and the mixture was heated at 
120°C for 45 min and at 110°C for 10 h. After cooling, aq. AcOH (50 mL, 20%) was 
added and the mixture stirred for 1 h at 20°C. Evaporation and column 
chromatography (EtOAc / hexane 1:2) gave (6 8 ) (1.43 g, 77%) as orange crystals, 









Pentane-2,4-dione (43 mg, 430 pmol) was heated with B2O3 (117 mg, 1.7 mmol) in 
dry DMF (90 pL) at 120°C for 15 min. Compound (231) (134 mg, 876 pmol) in dry 
DMF (300 pL) was added and the mixture was stirred for 15 min at 120°C. 1,2,3,4- 
Tetrahydroquinoline (10.6 mg, 80 pmol) and glacial AcOH (26 mg, 437 pmol) were 
added and the mixture was stirred for 8.5 h at 110°C. Aq. AcOH (20%, 5 mL) was 
added and the mixture was stirred for 16 h at 20°C. Evaporation and column 
chromatography (EtOAc / hexane 1:1) gave (234) (70 mg, 43%) as an orange-brown 
solid: mp 183-185°C (lit.237 mp 185-186°C (unlabelled material)); TLC R f = 0.9 
(EtOAc); ‘H NMR ((CD3)2 SO) 6  3.84 ( 6  H, s, 2 x CH3), 6.06 (1 H, s, 4-H), 6.75 (2 
H, d, / =  15.6 Hz, 2, 6 -H2), 6.82 (2 H, d, J = 8.1 Hz, 2 x Ar 5-H), 7.16 (2 H, dd, J =  
8.1, 1.5 Hz, 2 x Ar 6 -H), 7.33 (2 H, d, J = 1.5 Hz, 2 x Ar 2-H), 9.67 (2 H, brs, 2x 
ArOH); 8 c 55.46 (2 x CH3), 101.46 (4-C), 111.97, 116.33, 121.60, 123.71, 126.88, 
140.92 (br 1 , 7-C2), 148.54, 149.89, 183.67 (3, 5-C2); 3400 and 1580 cm'1; MS
(FAB+) m/z 372.1544 (M +H) (^ C i^ C zo ^ H i^ O e  requires 372.1464), 371.1489 





Pentane-2,4-dione (117 mg, 117 pmol) was heated with B20 3 (28.0 mg, 402 pmol) in 
dry DMF (223 pL) at 120°C for 15 min. Compound (233) (35.4 mg, 233 pmol, 1.48 
MBq) in dry DMF (500 pL) was added and the mixture was stirred for 15 min at
159
120°C. 1,2,3,4-Tetrahydroquinoline (2.7 mg, 20 pmol) and glacial AcOH (7.9 mg, 
131 pmol) were added and the mixture was stirred for 24 at 110°C h. Aq. AcOH 
(20%, 1.0 mL) was added and the mixture was stirred for 24 h at 20°C. Evaporation 
and column chromatography (EtOAc / hexane 1:4) gave (235) (34.7 mg, 81% 
chemical yield; 1.20 MBq, 81% radiochemical yield, specific radioactivity 12.7 MBq 
mmol'1) as an orange-brown solid chromatographically identical to (6 8 ).
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